

# CITATION REPORT

List of articles citing

## Coordinated regulation of myeloid cells by tumours

DOI: [10.1038/nri3175](https://doi.org/10.1038/nri3175)

Nature Reviews Immunology, 2012, 12, 253-68.

**Source:** <https://exaly.com/paper-pdf/53133992/citation-report.pdf>

**Version:** 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2284	Differential Content of Proteins, mRNAs, and miRNAs Suggests that MDSC and Their Exosomes May Mediate Distinct Immune Suppressive Functions.		
2283	Molecular pathways: tumor-infiltrating myeloid cells and reactive oxygen species in regulation of tumor microenvironment. <b>2012</b> , 18, 4877-82		87
2282	Endoneurial macrophages induce perineural invasion of pancreatic cancer cells by secretion of GDNF and activation of RET tyrosine kinase receptor. <b>2012</b> , 72, 5733-43		94
2281	Redirecting neutrophils against bladder cancer cells by BCG and Smac mimetic combination. <b>2012</b> , 1, 1161-1162		20
2280	Trial watch: Peptide vaccines in cancer therapy. <b>2012</b> , 1, 1557-1576		73
2279	Guest editorial. <b>2012</b> , 41, 555-61		
2278	Instruction of myeloid cells by the tumor microenvironment: Open questions on the dynamics and plasticity of different tumor-associated myeloid cell populations. <b>2012</b> , 1, 1135-1145		44
2277	Regulatory dendritic cells: there is more than just immune activation. <b>2012</b> , 3, 274		133
2276	Intragraft CD11b(+) IDO(+) cells mediate cardiac allograft tolerance by ECDI-fixed donor splenocyte infusions. <b>2012</b> , 12, 2920-9		50
2275	Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma. <b>2012</b> , 189, 5147-54		90
2274	Tailor-made renal cell carcinoma vaccines. <b>2012</b> , 22, 287-9		3
2273	Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. <b>2012</b> , 2, 628-39		152
2272	The multi-faceted roles of prostaglandin E2 in cancer-infiltrating mononuclear phagocyte biology. <b>2012</b> , 217, 1225-32		19
2271	Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. <b>2012</b> , 490, 412-6		397
2270	Tumor-induced myeloid-derived suppressor cell function is independent of IFN- $\gamma$ and IL-4R $\alpha$ . <b>2012</b> , 42, 2052-9		58
2269	From China to Glasgow. <b>2012</b> , 42, i-ii		
2268	CD11b+Ly6C++Ly6G- cells show distinct function in mice with chronic inflammation or tumor burden. <b>2012</b> , 13, 69		19

2267	Myeloid cells in tumor inflammation. <b>2012</b> , 4, 14		50
2266	Cellular immune suppressor mechanisms in patients with hepatocellular carcinoma. <b>2012</b> , 30, 477-82		28
2265	The tumor microenvironment at a glance. <b>2012</b> , 125, 5591-6		1029
2264	Anti-tumor immunity: myeloid leukocytes control the immune landscape. <b>2012</b> , 278, 21-6		18
2263	Myeloid-derived suppressor cells (MDSCs) in gliomas and glioma-development. <b>2012</b> , 41, 658-79		44
2262	Mechanical disruption of tumors by iron particles and magnetic field application results in increased anti-tumor immune responses. <b>2012</b> , 7, e48049		23
2261	M1 and M2 Macrophages: Oracles of Health and Disease. <b>2012</b> , 32, 463-88		635
2260	Cancer as an immune-mediated disease. <b>2012</b> , 1, 1-6		22
2259	Recent Advances in Immunotherapy of Lung Cancer. <b>2012</b> , 11, 1		1
2258	Adoptive immunotherapy for cancer: harnessing the T cell response. <i>Nature Reviews Immunology</i> , <b>2012</b> , 12, 269-81	36.5	1192
2257	The tumor immunosuppressive microenvironment impairs the therapy of anti-HER2/neu antibody. <b>2012</b> , 3, 441-9		5
2256	Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. <b>2012</b> , 22, 275-81		378
2255	Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response to NAC. <b>2013</b> , 11, 16		39
2254	Multifaceted roles of PGE2 in inflammation and cancer. <b>2013</b> , 35, 123-37		376
2253	Monocytes and macrophages in cancer: development and functions. <b>2013</b> , 6, 179-91		112
2252	Mast cells and macrophages exert beneficial and detrimental effects on tumor progression and angiogenesis. <b>2013</b> , 152, 83-8		61
2251	The role and potential therapeutic application of myeloid-derived suppressor cells in TNBS-induced colitis. <b>2013</b> , 94, 803-11		43
2250	CaMKK2: a novel target for shaping the androgen-regulated tumor ecosystem. <b>2013</b> , 19, 83-8		17

2249	Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer. <b>2013</b> , 1, 10	215
2248	<i>Fusobacterium nucleatum</i> potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. <b>2013</b> , 14, 207-15	1275
2247	Modulation of CD8(+) T-cell activation events by monocytic and granulocytic myeloid-derived suppressor cells. <b>2013</b> , 218, 1385-91	34
2246	Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. <b>2013</b> , 62, 909-18	215
2245	Protumor and antitumor functions of neutrophil granulocytes. <b>2013</b> , 35, 163-76	103
2244	An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. <b>2013</b> , 19, 1114-23	321
2243	The role of CD200-CD200R in tumor immune evasion. <b>2013</b> , 328, 65-76	16
2242	Putting the brakes on anticancer therapies: suppression of innate immune pathways by tumor-associated myeloid cells. <b>2013</b> , 19, 536-45	12
2241	A novel role of hematopoietic CCL5 in promoting triple-negative mammary tumor progression by regulating generation of myeloid-derived suppressor cells. <b>2013</b> , 23, 394-408	90
2240	IL-17 mediates resistance to anti-VEGF therapy. <b>2013</b> , 19, 1092-4	21
2239	Proliferating macrophages prevail in atherosclerosis. <b>2013</b> , 19, 1094-5	37
2238	Deciphering and reversing tumor immune suppression. <b>2013</b> , 39, 61-73	392
2237	The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. <b>2013</b> , 15, 848-62	289
2236	Blockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma. <b>2013</b> , 15, 1400-9	101
2235	Multipotent human mesenchymal stromal cells mediate expansion of myeloid-derived suppressor cells via hepatocyte growth factor/c-met and STAT3. <b>2013</b> , 1, 139-51	105
2234	Standard therapies versus novel therapies in Hodgkin lymphoma. <b>2013</b> , 155, 56-9	9
2233	Inflammatory networks and immune surveillance of pancreatic carcinoma. <b>2013</b> , 25, 200-5	134
2232	Dysregulated hematopoiesis caused by mammary cancer is associated with epigenetic changes and hox gene expression in hematopoietic cells. <b>2013</b> , 73, 5892-904	29

2231	Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events. <b>2013</b> , 43, 2930-42	61
2230	Mesenchymal stromal cells: sensors and switchers of inflammation. <b>2013</b> , 13, 392-402	877
2229	Influence of tumour micro-environment heterogeneity on therapeutic response. <b>2013</b> , 501, 346-54	1579
2228	Exploiting dendritic cells in the development of cancer vaccines. <b>2013</b> , 12, 1195-210	12
2227	Tumor-induced Myeloid-derived Suppressor Cells. <b>2013</b> , 473-496	2
2226	Arginase, Nitric Oxide Synthase, and Novel Inhibitors of L-arginine Metabolism in Immune Modulation. <b>2013</b> , 597-634	2
2225	Immunologically augmented cancer treatment using modern radiotherapy. <b>2013</b> , 19, 565-82	73
2224	The emerging role of immunosurveillance in dictating metastatic spread in breast cancer. <b>2013</b> , 73, 5852-7	43
2223	Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow. <b>2013</b> , 190, 3815-23	146
2222	Microenvironmental regulation of tumor progression and metastasis. <b>2013</b> , 19, 1423-37	3959
2221	CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. <b>2013</b> , 24, 631-44	306
2220	The spleen in local and systemic regulation of immunity. <b>2013</b> , 39, 806-18	477
2219	Myeloid derived suppressor cells in physiological and pathological conditions: the good, the bad, and the ugly. <b>2013</b> , 57, 172-84	80
2218	Reciprocal relationship between myeloid-derived suppressor cells and T cells. <b>2013</b> , 191, 17-23	132
2217	A new twist on radiation oncology: low-dose irradiation elicits immunostimulatory macrophages that unlock barriers to tumor immunotherapy. <b>2013</b> , 24, 559-61	29
2216	Immune-checkpoint blockade and active immunotherapy for glioma. <b>2013</b> , 5, 1379-412	31
2215	Myeloid-derived suppressor cell function is reduced by Withaferin A, a potent and abundant component of Withania somnifera root extract. <b>2013</b> , 62, 1663-73	41
2214	Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression. <b>2013</b> , 62, 1745-56	210

2213	Arginase-1 mRNA expression correlates with myeloid-derived suppressor cell levels in peripheral blood of NSCLC patients. <b>2013</b> , 81, 468-474	53
2212	Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer. <b>2013</b> , 122, 1105-13	115
2211	Chronic myeloid leukemic cells trigger poly(ADP-ribose) polymerase-dependent inactivation and cell death in lymphocytes. <b>2013</b> , 93, 155-60	14
2210	Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer. <b>2013</b> , 73, 672-82	125
2209	Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. <b>2013</b> , 73, 1128-41	644
2208	Molecular pathways: comparing the effects of drugs and T cells to effectively target oncogenes. <b>2013</b> , 19, 320-6	11
2207	Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. <b>2013</b> , 14, 211-20	252
2206	The dichotomy of neutrophil granulocytes in cancer. <b>2013</b> , 23, 139-40	20
2205	Premetastatic soil and prevention of breast cancer brain metastasis. <b>2013</b> , 15, 891-903	54
2204	Preconditioning thermal therapy: flipping the switch on IL-6 for anti-tumour immunity. <b>2013</b> , 29, 464-73	25
2203	Targeting tumor-infiltrating macrophages to combat cancer. <b>2013</b> , 5, 1075-87	122
2202	The emerging "hallmarks" of metabolic reprogramming and immune evasion: distinct or linked?. <b>2013</b> , 73, 2737-42	84
2201	The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. <b>2013</b> , 138, 105-15	491
2200	Myeloid-cell differentiation redefined in cancer. <b>2013</b> , 14, 197-9	18
2199	Changing course by lymphocyte lineage redirection. <b>2013</b> , 14, 199-201	5
2198	Macrophage regulation of tumor responses to anticancer therapies. <b>2013</b> , 23, 277-86	724
2197	Dichloroacetate improves immune dysfunction caused by tumor-secreted lactic acid and increases antitumor immunoreactivity. <b>2013</b> , 133, 1107-18	93
2196	Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. <b>2013</b> , 190, 3783-97	376

2195	Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion. <b>2013</b> , 19, 465-72	328
2194	Using macrophage activation to augment immunotherapy of established tumours. <b>2013</b> , 108, 1288-97	48
2193	Applying pressure on macrophages. <b>2013</b> , 38, 205-6	2
2192	Angiotensin II drives the production of tumor-promoting macrophages. <b>2013</b> , 38, 296-308	129
2191	Collapse of the tumor stroma is triggered by IL-12 induction of Fas. <b>2013</b> , 21, 1369-77	54
2190	Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. <b>2013</b> , 38, 729-41	439
2189	Redox control of inflammation in macrophages. <b>2013</b> , 19, 595-637	236
2188	The kinship of neutrophils and granulocytic myeloid-derived suppressor cells in cancer: cousins, siblings or twins?. <b>2013</b> , 23, 171-82	114
2187	The pre-metastatic niche: finding common ground. <b>2013</b> , 32, 449-64	298
2186	Tumor microenvironment and myeloid-derived suppressor cells. <b>2013</b> , 6, 169-77	90
2185	Neutrophils in innate and adaptive immunity. <b>2013</b> , 35, 377-94	169
2184	Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies. <b>2013</b> , 62, 299-307	50
2183	Central and peripheral nervous systems: master controllers in cancer metastasis. <b>2013</b> , 32, 603-21	25
2182	Myeloid-derived suppressor cells in cancer: recent progress and prospects. <b>2013</b> , 91, 493-502	168
2181	Myeloid-derived suppressor cells in breast cancer. <b>2013</b> , 140, 13-21	118
2180	The Tumor Immunoenvironment. <b>2013</b> ,	3
2179	Cell-extrinsic effects of the tumor unfolded protein response on myeloid cells and T cells. <b>2013</b> , 1284, 6-11	16
2178	Reactive oxygen species in the immune system. <b>2013</b> , 32, 249-70	253

2177	Exposing a deadly alliance: novel insights into the biological links between COPD and lung cancer. <b>2013</b> , 26, 544-54	33
2176	Modulation of bacterial ghosts--induced nitric oxide production in macrophages by bacterial ghost-delivered resveratrol. <b>2013</b> , 280, 1214-25	13
2175	From tumor cell metabolism to tumor immune escape. <b>2013</b> , 45, 106-13	64
2174	Innate immune cells in inflammation and cancer. <b>2013</b> , 1, 77-84	83
2173	Monocytic myeloid-derived suppressor cells accumulate in renal transplant patients and mediate CD4(+) Foxp3(+) Treg expansion. <b>2013</b> , 13, 3123-31	110
2172	Cancer vaccination by electro-gene-transfer. <b>2013</b> , 12, 1127-37	24
2171	Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. <b>2013</b> , 19, 3404-15	360
2170	Immune microenvironment profiles of tumor immune equilibrium and immune escape states of mouse sarcoma. <b>2013</b> , 340, 124-33	42
2169	The oxysterol-CXCR2 axis plays a key role in the recruitment of tumor-promoting neutrophils. <b>2013</b> , 210, 1711-28	127
2168	Tumor-infiltrating CD14-positive myeloid cells and CD8-positive T-cells prolong survival in patients with cervical carcinoma. <b>2013</b> , 133, 2884-94	75
2167	Carbon nanotubes enhance metastatic growth of lung carcinoma via up-regulation of myeloid-derived suppressor cells. <b>2013</b> , 9, 1691-5	51
2166	The role of IL-1 $\beta$ in the early tumor cell-induced angiogenic response. <b>2013</b> , 190, 3500-9	136
2165	Mobilizing and evaluating anticancer T cells: pitfalls and solutions. <b>2013</b> , 12, 1325-40	4
2164	Pathological mobilization and activities of dendritic cells in tumor-bearing hosts: challenges and opportunities for immunotherapy of cancer. <b>2013</b> , 4, 435	16
2163	The tumor microenvironment: a pitch for multiple players. <b>2013</b> , 3, 90	102
2162	Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes. <b>2013</b> , 3, 231	102
2161	Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy. <b>2013</b> , 3, 63	66
2160	The irradiated tumor microenvironment: role of tumor-associated macrophages in vascular recovery. <b>2013</b> , 4, 157	86



2159	Trp53 inactivation in the tumor microenvironment promotes tumor progression by expanding the immunosuppressive lymphoid-like stromal network. <b>2013</b> , 73, 1668-75	45
2158	Enhancement of antitumor immunity in lung cancer by targeting myeloid-derived suppressor cell pathways. <b>2013</b> , 73, 6609-20	62
2157	Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics. <b>2013</b> , 19, 353-64	43
2156	Myeloid-derived suppressor cells as osteoclast progenitors: a novel target for controlling osteolytic bone metastasis. <b>2013</b> , 73, 4606-10	56
2155	Cyclooxygenase-2. <b>2013</b> , 2, e25157	1
2154	Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer. <b>2013</b> , 19, 490-501	48
2153	Myeloid-derived suppressor cells in allogeneic hematopoietic stem cell transplantation: A double-edged sword?. <b>2013</b> , 2, e25009	9
2152	Deregulation of apoptotic factors Bcl-xL and Bax confers apoptotic resistance to myeloid-derived suppressor cells and contributes to their persistence in cancer. <b>2013</b> , 288, 19103-15	54
2151	A novel probe for the non-invasive detection of tumor-associated inflammation. <b>2013</b> , 2, e23034	80
2150	Use of CpG oligonucleotides for cancer immunotherapy and their effect on immunity in the tumor microenvironment. <b>2013</b> , 5, 787-9	7
2149	Temperature matters! And why it should matter to tumor immunologists. <b>2013</b> , 1, 210-6	129
2148	Mast cell-deficient Kit(W-sh) "Sash" mutant mice display aberrant myelopoiesis leading to the accumulation of splenocytes that act as myeloid-derived suppressor cells. <b>2013</b> , 190, 5534-44	32
2147	Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. <b>2013</b> , 73, 3007-18	267
2146	Unique Versus Redundant Functions of IL-1 $\beta$ and IL-1 $\alpha$ in the Tumor Microenvironment. <b>2013</b> , 4, 177	78
2145	Immunosuppressive microenvironment in neuroblastoma. <b>2013</b> , 3, 167	49
2144	Dendritic Cell Plasticity in Tumor-Conditioned Skin: CD14(+) Cells at the Cross-Roads of Immune Activation and Suppression. <b>2013</b> , 4, 403	26
2143	Tumor-altered dendritic cell function: implications for anti-tumor immunity. <b>2013</b> , 4, 192	74
2142	Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer. <b>2013</b> , 3, 49	114

2141	Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation. <b>2013</b> , 2, e22837	22
2140	The S100A8/A9 complex reduces CTLA4 expression by immature myeloid cells: Implications for pancreatic cancer-driven immunosuppression. <b>2013</b> , 2, e24441	11
2139	Infection and cancer: reevaluation of the hygiene hypothesis. <b>2013</b> , 19, 2834-41	43
2138	Ret transgenic mouse model of spontaneous skin melanoma: focus on regulatory T cells. <b>2013</b> , 26, 457-63	9
2137	Local expression of interleukin-2 by B16 melanoma cells results in decreased tumour growth and long-term tumour dormancy. <b>2013</b> , 138, 280-92	16
2136	Schedule-dependent therapeutic efficacy of L19mTNF- $\alpha$ and melphalan combined with gemcitabine. <b>2013</b> , 2, 478-87	12
2135	Regulators with potential: substantiating myeloid-derived suppressor cells in human organ transplantation. <b>2013</b> , 13, 3061-2	4
2134	Functional characterization of a STAT3-dependent dendritic cell-derived CD14 cell population arising upon IL-10-driven maturation. <b>2013</b> , 2, e23837	26
2133	Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. <b>2013</b> , 19, 4079-91	213
2132	Myeloid-derived suppressor cells as a Trojan horse: A cellular vehicle for the delivery of oncolytic viruses. <b>2013</b> , 2, e25083	12
2131	Eradication of liver-implanted tumors by Semliki Forest virus expressing IL-12 requires efficient long-term immune responses. <b>2013</b> , 190, 2994-3004	14
2130	Hypoxia-driven immunosuppression contributes to the pre-metastatic niche. <b>2013</b> , 2, e22355	51
2129	The immunological profile of tumor-bearing animals determines the outcome of cancer immunotherapy. <b>2013</b> , 2, e24499	3
2128	Tumor-derived lactate and myeloid-derived suppressor cells: Linking metabolism to cancer immunology. <b>2013</b> , 2, e26383	60
2127	Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma. <b>2013</b> , 2, e23562	110
2126	Myeloid-derived suppressor cells in glioma. <b>2013</b> , 13, 1395-406	29
2125	Vascular normalization as an emerging strategy to enhance cancer immunotherapy. <b>2013</b> , 73, 2943-8	398
2124	Hypoxia-mediated regulation of macrophage functions in pathophysiology. <b>2013</b> , 25, 67-75	58

2123	KIT oncogene inhibition drives intratumoral macrophage M2 polarization. <b>2013</b> , 210, 2873-86	95
2122	New roles of Rb1 in expansion of MDSCs in cancer. <b>2013</b> , 12, 1329-30	9
2121	Myeloid-derived suppressor cells as a novel target for the control of osteolytic bone disease. <b>2013</b> , 2, e24064	11
2120	Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model. <b>2013</b> , 190, 2464-71	156
2119	Potential therapeutic anti-tumor effect of a Salmonella-based vaccine. <b>2013</b> , 9, 1654-60	12
2118	A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous metastasis through IL-6 trans-signaling in a murine model. <b>2013</b> , 15, R79	99
2117	Differently immunogenic cancers in mice induce immature myeloid cells that suppress CTL in vitro but not in vivo following transfer. <b>2013</b> , 121, 1740-8	21
2116	Cancer makes new friends with old tricks. <b>2013</b> , 122, 1093-4	3
2115	HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. <b>2013</b> , 11, 88	124
2114	Recruitment of a myeloid cell subset (CD11b/Gr1 mid) via CCL2/CCR2 promotes the development of colorectal cancer liver metastasis. <b>2013</b> , 57, 829-39	156
2113	Myeloid-derived suppressor cells in the inflammatory bowel diseases. <b>2013</b> , 19, 2468-77	39
2112	The role of tumor-associated macrophages in tumor vascularization. <b>2013</b> , 5, 20	76
2111	Hypoxia Immunity, Metabolism, and Hyperthermia. <b>2013</b> , 2013, 1-5	
2110	Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. <b>2013</b> , 8, e57114	183
2109	Common interactions between S100A4 and S100A9 defined by a novel chemical probe. <b>2013</b> , 8, e63012	30
2108	Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go. <b>2013</b> , 4, 417	53
2107	Immunosuppressive MDSCs induced by TLR signaling during infection and role in resolution of inflammation. <b>2013</b> , 3, 52	71
2106	The immunologic basis for severe neonatal herpes disease and potential strategies for therapeutic intervention. <b>2013</b> , 2013, 369172	33

2105	The controversial role of microglia in malignant gliomas. <b>2013</b> , 2013, 285246	132
2104	Protumor activities of the immune response: insights in the mechanisms of immunological shift, oncotraining, and oncopromotion. <b>2013</b> , 2013, 835956	35
2103	Inhibition of CSF-1R supports T-cell mediated melanoma therapy. <b>2014</b> , 9, e104230	41
2102	Role of the ERK pathway for oxidant-induced parthanatos in human lymphocytes. <b>2014</b> , 9, e89646	25
2101	Dendritic cell-secreted lipocalin2 induces CD8+ T-cell apoptosis, contributes to T-cell priming and leads to a TH1 phenotype. <b>2014</b> , 9, e101881	21
2100	Feasibility of Applying Helper-Dependent Adenoviral Vectors for Cancer Immunotherapy. <b>2014</b> , 2, 110-131	3
2099	Six-color intravital two-photon imaging of brain tumors and their dynamic microenvironment. <b>2014</b> , 8, 57	47
2098	Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. <b>2014</b> , 124, 5466-80	330
2097	A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice. <b>2014</b> , 5, 7843-57	51
2096	Immunological deregulation in classic hodgkin lymphoma. <b>2014</b> , 6, e2014039	13
2095	Myeloid-derived suppressor cells in autoimmune diseases. <b>2014</b> , 34, 124-128	1
2094	Myeloid Derived Suppressor Cells: Fuel the Fire. <b>2014</b> , 3, e123	10
2093	Complex role for the immune system in initiation and progression of pancreatic cancer. <b>2014</b> , 20, 11160-81	85
2092	The preoperative lymphocyte to monocyte ratio predicts clinical outcomes in patients with stage II/III gastric cancer. <b>2014</b> , 35, 11659-66	52
2091	The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment. <b>2014</b> , 7, 807-18	43
2090	The dual targeting of immunosuppressive cells and oxidants promotes effector and memory T-cell functions against lung cancer. <b>2014</b> , 3, e27401	4
2089	Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses. <b>2014</b> , 3, e27622	18
2088	Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination. <b>2014</b> , 10, 3251-60	33

2087	slanDCs selectively accumulate in carcinoma-draining lymph nodes and marginate metastatic cells. <b>2014</b> , 5, 3029	31
2086	Targeting the IL-12/IL-23 axis: An alternative approach to removing tumor induced immune suppression. <b>2014</b> , 3, e28964	6
2085	Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies. <b>2014</b> , 10, 3125-31	44
2084	Intermittent hypoxia-induced changes in tumor-associated macrophages and tumor malignancy in a mouse model of sleep apnea. <b>2014</b> , 189, 593-601	132
2083	Myeloid-derived cells are key targets of tumor immunotherapy. <b>2014</b> , 3, e28398	44
2082	Peptide-based vaccines for cancer therapy. <b>2014</b> , 10, 3175-8	52
2081	Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. <b>2014</b> , 21, 15-25	526
2080	Monocytic myeloid-derived suppressor cells in advanced melanoma patients: Indirect impact on prognosis through inhibition of tumor-specific T-cell responses?. <b>2014</b> , 3, e27845	16
2079	Aberrant expression of sphingosine-1-phosphate receptor 1 correlates with metachronous liver metastasis and poor prognosis in colorectal cancer. <b>2014</b> , 35, 9743-50	10
2078	Targeting hypoxia at the forefront of anticancer immune responses. <b>2014</b> , 3, e954463	47
2077	Deficiency of Kruppel-like factor KLF4 in myeloid-derived suppressor cells inhibits tumor pulmonary metastasis in mice accompanied by decreased fibrocytes. <b>2014</b> , 3, e129	27
2076	The roles of myeloid-derived suppressor cells in transplantation. <b>2014</b> , 10, 1385-94	26
2075	A multidisciplinary study using in vivo tumor models and microfluidic cell-on-chip approach to explore the cross-talk between cancer and immune cells. <b>2014</b> , 11, 337-46	38
2074	Dendritic cell defects in the colorectal cancer. <b>2014</b> , 10, 3224-35	53
2073	ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment. <b>2014</b> , 5, e1135	83
2072	Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells. <b>2014</b> , 20, 1601-9	192
2071	The impact of the TIM gene family on tumor immunity and immunosuppression. <b>2014</b> , 11, 41-8	21
2070	Modulation of bone morphogenic protein signaling in T-cells for cancer immunotherapy. <b>2014</b> , 11, 319-27	13

2069	Pancreatic Cancer Cells Isolated from Muc1-Null Tumors Favor the Generation of a Mature Less Suppressive MDSC Population. <b>2014</b> , 5, 67	8
2068	Baccatin III, a precursor for the semisynthesis of paclitaxel, inhibits the accumulation and suppressive activity of myeloid-derived suppressor cells in tumor-bearing mice. <b>2014</b> , 21, 487-93	11
2067	Targeting angiogenesis and tumor microenvironment in metastatic colorectal cancer: role of aflibercept. <b>2014</b> , 2014, 526178	39
2066	Immune escape mechanisms in colorectal cancer pathogenesis and liver metastasis. <b>2014</b> , 2014, 686879	63
2065	Stressful presentations: mild cold stress in laboratory mice influences phenotype of dendritic cells in naïve and tumor-bearing mice. <b>2014</b> , 5, 23	31
2064	Orchestration of angiogenesis by immune cells. <b>2014</b> , 4, 131	74
2063	The role of inflammation in kidney cancer. <b>2014</b> , 816, 197-234	62
2062	Boosting the MHC Class II-Restricted Tumor Antigen Presentation to CD4+ T Helper Cells: A Critical Issue for Triggering Protective Immunity and Re-Orienting the Tumor Microenvironment Toward an Anti-Tumor State. <b>2014</b> , 4, 32	33
2061	Tumor cells hijack macrophages via lactic acid. <b>2014</b> , 92, 647-9	27
2060	Combinations of immunotherapy and radiation in cancer therapy. <b>2014</b> , 4, 325	164
2059	Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities. <b>2014</b> , 4, 348	48
2058	Monocytic cell differentiation from band-stage neutrophils under inflammatory conditions via MKK6 activation. <b>2014</b> , 124, 2713-24	30
2057	Myeloid colony-stimulating factors as regulators of macrophage polarization. <b>2014</b> , 5, 554	113
2056	The role IL-1 in tumor-mediated angiogenesis. <b>2014</b> , 5, 114	136
2055	Specific Inhibition of the VEGFR-3 Tyrosine Kinase by SAR131675 Reduces Peripheral and Tumor Associated Immunosuppressive Myeloid Cells. <b>2014</b> , 6, 472-90	22
2054	Dissecting the role of bone marrow stromal cells on bone metastases. <b>2014</b> , 2014, 875305	17
2053	A novel strategy for inducing the antitumor effects of triterpenoid compounds: blocking the protumoral functions of tumor-associated macrophages via STAT3 inhibition. <b>2014</b> , 2014, 348539	39
2052	Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse. <b>2014</b> , 134, 32-42	168

2051 Bacterial Vaccines. **2014**, 1-18

2050 Tumor-induced STAT3 signaling in myeloid cells impairs dendritic cell generation by decreasing PKC $\beta$  abundance. **2014**, 7, ra16 34

2049 Chemokines in cancer. **2014**, 2, 1125-31 299

2048 Trafficking of T cells into tumors. **2014**, 74, 7168-74 225

2047 Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes. **2014**, 2, 812-21 97

2046 Exposure to cigarette smoke impacts myeloid-derived regulatory cell function and exacerbates airway hyper-responsiveness. **2014**, 94, 1312-25 5

2045 Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways. **2014**, 41, 947-59 101

2044 Adoptive cellular therapy of cancer: exploring innate and adaptive cellular crosstalk to improve anti-tumor efficacy. **2014**, 10, 1779-94 7

2043 Intravital imaging reveals distinct responses of depleting dynamic tumor-associated macrophage and dendritic cell subpopulations. **2014**, 111, E5086-95 79

2042 Advances in Tumor Immunology and Immunotherapy. **2014**, 0

2041 Exploiting the curative potential of adoptive T-cell therapy for cancer. **2014**, 257, 56-71 338

2040 Nano-Oncologicals. **2014**, 4

2039 Combretastatin (CA)-4 and its novel analogue CA-432 impair T-cell migration through the Rho/ROCK signalling pathway. **2014**, 92, 544-57 12

2038 CD40L gene therapy tilts the myeloid cell profile and promotes infiltration of activated T lymphocytes. **2014**, 21, 95-102 14

2037 Impact of prostate inflammation on lesion development in the POET3(+)/Pten(+/-) mouse model of prostate carcinogenesis. **2014**, 184, 3176-91 8

2036 Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells. **2014**, 134, 1810-22 36

2035 Tumour-induced immune suppression: role of inflammatory mediators released by myelomonocytic cells. **2014**, 276, 154-70 43

2034 Immune regulation of bone metastasis. **2014**, 3, 600 24

2033	Tumor-associated macrophages exhibit pro- and anti-inflammatory properties by which they impact on pancreatic tumorigenesis. <b>2014</b> , 135, 843-61	170
2032	Complexity and challenges in defining myeloid-derived suppressor cells. <b>2014</b> ,	82
2031	Nanotechnology Approaches for Cancer Immunotherapy and Immunomodulation. <b>2014</b> , 215-242	0
2030	Origin and pharmacological modulation of tumor-associated regulatory dendritic cells. <b>2014</b> , 134, 2633-45	39
2029	Oxidized lipids block antigen cross-presentation by dendritic cells in cancer. <b>2014</b> , 192, 2920-31	142
2028	Myeloid-derived suppressor cells are key players in the resolution of inflammation during a model of acute infection. <b>2014</b> , 44, 184-94	51
2027	Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. <b>2014</b> , 111, 11774-9	426
2026	Mild cold-stress depresses immune responses: Implications for cancer models involving laboratory mice. <b>2014</b> , 36, 884-91	24
2025	A Systems Biology Approach to Blood. <b>2014</b> ,	2
2024	Lessons from patient-derived xenografts for better in vitro modeling of human cancer. <b>2014</b> , 79-80, 222-37	126
2023	MIF deficiency does not alter glucose homeostasis or adipose tissue inflammatory cell infiltrates during diet-induced obesity. <b>2014</b> , 22, 418-25	8
2022	Myeloid-derived suppressor cells in the development of lung cancer. <b>2014</b> , 2, 50-8	75
2021	Targeting the adenosine A2b receptor in the tumor microenvironment overcomes local immunosuppression by myeloid-derived suppressor cells. <b>2014</b> , 3, e27989	21
2020	Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. <b>2014</b> , 74, 153-161	199
2019	Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab. <b>2014</b> , 2, 31	68
2018	Myeloid-derived suppressor cells link inflammation to cancer. <b>2014</b> , 3, e28581	7
2017	Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression. <b>2014</b> , 3, e28499	51
2016	TNFR2 maintains adequate IL-12 production by dendritic cells in inflammatory responses by regulating endogenous TNF levels. <b>2014</b> , 20, 712-20	11



2015	DNA demethylating agent 5-azacytidine inhibits myeloid-derived suppressor cells induced by tumor growth and cyclophosphamide treatment. <b>2014</b> , 95, 743-753	38
2014	Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. <b>2014</b> , 6, 237ra67	432
2013	Immunoguiding, the Final Frontier in the Immunotherapy of Cancer. <b>2014</b> , 37-51	
2012	Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer. <b>2014</b> , 3, e962397	22
2011	A novel cinnamide YLT26 induces breast cancer cells apoptosis via ROS-mitochondrial apoptotic pathway in vitro and inhibits lung metastasis in vivo. <b>2014</b> , 34, 1863-76	29
2010	A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients. <b>2014</b> , 2014, 659294	80
2009	Is Infant Immunity Actively Suppressed or Immature?. <b>2014</b> , 2014, 1-9	25
2008	Therapeutic implications of immunogenic cell death in human cancer. <b>2014</b> , 4, 503	19
2007	The role of myeloid cell activation and arginine metabolism in the pathogenesis of virus-induced diseases. <b>2014</b> , 5, 428	47
2006	The emerging immunological role of post-translational modifications by reactive nitrogen species in cancer microenvironment. <b>2014</b> , 5, 69	48
2005	Mechanisms driving macrophage diversity and specialization in distinct tumor microenvironments and parallelisms with other tissues. <b>2014</b> , 5, 127	113
2004	TGFβ inhibition prior to hypofractionated radiation enhances efficacy in preclinical models. <b>2014</b> , 2, 1011-22	40
2003	CD14(+) HLA-DR low/(-) monocytes as indicator of disease aggressiveness in B-cell non-Hodgkin lymphoma. <b>2014</b> , 36, 650-5	15
2002	The heterogeneous immune microenvironment in breast cancer is affected by hypoxia-related genes. <b>2014</b> , 219, 158-65	28
2001	A personalized view on cancer immunotherapy. <b>2014</b> , 352, 113-25	45
2000	Critical role of the mTOR pathway in development and function of myeloid-derived suppressor cells in Irf1 <sup>-/-</sup> mice. <b>2014</b> , 184, 397-408	26
1999	Treg cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. <b>2014</b> , 40, 785-800	325
1998	The synthetic retinoid Am80 delays recovery in a model of multiple sclerosis by modulating myeloid-derived suppressor cell fate and viability. <b>2014</b> , 67, 149-64	18

1997	The immune network in pancreatic cancer development and progression. <b>2014</b> , 33, 2956-67	136
1996	Integrating new discoveries into the "vicious cycle" paradigm of prostate to bone metastases. <b>2014</b> , 33, 511-25	58
1995	Harnessing the immune system for the treatment of breast cancer. <b>2014</b> , 15, 1-15	24
1994	Antitumor immune responses induced by ionizing irradiation and further immune stimulation. <b>2014</b> , 63, 29-36	103
1993	Ion channels and anti-cancer immunity. <b>2014</b> , 369, 20130106	32
1992	Challenges facing the development of cancer vaccines. <b>2014</b> , 1139, 543-53	5
1991	Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. <b>2014</b> , 63, 247-57	367
1990	Interleukin 12: still a promising candidate for tumor immunotherapy?. <b>2014</b> , 63, 419-35	261
1989	In vivo evidence that secretion of HLA-G by immunogenic tumor cells allows their evasion from immunosurveillance. <b>2014</b> , 135, 2107-17	51
1988	The immune contexture of primary and metastatic human tumours. <b>2014</b> , 27, 8-15	85
1987	Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. <b>2014</b> , 74, 104-18	247
1986	CD11b+ Ly6Chi Ly6G- immature myeloid cells recruited in response to Salmonella enterica serovar Typhimurium infection exhibit protective and immunosuppressive properties. <b>2014</b> , 82, 2606-14	35
1985	T helper 17 cells play a critical pathogenic role in lung cancer. <b>2014</b> , 111, 5664-9	205
1984	The colon cancer stem cell microenvironment holds keys to future cancer therapy. <b>2014</b> , 18, 1040-8	28
1983	Effect of tumor cells and tumor microenvironment on NK-cell function. <b>2014</b> , 44, 1582-92	237
1982	Extracellular adenosine metabolism in immune cells in melanoma. <b>2014</b> , 63, 1073-80	42
1981	T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. <b>2014</b> , 4, 522-6	246
1980	Obesity corrupts myelopoiesis. <b>2014</b> , 19, 735-6	10

1979	PD-L1 is a novel direct target of HIF-1 $\beta$ and its blockade under hypoxia enhanced MDSC-mediated T cell activation. <b>2014</b> , 211, 781-90	1136
1978	The two faces of IL-6 in the tumor microenvironment. <b>2014</b> , 26, 38-47	339
1977	Circulating hematopoietic stem and progenitor cells are myeloid-biased in cancer patients. <b>2014</b> , 111, 4221-6	101
1976	"In vitro" 3D models of tumor-immune system interaction. <b>2014</b> , 79-80, 145-54	63
1975	The tumor microenvironment shapes lineage, transcriptional, and functional diversity of infiltrating myeloid cells. <b>2014</b> , 2, 655-67	53
1974	TNF $\beta$ -dependent hematopoiesis following Bcl11b deletion in T cells restricts metastatic melanoma. <b>2014</b> , 192, 1946-53	14
1973	Novel insights into exosome-induced, tumor-associated inflammation and immunomodulation. <b>2014</b> , 28, 51-7	58
1972	Inflammatory cytokines in human pancreatic cancer. <b>2014</b> , 345, 157-63	88
1971	Delayed apoptosis of tumor associated neutrophils in the absence of endogenous IFN $\beta$ . <b>2015</b> , 136, 572-83	45
1970	Cellular and molecular mechanisms in cancer immune escape: a comprehensive review. <b>2014</b> , 10, 41-62	77
1969	Merging the best of both worlds: hybrid lipid-enveloped matrix nanocomposites in drug delivery. <b>2014</b> , 43, 444-72	133
1968	Interaction of Immune and Cancer Cells. <b>2014</b> ,	
1967	Transmission of "split energy" from tumor infiltrating to peripheral NK cells in a manner similar to "infectious tolerance". <b>2014</b> , 82, 129-33	3
1966	Macrophages are more potent immune suppressors ex vivo than immature myeloid-derived suppressor cells induced by metastatic murine mammary carcinomas. <b>2014</b> , 192, 512-22	26
1965	Clinical evaluation of systemic and local immune responses in cancer: time for integration. <b>2014</b> , 63, 45-57	48
1964	Effects of notch signaling on regulation of myeloid cell differentiation in cancer. <b>2014</b> , 74, 141-52	68
1963	Interleukin-30 expression in prostate cancer and its draining lymph nodes correlates with advanced grade and stage. <b>2014</b> , 20, 585-94	38
1962	Primary 4T1 tumor resection provides critical "window of opportunity" for immunotherapy. <b>2014</b> , 31, 185-98	18

1961	Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. <b>2014</b> , 26, 605-22	881
1960	Intravenous immunoglobulin promotes antitumor responses by modulating macrophage polarization. <b>2014</b> , 193, 5181-9	30
1959	Myeloid-derived suppressor cells confer tumor-suppressive functions on natural killer cells via polyinosinic:polycytidylic acid treatment in mouse tumor models. <b>2014</b> , 6, 293-305	30
1958	Myeloid suppressor cells require membrane TNFR2 expression for suppressive activity. <b>2014</b> , 2, 121-30	59
1957	Macrophages: Biology and Role in the Pathology of Diseases. <b>2014</b> ,	8
1956	Tumor-educated myeloid cells: impact the micro- and macroenvironment. <b>2014</b> , 23, 157-8	5
1955	Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways. <b>2014</b> , 134, 2853-64	160
1954	Innate immune cell collaborations instigate transplant tolerance. <b>2014</b> , 14, 2441-3	4
1953	Microfluidic platform for the study of intercellular communication via soluble factor-cell and cell-cell paracrine signaling. <b>2014</b> , 8, 044104	18
1952	Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. <b>2014</b> , 155, 160-75	113
1951	Mechanisms of intimate and long-distance cross-talk between glioma and myeloid cells: how to break a vicious cycle. <b>2014</b> , 1846, 560-75	31
1950	Gangliosides drive the tumor infiltration and function of myeloid-derived suppressor cells. <b>2014</b> , 74, 5449-57	25
1949	Immunotherapy for brain cancer: recent progress and future promise. <b>2014</b> , 20, 3651-9	67
1948	Immunomodulation in cancer. <b>2014</b> , 17, 17-21	24
1947	Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment. <b>2014</b> , 143, 512-9	202
1946	Role of TGF- $\beta$ signaling in generation of CD39 <sup>+</sup> CD73 <sup>+</sup> myeloid cells in tumors. <b>2014</b> , 193, 3155-64	79
1945	Noncanonical NF- $\kappa$ B activation mediates STAT3-stimulated IDO upregulation in myeloid-derived suppressor cells in breast cancer. <b>2014</b> , 193, 2574-86	128
1944	Acquired and intrinsic resistance in cancer immunotherapy. <b>2014</b> , 8, 1132-9	133

1943	Myeloid-derived suppressor cells in malignant melanoma. <b>2014</b> , 12, 1021-7	33
1942	VDR status arbitrates the prometastatic effects of tumor-associated macrophages. <b>2014</b> , 12, 1181-91	34
1941	Arginine Metabolism, a Major Pathway for the Suppressive Function of Myeloid-Derived Suppressor Cells. <b>2014</b> , 369-386	1
1940	Functional significance of mononuclear phagocyte populations generated through adult hematopoiesis. <b>2014</b> , 96, 969-80	16
1939	Tumor-infiltrating myeloid cells activate Dll4/Notch/TGF- $\beta$ signaling to drive malignant progression. <b>2014</b> , 74, 2038-49	31
1938	Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer. <b>2014</b> , 515, 134-7	211
1937	Ubiquitinated proteins in exosomes secreted by myeloid-derived suppressor cells. <b>2014</b> , 13, 5965-72	33
1936	Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression. <b>2014</b> , 34, 2017-28	74
1935	Impact of myeloid cells on the efficacy of anticancer chemotherapy. <b>2014</b> , 30, 24-31	28
1934	Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes. <b>2014</b> , 2, 436-47	147
1933	Osteopontin shapes immunosuppression in the metastatic niche. <b>2014</b> , 74, 4706-19	84
1932	Tumor-associated macrophages: from mechanisms to therapy. <b>2014</b> , 41, 49-61	2228
1931	Intratumoral CD4+ T lymphodepletion sensitizes poorly immunogenic melanomas to immunotherapy with an OX40 agonist. <b>2014</b> , 134, 1884-1892	11
1930	Myeloid-derived suppressor cell heterogeneity in human cancers. <b>2014</b> , 1319, 47-65	280
1929	Tumour microenvironment of both early- and late-stage colorectal cancer is equally immunosuppressive. <b>2014</b> , 111, 927-32	24
1928	Gr-1dimCD11b+ immature myeloid-derived suppressor cells but not neutrophils are markers of lethal tuberculosis infection in mice. <b>2014</b> , 192, 4718-27	82
1927	Cross-talk among myeloid-derived suppressor cells, macrophages, and tumor cells impacts the inflammatory milieu of solid tumors. <b>2014</b> , 96, 1109-18	108
1926	Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. <b>2014</b> , 32, 2050-8	135

1925	Molecular pathways: myeloid complicity in cancer. <b>2014</b> , 20, 5157-70	37
1924	The protective role of myeloid-derived suppressor cells in concanavalin A-induced hepatic injury. <b>2014</b> , 5, 714-24	19
1923	Dendritic cell-mediated survival signals in EμMyc B-cell lymphoma depend on the transcription factor C/EBPβ. <b>2014</b> , 5, 5057	14
1922	The stress-response sensor chop regulates the function and accumulation of myeloid-derived suppressor cells in tumors. <b>2014</b> , 41, 389-401	155
1921	Human fibrocytic myeloid-derived suppressor cells express IDO and promote tolerance via Treg-cell expansion. <b>2014</b> , 44, 3307-19	81
1920	A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. <b>2014</b> , 16, 1105-17	294
1919	Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer. <b>2014</b> , 63, 513-28	144
1918	Salmonella-mediated tumor regression involves targeting of tumor myeloid suppressor cells causing a shift to M1-like phenotype and reduction in suppressive capacity. <b>2014</b> , 63, 587-99	43
1917	Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer. <b>2014</b> , 2, 14	88
1916	Very small size proteoliposomes abrogate cross-presentation of tumor antigens by myeloid-derived suppressor cells and induce their differentiation to dendritic cells. <b>2014</b> , 2, 5	7
1915	Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. <b>2014</b> , 63, 1769-81	202
1914	Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications. <b>2014</b> , 41, 174-84	128
1913	Adoptive immunotherapy for cancer. <b>2014</b> , 257, 14-38	100
1912	Myeloid suppressors decrease melanoma survival by abating tumor-fighting T cells. <b>2014</b> , 20, 1401-3	2
1911	Immune suppression via glucocorticoid-stimulated monocytes: a novel mechanism to cope with inflammation. <b>2014</b> , 193, 1090-9	22
1910	Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells. <b>2014</b> , 37, 1234-40	47
1909	Krebs und das Immunsystem. <b>2014</b> , 29, 105-111	
1908	Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis. <b>2014</b> , 74, 3441-53	100

1907	Mast cell histamine promotes the immunoregulatory activity of myeloid-derived suppressor cells. <b>2014</b> , 96, 151-9	34
1906	Lung-residing myeloid-derived suppressors display dual functionality in murine pulmonary tuberculosis. <b>2014</b> , 190, 1053-66	110
1905	Cancer-related inflammation and treatment effectiveness. <b>2014</b> , 15, e493-503	945
1904	Tumor-Induced Immune Suppression. <b>2014</b> ,	1
1903	Immunological off-target effects of standard treatments in gastrointestinal cancers. <b>2014</b> , 25, 24-32	37
1902	Editorial: the contribution of myeloid-derived suppression to inflammatory disease. <b>2014</b> , 96, 361-4	7
1901	Bevacizumab plus ipilimumab in patients with metastatic melanoma. <b>2014</b> , 2, 632-42	428
1900	Granulocyte macrophage colony-stimulating factor and the intestinal innate immune cell homeostasis in Crohn's disease. <b>2014</b> , 306, G455-65	34
1899	Angiogenesis and the tumor microenvironment: vascular endothelial growth factor and beyond. <b>2014</b> , 41, 235-51	104
1898	CD68(+)HLA-DR(+) M1-like macrophages promote motility of HCC cells via NF- $\kappa$ B/FAK pathway. <b>2014</b> , 345, 91-9	55
1897	Host immune response to infection and cancer: unexpected commonalities. <b>2014</b> , 15, 295-305	99
1896	The ground state of innate immune responsiveness is determined at the interface of genetic, epigenetic, and environmental influences. <b>2014</b> , 193, 13-9	21
1895	Inactivation of PI(3)K p110 $\beta$ breaks regulatory T-cell-mediated immune tolerance to cancer. <b>2014</b> , 510, 407-411	361
1894	VISTA Regulates the Development of Protective Antitumor Immunity. <b>2014</b> , 74, 1933-44	267
1893	Monocyte-derived cells of the brain in malignant gliomas. <b>2014</b> , 82, 1012-4	
1892	Tumor Restrictions to Oncolytic Virus. <b>2014</b> , 2, 163-194	41
1891	GPC3 expression in mouse ovarian cancer induces GPC3-specific T cell-mediated immune response through M1 macrophages and suppresses tumor growth. <b>2014</b> , 32, 913-21	10
1890	Myeloide Suppressorzellen (MDSC) beim malignen Melanom. <b>2014</b> , 12, 1021-1027	13

1889	Regulatory myeloid cells in transplantation. <b>2014</b> , 97, 367-79	25
1888	The Role of Stroma in Tumor Development. <b>2015</b> , 21, 250-3	79
1887	Tumor-induced CD11b(+) Gr-1(+) myeloid-derived suppressor cells exacerbate immune-mediated hepatitis in mice in a CD40-dependent manner. <b>2015</b> , 45, 1148-58	8
1886	Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients. <b>2015</b> , 136, 2352-60	112
1885	In vitro-generated MDSCs prevent murine GVHD by inducing type 2 T cells without disabling antitumor cytotoxicity. <b>2015</b> , 126, 1138-48	59
1884	Severity of DSS-induced colitis is reduced in Ido1-deficient mice with down-regulation of TLR-MyD88-NF- $\kappa$ B transcriptional networks. <b>2015</b> , 5, 17305	48
1883	Myeloid-Derived Suppressor Cells. <b>2015</b> , 1-8	6
1882	The cholesterol-binding protein NPC2 restrains recruitment of stromal macrophage-lineage cells to early-stage lung tumours. <b>2015</b> , 7, 1119-37	14
1881	Physiological Role of TNF in Mucosal Immunology: Regulation of Macrophage/Dendritic Cell Function. 9-26	
1880	Identification of a FOXP3(+)CD3(+)CD56(+) population with immunosuppressive function in cancer tissues of human hepatocellular carcinoma. <b>2015</b> , 5, 14757	12
1879	IL-11 induces differentiation of myeloid-derived suppressor cells through activation of STAT3 signalling pathway. <b>2015</b> , 5, 13650	13
1878	Immunoregulatory Role of Myeloid-derived Cells in Inflammatory Bowel Disease. <b>2015</b> , 21, 2936-47	15
1877	Avian pathogenic Escherichia coli (APEC) infection alters bone marrow transcriptome in chickens. <b>2015</b> , 16, 690	24
1876	The NF- $\kappa$ B p65 and p50 homodimer cooperate with IRF8 to activate iNOS transcription. <b>2015</b> , 15, 770	36
1875	Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastases. <b>2015</b> , 17, 45	73
1874	Differential infiltration of neutrophils in T1-T2 versus T3-T4 oral squamous cell carcinomas: a preliminary study. <b>2015</b> , 8, 569	16
1873	Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients. <b>2015</b> , 3, 54	30
1872	Secreted IL-1 $\beta$ promotes T-cell activation and expansion of CD11b(+) Gr1(+) cells in carbon tetrachloride-induced liver injury in mice. <b>2015</b> , 45, 2084-98	10



1871	Myeloid cells in hepatocellular carcinoma. <b>2015</b> , 62, 1304-12	83
1870	The Monocyte That Wasn't. <b>2015</b> , 43, 1532-4	1
1869	Peripheral myeloid-derived suppressor and T regulatory PD-1 positive cells predict response to neoadjuvant short-course radiotherapy in rectal cancer patients. <b>2015</b> , 6, 8261-70	44
1868	Lymphoma: immune evasion strategies. <b>2015</b> , 7, 736-62	29
1867	IL-17 producing mast cells promote the expansion of myeloid-derived suppressor cells in a mouse allergy model of colorectal cancer. <b>2015</b> , 6, 32966-79	24
1866	Ex vivo generation of myeloid-derived suppressor cells that model the tumor immunosuppressive environment in colorectal cancer. <b>2015</b> , 6, 12369-82	46
1865	A core of kinase-regulated interactomes defines the neoplastic MDSC lineage. <b>2015</b> , 6, 27160-75	39
1864	Manipulation of Innate Immunity for Cancer Therapy in Dogs. <b>2015</b> , 2, 423-439	12
1863	Innate Immunity and Inflammation Post-Stroke: An $\alpha$ -Nicotinic Agonist Perspective. <b>2015</b> , 16, 29029-46	38
1862	Therapeutic potential and challenges of natural killer cells in treatment of solid tumors. <b>2015</b> , 6, 202	102
1861	Critical Role of Tumor Microenvironment in Shaping NK Cell Functions: Implication of Hypoxic Stress. <b>2015</b> , 6, 482	82
1860	Clinical Impact of the Immunome in Lymphoid Malignancies: The Role of Myeloid-Derived Suppressor Cells. <b>2015</b> , 5, 104	7
1859	Myeloid derived suppressor cells in chronic myeloid leukemia. <b>2015</b> , 5, 107	26
1858	Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites. <b>2015</b> , 5, 153	98
1857	Recapitulating the Tumor Ecosystem Along the Metastatic Cascade Using 3D Culture Models. <b>2015</b> , 5, 170	21
1856	Plasticity of neutrophils reveals modulatory capacity. <b>2015</b> , 48, 665-75	30
1855	A method for identification and analysis of non-overlapping myeloid immunophenotypes in humans. <b>2015</b> , 10, e0121546	67
1854	Systemic Monocytic-MDSCs Are Generated from Monocytes and Correlate with Disease Progression in Breast Cancer Patients. <b>2015</b> , 10, e0127028	84

1853	Identification of Reprogrammed Myeloid Cell Transcriptomes in NSCLC. <b>2015</b> , 10, e0129123	17
1852	Rapamycin Promotes Mouse 4T1 Tumor Metastasis that Can Be Reversed by a Dendritic Cell-Based Vaccine. <b>2015</b> , 10, e0138335	10
1851	Myeloid Cell Arg1 Inhibits Control of Arthritogenic Alphavirus Infection by Suppressing Antiviral T Cells. <b>2015</b> , 11, e1005191	14
1850	Myeloid-derived suppressor cells in inflammatory bowel disease. <b>2015</b> , 13, 105-11	15
1849	Prognostic value of the neutrophil to lymphocyte ratio in lung cancer: A meta-analysis. <b>2015</b> , 70, 524-30	95
1848	Bone Marrow Cells in Acute Lymphoblastic Leukemia Create a Proinflammatory Microenvironment Influencing Normal Hematopoietic Differentiation Fates. <b>2015</b> , 2015, 386165	24
1847	Analysis of monocytic and granulocytic myeloid-derived suppressor cells subsets in patients with hepatitis C virus infection and their clinical significance. <b>2015</b> , 2015, 385378	16
1846	Beyond the Immune Suppression: The Immunotherapy in Prostate Cancer. <b>2015</b> , 2015, 794968	14
1845	From mice to humans: developments in cancer immunoediting. <b>2015</b> , 125, 3338-46	188
1844	Molecular Pathways: Targeting Tumor-Infiltrating Myeloid-Derived Suppressor Cells for Cancer Therapy. <b>2015</b> , 21, 3108-12	30
1843	A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy. <b>2015</b> , 23, 1507-18	68
1842	TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients. <b>2015</b> , 21, 3771-82	117
1841	Fusobacterium nucleatum and T Cells in Colorectal Carcinoma. <b>2015</b> , 1, 653-61	336
1840	Inflammatory and Innate Immune Cells in Cancer Microenvironment and Progression. <b>2015</b> , 9-28	4
1839	6-Thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells and enhance the efficacy of T cell immunotherapy in tumor-bearing mice. <b>2015</b> , 64, 1033-46	50
1838	Myeloid-derived suppressor cells in immunity and autoimmunity. <b>2015</b> , 11, 911-9	12
1837	Optical in vivo imaging of the alarmin S100A9 in tumor lesions allows for estimation of the individual malignant potential by evaluation of tumor-host cell interaction. <b>2015</b> , 56, 450-6	24
1836	Spotlights on immunological effects of reactive nitrogen species: When inflammation says nitric oxide. <b>2015</b> , 5, 64-76	48

1835	International society for gastrointestinal hereditary tumours-InSiGHT. <b>2015</b> , 14 Suppl 1, 1-91	1
1834	The Tumor Microenvironment: Cancer-Promoting Networks Beyond Tumor Beds. <b>2015</b> , 128, 235-62	38
1833	Kidney Cancer. <b>2015</b> ,	1
1832	Cancer and the Immune System: Basic Concepts and Targets for Intervention. <b>2015</b> , 42, 523-38	168
1831	Inflammation and skeletal metastasis. <b>2015</b> , 4, 706	17
1830	Wound healing-like immune program facilitates postpartum mammary gland involution and tumor progression. <b>2015</b> , 136, 1803-13	82
1829	Intraepithelial macrophage infiltration is related to a high number of regulatory T cells and promotes a progressive course of HPV-induced vulvar neoplasia. <b>2015</b> , 136, E85-94	29
1828	Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. <b>2015</b> , 28, 690-714	828
1827	Radiotherapy and Immunotherapy: Improving Cancer Treatment through Synergy. <b>2015</b> , 42, 67-78	17
1826	Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment. <b>2015</b> , 3, 53	37
1825	Toll-like Receptor 2 Activation Promotes Tumor Dendritic Cell Dysfunction by Regulating IL-6 and IL-10 Receptor Signaling. <b>2015</b> , 13, 2851-64	75
1824	Histamine promotes the development of monocyte-derived dendritic cells and reduces tumor growth by targeting the myeloid NADPH oxidase. <b>2015</b> , 194, 5014-21	24
1823	MiR-127 modulates macrophage polarization and promotes lung inflammation and injury by activating the JNK pathway. <b>2015</b> , 194, 1239-51	123
1822	Role of Myeloid-Derived Suppressor Cells in Glucocorticoid-Mediated Amelioration of FSGS. <b>2015</b> , 26, 2183-97	25
1821	Dendritic cell-based vaccine research against cancer. <b>2015</b> , 11, 213-32	23
1820	Complexity and challenges in defining myeloid-derived suppressor cells. <b>2015</b> , 88, 77-91	86
1819	Fas and TRAIL 'death receptors' as initiators of inflammation: Implications for cancer. <b>2015</b> , 39, 26-34	51
1818	Immature myeloid cells directly contribute to skin tumor development by recruiting IL-17-producing CD4+ T cells. <b>2015</b> , 212, 351-67	53

1817	Targeting the tumor vasculature to enhance T cell activity. <b>2015</b> , 33, 55-63	169
1816	Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease. <b>2015</b> , 64, 149-59	83
1815	Nitric oxide synthase in innate and adaptive immunity: an update. <b>2015</b> , 36, 161-78	489
1814	SOCS3 Deficiency in Myeloid Cells Promotes Tumor Development: Involvement of STAT3 Activation and Myeloid-Derived Suppressor Cells. <b>2015</b> , 3, 727-40	37
1813	Pam2 lipopeptides systemically increase myeloid-derived suppressor cells through TLR2 signaling. <b>2015</b> , 457, 445-50	28
1812	Microbiota modulation of myeloid cells in cancer therapy. <b>2015</b> , 3, 103-9	28
1811	T-cell-mediated antitumor immunity in B-cell non-Hodgkin lymphoma: activation, suppression and exhaustion. <b>2015</b> , 56, 2498-504	15
1810	Carbonic anhydrase IX promotes myeloid-derived suppressor cell mobilization and establishment of a metastatic niche by stimulating G-CSF production. <b>2015</b> , 75, 996-1008	88
1809	Mechanisms of tumor-induced T cell immune suppression and therapeutics to counter those effects. <b>2015</b> , 38, 1415-33	11
1808	Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage. <b>2015</b> , 3, 557-66	30
1807	Cellular and molecular actions of bisphosphonates. <b>2015</b> , 615-627	1
1806	The tumor microenvironment shapes hallmarks of mature B-cell malignancies. <b>2015</b> , 34, 4673-82	66
1805	IFN regulatory factor 8 represses GM-CSF expression in T cells to affect myeloid cell lineage differentiation. <b>2015</b> , 194, 2369-79	38
1804	High and interrelated rates of PD-L1+CD14+ antigen-presenting cells and regulatory T cells mark the microenvironment of metastatic lymph nodes from patients with cervical cancer. <b>2015</b> , 3, 48-58	75
1803	Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils. <b>2015</b> , 112, E566-75	230
1802	Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic. <b>2015</b> , 67, 46-57	81
1801	The addition of recombinant vaccinia HER2/neu to oncolytic vaccinia-GMCSF given into the tumor microenvironment overcomes MDSC-mediated immune escape and systemic anergy. <b>2015</b> , 22, 154-62	17
1800	Myeloid-derived suppressor cells: paradoxical roles in infection and immunity. <b>2015</b> , 7, 116-26	61

1799	Granulocytic myeloid-derived suppressor cells inversely correlate with plasma arginine and overall survival in critically ill patients. <b>2015</b> , 180, 280-8	19
1798	Immune cell promotion of metastasis. <i>Nature Reviews Immunology</i> , <b>2015</b> , 15, 73-86	36.5 710
1797	Myeloid-derived suppressor cells regulate T cell and B cell responses during autoimmune disease. <b>2015</b> , 97, 573-82	74
1796	Common TLR5 mutations control cancer progression. <b>2015</b> , 27, 1-3	20
1795	Tumor-associated macrophages as an emerging target against tumors: Creating a new path from bench to bedside. <b>2015</b> , 1855, 123-30	68
1794	Tapping CD4 T cells for cancer immunotherapy: the choice of personalized genomics. <b>2015</b> , 194, 2049-56	92
1793	Ebola: translational science considerations. <b>2015</b> , 13, 11	39
1792	The interaction of anticancer therapies with tumor-associated macrophages. <b>2015</b> , 212, 435-45	388
1791	Natural killer T cell activation overcomes immunosuppression to enhance clearance of postsurgical breast cancer metastasis in mice. <b>2015</b> , 4, e995562	34
1790	Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma. <b>2015</b> , 13, 9	48
1789	Differential response of myeloid-derived suppressor cells to the nonsteroidal anti-inflammatory agent indomethacin in tumor-associated and tumor-free microenvironments. <b>2015</b> , 194, 3452-62	21
1788	Heme oxygenase-1 in pregnancy and cancer: similarities in cellular invasion, cytoprotection, angiogenesis, and immunomodulation. <b>2014</b> , 5, 295	38
1787	Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment. <b>2015</b> , 128, 263-307	85
1786	Extracellular vesicle-mediated transfer of functional RNA in the tumor microenvironment. <b>2015</b> , 4, e1008371	182
1785	Tumor-Promoting Effects of Myeloid-Derived Suppressor Cells Are Potentiated by Hypoxia-Induced Expression of miR-210. <b>2015</b> , 75, 3771-87	84
1784	Tristetraprolin Limits Inflammatory Cytokine Production in Tumor-Associated Macrophages in an mRNA Decay-Independent Manner. <b>2015</b> , 75, 3054-64	29
1783	Immune Checkpoint Inhibition in Renal Cell Carcinoma. <b>2015</b> , 259-279	
1782	Phagocytes as Corrupted Policemen in Cancer-Related Inflammation. <b>2015</b> , 128, 141-71	58

1781	Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression. <b>2015</b> , 7, 499-512	16
1780	Classification and biology of tumour associated stromal cells. <b>2015</b> , 168, 175-82	26
1779	The DNA damage response and immune signaling alliance: Is it good or bad? Nature decides when and where. <b>2015</b> , 154, 36-56	104
1778	Mechanisms of Nitric Oxide-Dependent Regulation of Tumor Invasion and Metastasis. <b>2015</b> , 49-63	
1777	Activated cytotoxic lymphocytes promote tumor progression by increasing the ability of 3LL tumor cells to mediate MDSC chemoattraction via Fas signaling. <b>2015</b> , 12, 66-76	16
1776	CCL2 Promotes Colorectal Carcinogenesis by Enhancing Polymorphonuclear Myeloid-Derived Suppressor Cell Population and Function. <b>2015</b> , 12, 244-57	200
1775	ICAM-1 suppresses tumor metastasis by inhibiting macrophage M2 polarization through blockade of efferocytosis. <b>2015</b> , 6, e1780	63
1774	Oncolytic Viral Therapy Using Reovirus. <b>2015</b> , 1317, 187-223	26
1773	Allergen induced pulmonary inflammation enhances mammary tumor growth and metastasis: Role of CHI3L1. <b>2015</b> , 97, 929-940	8
1772	Gene Therapy of Solid Cancers. <b>2015</b> ,	1
1771	Development of individualized anti-metastasis strategies by engineering nanomedicines. <b>2015</b> , 44, 6258-86	96
1770	MicroRNA-9 Regulates the Differentiation and Function of Myeloid-Derived Suppressor Cells via Targeting Runx1. <b>2015</b> , 195, 1301-11	59
1769	Novel therapeutic strategies for multiple myeloma. <b>2015</b> , 43, 732-41	79
1768	Bone marrow mesenchymal stem cells suppress ascitogenous hepatoma progression in BALB/c mouse through reducing myeloid-derived suppressor cells. <b>2015</b> , 25, 167-77	2
1767	Inflammation and cancer: advances and new agents. <b>2015</b> , 12, 584-96	601
1766	Systemic expression of Kaposi sarcoma herpesvirus (KSHV) Vflap in endothelial cells leads to a profound proinflammatory phenotype and myeloid lineage remodeling in vivo. <b>2015</b> , 11, e1004581	28
1765	[Tasquinimod: How to act on microenvironment in metastatic prostate cancer]. <b>2015</b> , 25, 298-305	0
1764	Intratumoral Delivery of IL-21 Overcomes Anti-Her2/Neu Resistance through Shifting Tumor-Associated Macrophages from M2 to M1 Phenotype. <b>2015</b> , 194, 4997-5006	77

1763	The ins and outs of osteopontin. <b>2015</b> , 4, e978711	3
1762	Bone specific immunity and its impact on metastasis. <b>2015</b> , 4, 665	24
1761	Bone marrow mesenchymal stem cells suppress metastatic tumor development in mouse by modulating immune system. <b>2015</b> , 6, 45	22
1760	Subsets of myeloid-derived suppressor cells in hepatocellular carcinoma express chemokines and chemokine receptors differentially. <b>2015</b> , 26, 314-21	27
1759	Inflammatory models drastically alter tumor growth and the immune microenvironment in hepatocellular carcinoma. <b>2015</b> , 60, 762-772	5
1758	The emerging understanding of myeloid cells as partners and targets in tumor rejection. <b>2015</b> , 3, 313-9	37
1757	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy. <b>2015</b> , 17, 18	17
1756	Type 2 cytokines: mechanisms and therapeutic strategies. <i>Nature Reviews Immunology</i> , <b>2015</b> , 15, 271-82	36.5 398
1755	CpG Oligonucleotides as Cancer Vaccine Adjuvants. <b>2015</b> , 3, 390-407	79
1754	Tumor chemosensitization by physical exercise? Insights from an animal model. <b>2015</b> , 11, 885-7	2
1753	Presence of circulating Her2-reactive CD8 + T-cells is associated with lower frequencies of myeloid-derived suppressor cells and regulatory T cells, and better survival in older breast cancer patients. <b>2015</b> , 17, 34	45
1752	Classifying Cancers Based on T-cell Infiltration and PD-L1. <b>2015</b> , 75, 2139-45	864
1751	Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication. <b>2015</b> , 4, e989764	75
1750	TLR5 Ligand-Secreting T Cells Reshape the Tumor Microenvironment and Enhance Antitumor Activity. <b>2015</b> , 75, 1959-1971	26
1749	Macrophages and cancer: from mechanisms to therapeutic implications. <b>2015</b> , 36, 229-39	422
1748	Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma. <b>2015</b> , 3, 881-90	22
1747	Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells. <b>2015</b> , 21, 591-600	166
1746	Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy. <b>2015</b> , 4, e954829	172

1745	Mass-spectrometry-based molecular characterization of extracellular vesicles: lipidomics and proteomics. <b>2015</b> , 14, 2367-84	148
1744	Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. <b>2015</b> , 16, 609-17	264
1743	Strategies to relieve immunosuppression in pancreatic cancer. <b>2015</b> , 7, 363-76	16
1742	MDSC and TGF $\beta$ Are Required for Facilitation of Tumor Growth in the Lungs of Mice Exposed to Carbon Nanotubes. <b>2015</b> , 75, 1615-23	43
1741	In the hunt for therapeutic targets: mimicking the growth, metastasis, and stromal associations of early-stage lung cancer using a novel orthotopic animal model. <b>2015</b> , 10, 46-58	8
1740	Mesenchymal stem/stromal cells protect against autoimmunity via CCL2-dependent recruitment of myeloid-derived suppressor cells. <b>2015</b> , 194, 3634-45	47
1739	IL-12 promotes myeloid-derived suppressor cell recruitment and bacterial persistence during Staphylococcus aureus orthopedic implant infection. <b>2015</b> , 194, 3861-3872	86
1738	Newly recruited CD11b+, GR-1+, Ly6C(high) myeloid cells augment tumor-associated immunosuppression immediately following the therapeutic administration of oncolytic reovirus. <b>2015</b> , 194, 4397-412	26
1737	Immunologic correlates in the course of treatment with immunomodulating antibodies. <b>2015</b> , 42, 448-58	19
1736	Immune-mediated mechanisms influencing the efficacy of anticancer therapies. <b>2015</b> , 36, 198-216	93
1735	Interleukin-17 Superfamily and Cancer. <b>2015</b> , 261-289	
1734	The impact of circulating suppressor cells in multiple myeloma patients on clinical outcome of DLIs. <b>2015</b> , 50, 822-8	14
1733	Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2. <b>2015</b> , 27, 489-501	114
1732	The nitric oxide radical scavenger carboxy-PTIO reduces the immunosuppressive activity of myeloid-derived suppressor cells and potentiates the antitumor activity of adoptive cytotoxic T lymphocyte immunotherapy. <b>2015</b> , 4, e1019195	17
1731	Immunosuppression associated with chronic inflammation in the tumor microenvironment. <b>2015</b> , 36, 1085-93	192
1730	A subpopulation that may correspond to granulocytic myeloid-derived suppressor cells reflects the clinical stage and progression of cutaneous melanoma. <b>2016</b> , 28, 87-97	17
1729	Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients. <b>2015</b> , 21, 4327-36	153
1728	Immunotherapy of DC-CIK cells enhances the efficacy of chemotherapy for solid cancer: a meta-analysis of randomized controlled trials in Chinese patients. <b>2015</b> , 16, 743-56	7



1727	Impaired gp100-Specific CD8(+) T-Cell Responses in the Presence of Myeloid-Derived Suppressor Cells in a Spontaneous Mouse Melanoma Model. <b>2015</b> , 135, 2785-2793	15
1726	Non-steady-state hematopoiesis regulated by the C/EBP $\beta$ transcription factor. <b>2015</b> , 106, 797-802	32
1725	Cancer immunotherapy: Strategies for personalization and combinatorial approaches. <b>2015</b> , 9, 2043-53	68
1724	The chemokine receptor CCR6 facilitates the onset of mammary neoplasia in the MMTV-PyMT mouse model via recruitment of tumor-promoting macrophages. <b>2015</b> , 14, 115	41
1723	CpG expedites regression of local and systemic tumors when combined with activatable nanodelivery. <b>2015</b> , 220, 253-264	18
1722	FAS Death Receptor: A Breast Cancer Subtype-Specific Radiation Response Biomarker and Potential Therapeutic Target. <b>2015</b> , 184, 456-69	20
1721	ROR1C Regulates Differentiation of Myeloid-Derived Suppressor Cells. <b>2015</b> , 28, 147-9	14
1720	Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation. <b>2015</b> , 6, 6840	56
1719	Tumorigenic Th17 cells in oncogenic Kras-driven and inflammation-accelerated lung cancer. <b>2015</b> , 4, e955704	7
1718	Reduced Myeloid-derived Suppressor Cells in the Blood and Endometrium is Associated with Early Miscarriage. <b>2015</b> , 73, 479-86	50
1717	Serum inflammatory factors and circulating immunosuppressive cells are predictive markers for efficacy of radiofrequency ablation in non-small-cell lung cancer. <b>2015</b> , 180, 467-74	26
1716	Myeloid promotes formation of colitis-associated colorectal cancer in mice. <b>2015</b> , 4, e998529	19
1715	RORC1 Regulates Tumor-Promoting "Emergency" Granulo-Monocytopenesis. <b>2015</b> , 28, 253-69	121
1714	CCL9 Induced by TGF $\beta$ Signaling in Myeloid Cells Enhances Tumor Cell Survival in the Premetastatic Organ. <b>2015</b> , 75, 5283-98	49
1713	CD8+ T-cell immunosurveillance constrains lymphoid premetastatic myeloid cell accumulation. <b>2015</b> , 45, 71-81	23
1712	Epigenetic and Immune Regulation of Colorectal Cancer Stem Cells. <b>2015</b> , 11, 414-421	4
1711	Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. <b>2015</b> , 13, 412-24	275
1710	Plasticity beyond cancer cells and the "immunosuppressive switch". <b>2015</b> , 75, 4441-5	60

1709	Shikonin-enhanced cell immunogenicity of tumor vaccine is mediated by the differential effects of DAMP components. <b>2015</b> , 14, 174	49
1708	Polarization of Monocytic Myeloid-Derived Suppressor Cells by Hepatitis B Surface Antigen Is Mediated via ERK/IL-6/STAT3 Signaling Feedback and Restrains the Activation of T Cells in Chronic Hepatitis B Virus Infection. <b>2015</b> , 195, 4873-83	60
1707	Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies. <b>2015</b> , 3, 1236-47	260
1706	T cells in cancer. <i>Nature Reviews Immunology</i> , <b>2015</b> , 15, 683-91	36.5 320
1705	The CUL4B/AKT/ $\beta$ -Catenin Axis Restricts the Accumulation of Myeloid-Derived Suppressor Cells to Prohibit the Establishment of a Tumor-Permissive Microenvironment. <b>2015</b> , 75, 5070-83	32
1704	Nanomedicine and cancer immunotherapy - targeting immunosuppressive cells. <b>2015</b> , 23, 656-71	25
1703	Characterization of the myeloid-derived suppressor cell subset regulated by NK cells in malignant lymphoma. <b>2015</b> , 4, e995541	32
1702	The Dynamics of Interactions Among Immune and Glioblastoma Cells. <b>2015</b> , 17, 335-52	21
1701	Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab. <b>2015</b> , 21, 5453-9	237
1700	Carving out its niche: A role for carbonic anhydrase IX in pre-metastatic niche development. <b>2015</b> , 4, e1048955	7
1699	Role of Tumor Pericytes in the Recruitment of Myeloid-Derived Suppressor Cells. <b>2015</b> , 107,	46
1698	Expansion of myeloid-derived suppressor cells in chronic obstructive pulmonary disease and lung cancer: potential link between inflammation and cancer. <b>2015</b> , 64, 1261-70	23
1697	Norepinephrine-induced myeloid-derived suppressor cells block T-cell responses via generation of reactive oxygen species. <b>2015</b> , 37, 359-65	31
1696	PEITC treatment suppresses myeloid derived tumor suppressor cells to inhibit breast tumor growth. <b>2015</b> , 4, e981449	11
1695	Immunoglobulin-like transcript 3 is expressed by myeloid-derived suppressor cells and correlates with survival in patients with non-small cell lung cancer. <b>2015</b> , 4, e1014242	47
1694	17 $\beta$ -estradiol contributes to the accumulation of myeloid-derived suppressor cells in blood by promoting TNF- $\beta$ secretion. <b>2015</b> , 47, 620-9	22
1693	Fas Ligand Deficiency Impairs Tumor Immunity by Promoting an Accumulation of Monocytic Myeloid-Derived Suppressor Cells. <b>2015</b> , 75, 4292-301	19
1692	Re-wiring regulatory cell networks in immunity by galectin-glycan interactions. <b>2015</b> , 589, 3407-18	41

1691	Metabolic Reprogramming of Immune Cells in Cancer Progression. <b>2015</b> , 43, 435-49	301
1690	Histamine deficiency promotes accumulation of immunosuppressive immature myeloid cells and growth of murine gliomas. <b>2015</b> , 4, e1047581	7
1689	Transcriptional regulation of myeloid-derived suppressor cells. <b>2015</b> , 98, 913-22	188
1688	Hepatic myeloid-derived suppressor cells in cancer. <b>2015</b> , 64, 931-40	27
1687	Tetraspanin CD81 promotes tumor growth and metastasis by modulating the functions of T regulatory and myeloid-derived suppressor cells. <b>2015</b> , 75, 4517-26	49
1686	Trial watch: Naked and vectored DNA-based anticancer vaccines. <b>2015</b> , 4, e1026531	22
1685	T cell exhaustion and Interleukin 2 downregulation. <b>2015</b> , 71, 339-47	36
1684	Myeloid-derived cells in tumors: effects of radiation. <b>2015</b> , 25, 18-27	91
1683	Invasion and Metastasis. <b>2015</b> , 269-284.e2	4
1682	CSF1-ETS2-induced microRNA in myeloid cells promote metastatic tumor growth. <b>2015</b> , 34, 3651-61	52
1681	Renal Cell Carcinoma. <b>2015</b> ,	
1680	Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. <b>2015</b> , 263, 68-89	237
1679	Silence STAT3 in the procancer niche and activate CD8+ T cells to kill premetastatic myeloid intruders. <b>2015</b> , 45, 44-8	3
1678	PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. <b>2015</b> , 75, 508-518	133
1677	Monocytes and infection: modulator, messenger and effector. <b>2015</b> , 220, 210-4	36
1676	Myeloid-derived suppressor cells promote age-related increase of lung cancer growth via B7-H1. <b>2015</b> , 61, 84-91	19
1675	Myeloid cells in cancer-related inflammation. <b>2015</b> , 220, 249-53	50
1674	Macrophage iron homeostasis and polarization in the context of cancer. <b>2015</b> , 220, 295-304	50

1673	Balancing the innate immune system in tumor development. <b>2015</b> , 25, 214-20	83
1672	Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy. <b>2015</b> , 64, 1-13	79
1671	Tumour Microenvironment: Overview with an Emphasis on the Colorectal Liver Metastasis Pathway. <b>2015</b> , 8, 177-86	9
1670	The role of the microbiota in inflammation, carcinogenesis, and cancer therapy. <b>2015</b> , 45, 17-31	143
1669	Regulation of tumor metastasis by myeloid-derived suppressor cells. <b>2015</b> , 66, 97-110	310
1668	Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy. <b>2015</b> , 168, 689-700	57
1667	Stress Response Pathways in Cancer. <b>2015</b> ,	3
1666	l-Arginine depletion blunts antitumor T-cell responses by inducing myeloid-derived suppressor cells. <b>2015</b> , 75, 275-83	150
1665	Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function. <b>2015</b> , 63, 579-85	75
1664	Myeloid regulatory cells in tumor spreading and metastasis. <b>2015</b> , 220, 236-42	74
1663	MC1R, eumelanin and pheomelanin: their role in determining the susceptibility to skin cancer. <b>2015</b> , 91, 188-200	103
1662	The Measure of DAMPs and a role for S100A8 in recruiting suppressor cells in breast cancer lung metastasis. <b>2015</b> , 44, 174-88	14
1661	MicroRNA regulons in tumor microenvironment. <b>2015</b> , 34, 3085-94	129
1660	CD8 T Lymphocytes in Antitumor Immunity. <b>2016</b> , 434-440	
1659	Propranolol induces a favourable shift of anti-tumor immunity in a murine spontaneous model of melanoma. <b>2016</b> , 7, 77825-77837	44
1658	Exosomes released by granulocytic myeloid-derived suppressor cells attenuate DSS-induced colitis in mice. <b>2016</b> , 7, 15356-68	72
1657	Tumour progression and metastasis. <b>2016</b> , 10, 617	47
1656	p53 Mutation: Critical Mediator of Therapy Resistance against Tumor Microenvironment. <b>2016</b> , 5,	4

1655	Epigenetics in myeloid derived suppressor cells: a sheathed sword towards cancer. <b>2016</b> , 7, 57452-57463	32
1654	Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment. <b>2016</b> , 7, 75407-75424	41
1653	Kinetics of Circulating Plasma Cell-Free DNA in Paediatric Classical Hodgkin Lymphoma. <b>2016</b> , 7, 364-6	10
1652	Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer. <b>2016</b> , 22, 557-66	179
1651	Definitive activation of endogenous antitumor immunity by repetitive cycles of cyclophosphamide with interspersed Toll-like receptor agonists. <b>2016</b> , 7, 42919-42942	16
1650	Myeloid cell signatures in tumor microenvironment predicts therapeutic response in cancer. <b>2016</b> , 9, 1047-55	27
1649	Neutrophil-Derived Proteases in the Microenvironment of Pancreatic Cancer -Active Players in Tumor Progression. <b>2016</b> , 12, 302-13	54
1648	Growth and Metastasis of Intraocular Tumors in Aged Mice. <b>2016</b> , 57, 2366-76	5
1647	Multiple myeloma, immunotherapy and minimal residual disease. <b>2016</b> , 63, 651-8	1
1646	Modulation of Innate Immunity by Hypoxia. <b>2016</b> , 81-106	
1645	Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies. <b>2016</b> , 35, e450-8	22
1644	The prognostic effects of tumor infiltrating regulatory T cells and myeloid derived suppressor cells assessed by multicolor flow cytometry in gastric cancer patients. <b>2016</b> , 7, 7940-51	45
1643	Human mesenchymal stromal cell-secreted lactate induces M2-macrophage differentiation by metabolic reprogramming. <b>2016</b> , 7, 30193-210	82
1642	Cancer-Associated Immune Resistance and Evasion of Immune Surveillance in Colorectal Cancer. <b>2016</b> , 2016, 6261721	35
1641	Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC). <b>2016</b> , 7, 85764-85775	56
1640	Overcoming Hypoxia-Mediated Tumor Progression: Combinatorial Approaches Targeting pH Regulation, Angiogenesis and Immune Dysfunction. <b>2016</b> , 4, 27	83
1639	Monitoring of the Immune Dysfunction in Cancer Patients. <b>2016</b> , 4,	11
1638	Harnessing the immune system to improve cancer therapy. <b>2016</b> , 4, 261	167

1637	Myeloid-Derived Suppressor Cells in Bacterial Infections. <b>2016</b> , 6, 37	69
1636	Transplantation Tolerance Induction: Cell Therapies and Their Mechanisms. <b>2016</b> , 7, 87	36
1635	Cancer-Associated Myeloid Regulatory Cells. <b>2016</b> , 7, 113	49
1634	TNF Neutralization Results in the Delay of Transplantable Tumor Growth and Reduced MDSC Accumulation. <b>2016</b> , 7, 147	23
1633	Tertiary Lymphoid Organs in Cancer Tissues. <b>2016</b> , 7, 244	57
1632	Improved Antitumor Activity of a Therapeutic Melanoma Vaccine through the Use of the Dual COX-2/5-LO Inhibitor Licofelone. <b>2016</b> , 7, 537	9
1631	Increased Levels of Circulating and Tumor-Infiltrating Granulocytic Myeloid Cells in Colorectal Cancer Patients. <b>2016</b> , 7, 560	41
1630	Differential Regulation of Myeloid-Derived Suppressor Cells by Species. <b>2016</b> , 7, 1624	14
1629	MicroRNA Targeting to Modulate Tumor Microenvironment. <b>2016</b> , 6, 3	91
1628	A Perspective of Immunotherapy for Prostate Cancer. <b>2016</b> , 8,	21
1627	The Role of Chemokines in Promoting Colorectal Cancer Invasion/Metastasis. <b>2016</b> , 17,	78
1626	Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor Microenvironment. <b>2016</b> , 17,	61
1625	Pro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic Targets. <b>2016</b> , 17,	29
1624	[gMDSCs act as metabolic regulators of hepatitis B virus immunopathology]. <b>2016</b> , 32, 238-41	0
1623	Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients. <b>2016</b> , 11, e0158392	18
1622	Characterization of Arginase Expression in Glioma-Associated Microglia and Macrophages. <b>2016</b> , 11, e0165118	33
1621	Nitric Oxide Synthase 2 Improves Proliferation and Glycolysis of Peripheral T Cells. <b>2016</b> , 11, e0165639	8
1620	The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression. <b>2016</b> , 4,	187

1619	Radiation-induced immune responses: mechanisms and therapeutic perspectives. <b>2016</b> , 51, 157-163	31
1618	Myeloid-derived suppressor cells in gliomas. <b>2016</b> , 20, 345-351	18
1617	Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. <b>2016</b> , 1,	226
1616	Relevance of Interferon Regulatory Factor-8 Expression in Myeloid-Tumor Interactions. <b>2016</b> , 36, 442-53	17
1615	Prognostic significance of hematological profiles in melanoma patients. <b>2016</b> , 139, 1618-25	32
1614	Myeloid-derived suppressor cells as effectors of immune suppression in cancer. <b>2016</b> , 139, 1915-26	67
1613	Immune Checkpoint Therapy in Renal Cell Carcinoma. <b>2016</b> , 22, 92-5	18
1612	Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human. <b>2016</b> , 138, 1982-93	183
1611	The complex immunological and inflammatory network of adipose tissue in obesity. <b>2016</b> , 60, 43-57	111
1610	Peptide-based systems analysis of inflammation induced myeloid-derived suppressor cells reveals diverse signaling pathways. <b>2016</b> , 16, 1881-8	14
1609	Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression. <b>2016</b> , 239, 162-73	140
1608	The Phenotypic and Functional Features of Human M2 Macrophages Generated Under Low Serum Conditions. <b>2016</b> , 83, 151-9	14
1607	Clinical Significance of Myeloid-Derived Suppressor Cells in Human Immunodeficiency Virus-1/ Hepatitis C Virus-coinfected Patients. <b>2016</b> , 83, 438-44	8
1606	Myeloid-Derived Suppressor Cells and Proinflammatory Cytokines as Targets for Cancer Therapy. <b>2016</b> , 81, 1274-1283	18
1605	Re-polarizing Myeloid-derived Suppressor Cells (MDSCs) with Cationic Polymers for Cancer Immunotherapy. <b>2016</b> , 6, 24506	43
1604	C-reactive protein exacerbates renal ischemia-reperfusion injury: are myeloid-derived suppressor cells to blame?. <b>2016</b> , 311, F176-81	14
1603	A New VISTA on combination therapy for negative checkpoint regulator blockade. <b>2016</b> , 4, 86	27
1602	An overview of the necessary thymic contributions to tolerance in transplantation. <b>2016</b> , 173, 1-1	3

1601	Systemic Immune-Inflammation Index Predicts Prognosis of Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score-matched Analysis. <b>2016</b> , 6, 39482	104
1600	Tumor-Induced Myeloid-Derived Suppressor Cells. <b>2016</b> , 4,	21
1599	T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNF $\alpha$ Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma. <b>2016</b> , 39, 343-354	17
1598	GM-CSF signalling blockade and chemotherapeutic agents act in concert to inhibit the function of myeloid-derived suppressor cells. <b>2016</b> , 5, e119	20
1597	The Ontogeny and Microenvironmental Regulation of Tumor-Associated Macrophages. <b>2016</b> , 25, 775-791	34
1596	Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. <b>2016</b> , 17, 651-62	407
1595	Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. <b>2016</b> , 24, 1150-1158	79
1594	Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma. <b>2016</b> , 5, e1164919	31
1593	Tetraspanin CD81, a modulator of immune suppression in cancer and metastasis. <b>2016</b> , 5, e1120399	8
1592	Intratumoral delivery of mTORC2-deficient dendritic cells inhibits B16 melanoma growth by promoting CD8(+) effector T cell responses. <b>2016</b> , 5, e1146841	19
1591	Antagonizing Integrin $\alpha$ Increases Immunosuppression in Cancer. <b>2016</b> , 76, 3484-95	45
1590	Targeting cellular and molecular drivers of head and neck squamous cell carcinoma: current options and emerging perspectives. <b>2016</b> , 35, 413-26	32
1589	FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment via STAT3-CCL2 Signaling. <b>2016</b> , 76, 4124-35	263
1588	Malignant melanoma-The cradle of anti-neoplastic immunotherapy. <b>2016</b> , 106, 25-54	22
1587	Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation. <b>2016</b> , 18, 632-44	124
1586	Upregulated Glucose Metabolism Correlates Inversely with CD8+ T-cell Infiltration and Survival in Squamous Cell Carcinoma. <b>2016</b> , 76, 4136-48	60
1585	The Role of the Immune System and Immunoregulatory Mechanisms Relevant to Melanoma. <b>2016</b> , 31-65	
1584	EFIS lecture. Immune response to tuberculosis: How to control the most successful pathogen on earth. <b>2016</b> , 175, 50-7	4



1583	Emodin Inhibits Breast Cancer Growth by Blocking the Tumor-Promoting Feedforward Loop between Cancer Cells and Macrophages. <b>2016</b> , 15, 1931-42	46
1582	Role of the tumor microenvironment in tumor progression and the clinical applications (Review). <b>2016</b> , 35, 2499-515	167
1581	Dickkopf-related protein 1 (Dkk1) regulates the accumulation and function of myeloid derived suppressor cells in cancer. <b>2016</b> , 213, 827-40	82
1580	Myeloid-Derived Suppressor Cell Survival and Function Are Regulated by the Transcription Factor Nrf2. <b>2016</b> , 196, 3470-8	65
1579	Drafting the proteome landscape of myeloid-derived suppressor cells. <b>2016</b> , 16, 367-78	23
1578	Shaping the Immune Landscape in Cancer by Galectin-Driven Regulatory Pathways. <b>2016</b> , 428, 3266-3281	55
1577	IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer. <b>2016</b> , 76, 3189-99	114
1576	The role of innate immunity in the immunopathology and treatment of HBV infection. <b>2016</b> , 64, S60-S70	105
1575	Neutrophils Suppress Intraluminal NK Cell-Mediated Tumor Cell Clearance and Enhance Extravasation of Disseminated Carcinoma Cells. <b>2016</b> , 6, 630-49	257
1574	Emerging Opportunities and Challenges in Cancer Immunotherapy. <b>2016</b> , 22, 1845-55	172
1573	Tumor-infiltrating monocytes/macrophages promote tumor invasion and migration by upregulating S100A8 and S100A9 expression in cancer cells. <b>2016</b> , 35, 5735-5745	109
1572	Myeloid-derived suppressor cells enhance the expression of melanoma-associated antigen A4 in a Lewis lung cancer murine model. <b>2016</b> , 11, 809-816	11
1571	Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients. <b>2016</b> , 29, 587-601	259
1570	Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy. <b>2016</b> , 96, 47-62	98
1569	State-of-the-art of regulatory dendritic cells in cancer. <b>2016</b> , 164, 97-104	27
1568	Dissecting Complex Cellular Systems with High Dimensional Single Cell Mass Cytometry. <b>2016</b> , 15-26	2
1567	Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy. <b>2016</b> , 5, e1151595	39
1566	Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab. <b>2016</b> , 22, 4848-4858	108

1565	T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells. <b>2016</b> , 128, 1081-92	91
1564	Neutrophil heterogeneity: implications for homeostasis and pathogenesis. <b>2016</b> , 127, 2173-81	213
1563	T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells. <b>2016</b> , 30, 377-390	93
1562	Suppressive effects of low-dose 5-fluorouracil, busulfan or treosulfan on the expansion of circulatory neutrophils and myeloid derived immunosuppressor cells in tumor-bearing mice. <b>2016</b> , 40, 41-49	5
1561	Editorial: A matter of survival: HMGB1 regulates autophagy in tumor MDSC. <b>2016</b> , 100, 447-9	1
1560	Chemokines, cytokines and exosomes help tumors to shape inflammatory microenvironment. <b>2016</b> , 168, 98-112	77
1559	Progress and opportunities for immune therapeutics in osteosarcoma. <b>2016</b> , 8, 1233-44	28
1558	IL-1 $\beta$ induces IL-6 production and increases invasiveness and estrogen-independent growth in a TG2-dependent manner in human breast cancer cells. <b>2016</b> , 16, 724	45
1557	Immature myeloid Gr-1+ CD11b+ cells from lipopolysaccharide-immunosuppressed mice acquire inhibitory activity in the bone marrow and migrate to lymph nodes to exert their suppressive function. <b>2016</b> , 130, 259-71	11
1556	Myeloid-derived suppressor cells contribute to systemic lupus erythaematosus by regulating differentiation of Th17 cells and Tregs. <b>2016</b> , 130, 1453-67	52
1555	The blockage of Notch signalling promoted the generation of polymorphonuclear myeloid-derived suppressor cells with lower immunosuppression. <b>2016</b> , 68, 90-105	22
1554	Tumor-infiltrating Tim-3 T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk. <b>2016</b> , 5, e1200778	34
1553	Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies. <b>2016</b> , 88, 213-220	26
1552	CD4Foxp3 type 1 regulatory T cells in glioblastoma multiforme suppress T cell responses through multiple pathways and are regulated by tumor-associated macrophages. <b>2016</b> , 81, 1-9	20
1551	Immature myeloid cells are critical for enhancing bone fracture healing through angiogenic cascade. <b>2016</b> , 93, 113-124	11
1550	Myeloid-derived suppressor cells expressing a self-antigen ameliorate experimental autoimmune encephalomyelitis. <b>2016</b> , 286, 50-60	15
1549	B cells and macrophages pursue a common path toward the development and progression of chronic lymphocytic leukemia. <b>2016</b> , 30, 2293-2301	26
1548	Mesenchymal Transition of High-Grade Breast Carcinomas Depends on Extracellular Matrix Control of Myeloid Suppressor Cell Activity. <b>2016</b> , 17, 233-248	62

1547	[Prostate cancer microenvironment: Its structure, functions and therapeutic applications]. <b>2016</b> , 26, 464-76	o
1546	LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma. <b>2016</b> , 5, e1239005	64
1545	Interleukin 12: Antitumor Activity and Immunotherapeutic Potential in Oncology. <b>2016</b> ,	
1544	Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression. <b>2016</b> , 30, 533-547	247
1543	Myeloid cells as orchestrators of the tumor microenvironment: novel targets for nanoparticulate cancer therapy. <b>2016</b> , 11, 2735-2751	16
1542	Splenic Marginal Zone Granulocytes Acquire an Accentuated Neutrophil B-Cell Helper Phenotype in Chronic Lymphocytic Leukemia. <b>2016</b> , 76, 5253-65	16
1541	Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX-Bevacizumab Drug Treatment Regimen. <b>2016</b> , 76, 5241-52	140
1540	Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis. <b>2016</b> , 45, 389-401	318
1539	Nitric oxide synthase 2 is involved in the pro-tumorigenic potential of CD7 T cells in melanoma. <b>2016</b> , 5, e1208878	23
1538	Inhibition of mouse breast adenocarcinoma growth by ablation with intratumoral alpha-irradiation combined with inhibitors of immunosuppression and CpG. <b>2016</b> , 65, 1149-58	16
1537	The untold story of IFN- $\gamma$ in cancer biology. <b>2016</b> , 31, 73-81	65
1536	Chemokines accentuating protumoral activities in oral cancer microenvironment possess an imperious stratagem for therapeutic resolutions. <b>2016</b> , 60, 8-17	15
1535	Inflammation and Metastasis. <b>2016</b> ,	4
1534	Intratumoral Infection with Murine Cytomegalovirus Synergizes with PD-L1 Blockade to Clear Melanoma Lesions and Induce Long-term Immunity. <b>2016</b> , 24, 1444-55	17
1533	The pattern of GPI-80 expression is a useful marker for unusual myeloid maturation in peripheral blood. <b>2016</b> , 186, 373-386	3
1532	Defects in T Cell Trafficking and Resistance to Cancer Immunotherapy. <b>2016</b> ,	1
1531	Signal transducer and activator of transcription proteins: regulators of myeloid-derived suppressor cell-mediated immunosuppression in cancer. <b>2016</b> , 39, 1597-1608	28
1530	Elevated VEGF-D Modulates Tumor Inflammation and Reduces the Growth of Carcinogen-Induced Skin Tumors. <b>2016</b> , 18, 436-46	10

1529	Atorvastatin promotes the expansion of myeloid-derived suppressor cells and attenuates murine colitis. <b>2016</b> , 149, 432-446	24
1528	Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas. <b>2016</b> , 4, 869-880	185
1527	Neutrophils in the tumor microenvironment: trying to heal the wound that cannot heal. <b>2016</b> , 273, 329-43	102
1526	Identification of a human intestinal myeloid cell subset that regulates gut homeostasis. <b>2016</b> , 28, 533-545	17
1525	Regulatory circuits of T cell function in cancer. <i>Nature Reviews Immunology</i> , <b>2016</b> , 16, 599-611	36.5 320
1524	Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma. <b>2016</b> , 5, 1810-20	38
1523	Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade. <b>2016</b> , 5, e1232222	37
1522	Inhibiting MDSC differentiation from bone marrow with phytochemical polyacetylenes drastically impairs tumor metastasis. <b>2016</b> , 6, 36663	16
1521	Disruption of Anti-tumor T Cell Responses by Cancer-Associated Fibroblasts. <b>2016</b> , 77-98	1
1520	TLR7-based cancer immunotherapy decreases intratumoral myeloid-derived suppressor cells and blocks their immunosuppressive function. <b>2016</b> , 5, e1230578	44
1519	Cancer Stem Cells. <b>2016</b> , 341-366	4
1518	Neutrophils in cancer development and progression: Roles, mechanisms, and implications (Review). <b>2016</b> , 49, 857-67	57
1517	Tumor-Associated Macrophages and Myeloid-Derived Suppressor Cells as Immunosuppressive Mechanism in Ovarian Cancer Patients: Progress and Challenges. <b>2016</b> , 35, 372-385	19
1516	Targeting the tumour profile using broad spectrum chimaeric antigen receptor T-cells. <b>2016</b> , 44, 391-6	9
1515	Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study. <b>2016</b> , 130, 517-527	36
1514	Immune Suppressive Myeloid-Derived Suppressor Cells in Cancer. <b>2016</b> , 512-525	2
1513	Interleukin-10 attenuates tumour growth by inhibiting interleukin-6/signal transducer and activator of transcription 3 signalling in myeloid-derived suppressor cells. <b>2016</b> , 381, 156-64	23
1512	Doxorubicin resistant cancer cells activate myeloid-derived suppressor cells by releasing PGE2. <b>2016</b> , 6, 23824	43

1511	Cryo-thermal therapy elicits potent anti-tumor immunity by inducing extracellular Hsp70-dependent MDSC differentiation. <b>2016</b> , 6, 27136	32
1510	One microenvironment does not fit all: heterogeneity beyond cancer cells. <b>2016</b> , 35, 601-629	41
1509	Therapeutic targeting of myeloid-derived suppressor cells involves a novel mechanism mediated by clusterin. <b>2016</b> , 6, 29521	23
1508	Altered gp130 signalling ameliorates experimental colitis via myeloid cell-specific STAT3 activation and myeloid-derived suppressor cells. <b>2016</b> , 6, 20584	19
1507	High Level of Anaphylatoxin C5a Predicts Poor Clinical Outcome in Patients with Clear Cell Renal Cell Carcinoma. <b>2016</b> , 6, 29177	12
1506	Heparanase is required for activation and function of macrophages. <b>2016</b> , 113, E7808-E7817	60
1505	Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. <b>2016</b> , 1,	378
1504	Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients. <b>2016</b> , 2, 16025	47
1503	CD24 blunts oral squamous cancer development and dampens the functional expansion of myeloid-derived suppressor cells. <b>2016</b> , 5, e1226719	7
1502	The immune system's role in sepsis progression, resolution, and long-term outcome. <b>2016</b> , 274, 330-353	286
1501	Facteurs prédictifs et biomarqueurs précoces de réponse aux inhibiteurs de checkpoint immunologiques (anti-PD-1, anti-PD-L1). <b>2016</b> , 18, 533-542	2
1500	Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. <b>2016</b> , 7, 12150	1388
1499	M2-polarized macrophages contribute to neovasculogenesis, leading to relapse of oral cancer following radiation. <b>2016</b> , 6, 27548	54
1498	Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab. <b>2016</b> , 5, e1249559	35
1497	CXCR2-Dependent Accumulation of Tumor-Associated Neutrophils Regulates T-cell Immunity in Pancreatic Ductal Adenocarcinoma. <b>2016</b> , 4, 968-982	129
1496	Induction of IL-25 secretion from tumour-associated fibroblasts suppresses mammary tumour metastasis. <b>2016</b> , 7, 11311	23
1495	Pretreatment neutrophil-to-lymphocyte ratio and its dynamic changes are associated with the overall survival in advanced cancer patients undergoing palliative care. <b>2016</b> , 6, 31394	14
1494	Role of the Microenvironment in Liver Metastasis: From Pre- to Prometastatic Niches. <b>2016</b> , 22, 5971-5982	120

1493	Clinical Trials with IL-12 in Cancer Immunotherapy. <b>2016</b> , 43-75	1
1492	Trametinib Drives T-cell-Dependent Control of KRAS-Mutated Tumors by Inhibiting Pathological Myelopoiesis. <b>2016</b> , 76, 6253-6265	28
1491	Prognostic Significance of Monocytes and Monocytic Myeloid-Derived Suppressor Cells in Diffuse Large B-Cell Lymphoma Treated with R-CHOP. <b>2016</b> , 39, 521-30	16
1490	Myeloid-Derived Suppressor Cells Induce the Expansion of Regulatory B Cells and Ameliorate Autoimmunity in the Sanroque Mouse Model of Systemic Lupus Erythematosus. <b>2016</b> , 68, 2717-2727	71
1489	A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. <b>2016</b> , 122, 2158-67	115
1488	Simultaneous measurement of human hematopoietic stem and progenitor cells in blood using multicolor flow cytometry. <b>2016</b> , 90, 415-23	17
1487	Pharmacological Modulation of Proton Channel Hv1 in Cancer Therapy: Future Perspectives. <b>2016</b> , 90, 385-402	8
1486	Progress in Cancer Immunotherapy. <b>2016</b> ,	5
1485	Neutrophils in cancer: neutral no more. <b>2016</b> , 16, 431-46	829
1484	Radiobiology of Glioblastoma. <b>2016</b> ,	2
1483	Expansion of a BDCA1+CD14+ Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines. <b>2016</b> , 76, 4332-46	66
1482	The role of myeloid cells in cancer therapies. <b>2016</b> , 16, 447-62	363
1481	Immunotherapy for Head and Neck Squamous Cell Carcinoma. <b>2016</b> , 3, 74-81	6
1480	Trim33/Tif1 $\beta$ s involved in late stages of granulomonopoiesis in mice. <b>2016</b> , 44, 727-739.e6	10
1479	Prognostic impact of high levels of circulating plasmacytoid dendritic cells in breast cancer. <b>2016</b> , 14, 151	25
1478	Progress of dendritic cell-based cancer vaccines for patients with hematological malignancies. <b>2016</b> , 16, 1113-23	7
1477	A transcriptome-based global map of signaling pathways in the ovarian cancer microenvironment associated with clinical outcome. <b>2016</b> , 17, 108	64
1476	Oncolytic Immunotherapy for Treatment of Cancer. <b>2016</b> , 909, 241-83	10

1475	A clinical and biological perspective of human myeloid-derived suppressor cells in cancer. <b>2016</b> , 73, 4043-61	49
1474	Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma. <b>2016</b> , 4, 28	39
1473	mRNA-based dendritic cell immunization improves survival in ret transgenic mouse melanoma model. <b>2016</b> , 5, e1160183	3
1472	The Immune System and Its Contribution to the Radiotherapeutic Response of Glioblastoma. <b>2016</b> , 155-175	
1471	Predictive immune markers in advanced melanoma patients treated with ipilimumab. <b>2016</b> , 5, e1158901	16
1470	Anticancer metal drugs and immunogenic cell death. <b>2016</b> , 165, 71-79	76
1469	Improving cancer immunotherapy by targeting the STATe of MDSCs. <b>2016</b> , 5, e1196312	39
1468	Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies. <b>2016</b> , 73, 1569-89	62
1467	Low doses of gamma irradiation potentially modifies immunosuppressive tumor microenvironment by retuning tumor-associated macrophages: lesson from insulinoma. <b>2016</b> , 37, 301-313	49
1466	IL-6 down-regulates HLA class II expression and IL-12 production of human dendritic cells to impair activation of antigen-specific CD4(+) T cells. <b>2016</b> , 65, 193-204	55
1465	Amino acid auxotrophy as a system of immunological control nodes. <b>2016</b> , 17, 132-9	130
1464	Yeast-Derived Particulate $\beta$ -Glucan Treatment Subverts the Suppression of Myeloid-Derived Suppressor Cells (MDSC) by Inducing Polymorphonuclear MDSC Apoptosis and Monocytic MDSC Differentiation to APC in Cancer. <b>2016</b> , 196, 2167-80	65
1463	MIF inhibition reverts the gene expression profile of human melanoma cell line-induced MDSCs to normal monocytes. <b>2016</b> , 7, 240-2	9
1462	The potential therapeutic role of myeloid-derived suppressor cells in autoimmune arthritis. <b>2016</b> , 45, 490-5	33
1461	Synergistic COX2 Induction by IFN $\gamma$ and TNF $\alpha$ Self-Limits Type-1 Immunity in the Human Tumor Microenvironment. <b>2016</b> , 4, 303-11	46
1460	Myeloid cells in the tumor microenvironment: Role of adenosine. <b>2016</b> , 5, e1108515	27
1459	Rubus occidentalis: The black raspberry--its potential in the prevention of cancer. <b>2016</b> , 68, 18-28	14
1458	Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. <b>2016</b> , 22, 2908-18	372

1457	Tumor-associated macrophages of the M2 phenotype contribute to progression in gastric cancer with peritoneal dissemination. <b>2016</b> , 19, 1052-1065	122
1456	Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study. <b>2016</b> , 65, 161-9	140
1455	Myeloid derived suppressor cells in inflammatory conditions of the central nervous system. <b>2016</b> , 1862, 368-80	27
1454	Tumor microenvironment (TME)-driven immune suppression in B cell malignancy. <b>2016</b> , 1863, 471-482	67
1453	Myeloid-Derived Suppressor Cells: Possible Link Between Chronic Obstructive Pulmonary Disease and Lung Cancer. <b>2016</b> , 52, 29-35	1
1452	Drug delivery to macrophages: Challenges and opportunities. <b>2016</b> , 240, 202-211	71
1451	Circulating tumor-associated neutrophils (cTAN) contribute to circulating tumor cell survival by suppressing peripheral leukocyte activation. <b>2016</b> , 37, 5397-404	34
1450	B7-H4(B7x)-Mediated Cross-talk between Glioma-Initiating Cells and Macrophages via the IL6/JAK/STAT3 Pathway Lead to Poor Prognosis in Glioma Patients. <b>2016</b> , 22, 2778-2790	83
1449	Dendritic Cells in the Context of Human Tumors: Biology and Experimental Tools. <b>2016</b> , 35, 116-35	11
1448	Interaction of natural killer cells with neutrophils exerts a significant antitumor immunity in hematopoietic stem cell transplantation recipients. <b>2016</b> , 5, 49-60	9
1447	Induced arginine transport via cationic amino acid transporter-1 is necessary for human T-cell proliferation. <b>2016</b> , 46, 92-103	30
1446	Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas. <b>2016</b> , 18, 1157-68	53
1445	Invariant NKT cells are resistant to circulating CD15+ myeloid-derived suppressor cells in patients with head and neck cancer. <b>2016</b> , 107, 207-16	19
1444	Myeloid-Derived Suppressor Cells and Cancer. <b>2016</b> ,	2
1443	CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation. <b>2016</b> , 44, 303-15	227
1442	Ontogeny of Tumor-associated Macrophages and Its Implication in Cancer Regulation. <b>2016</b> , 2, 20-34	78
1441	Inflammatory Cells in Tumor Microenvironment. <b>2016</b> , 27-50	
1440	Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment. <b>2016</b> , 76, 2125-36	121



1439	Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?. <b>2016</b> , 16, 655-74	15
1438	Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab. <b>2016</b> , 4, 345-53	172
1437	RNAi nanomaterials targeting immune cells as an anti-tumor therapy: the missing link in cancer treatment?. <b>2016</b> , 19, 29-43	26
1436	High-mobility group box protein 1 promotes the survival of myeloid-derived suppressor cells by inducing autophagy. <b>2016</b> , 100, 463-70	41
1435	The clinical and prognostic significance of CD14(+)HLA-DR(-/low) myeloid-derived suppressor cells in hepatocellular carcinoma patients receiving radiotherapy. <b>2016</b> , 37, 10427-33	52
1434	miR-34a inhibits the apoptosis of MDSCs by suppressing the expression of N-myc. <b>2016</b> , 94, 563-72	9
1433	The emerging role of myeloid-derived suppressor cells in lung diseases. <b>2016</b> , 47, 967-77	31
1432	Aquaporin-3 Controls Breast Cancer Cell Migration by Regulating Hydrogen Peroxide Transport and Its Downstream Cell Signaling. <b>2016</b> , 36, 1206-18	74
1431	The Role of Microenvironment in the Control of Tumor Angiogenesis. <b>2016</b> ,	3
1430	The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. <b>2016</b> , 37, 208-220	1056
1429	Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies. <b>2016</b> , 11, 524-36	32
1428	Phorbol ester-induced neutrophilic inflammatory responses selectively promote metastatic spread of melanoma in a TLR4-dependent manner. <b>2016</b> , 5, e1078964	11
1427	Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition. <b>2016</b> , 18, 21	32
1426	The role of NF-κB in modulating antitumor immunity. <b>2016</b> , 5, e1005522	9
1425	Immune modulation by ER stress and inflammation in the tumor microenvironment. <b>2016</b> , 380, 227-36	30
1424	Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm. <b>2016</b> , 43, 39-43	35
1423	Influence of Immune Myeloid Cells on the Extracellular Matrix During Cancer Metastasis. <b>2016</b> , 9, 45-61	23
1422	The Basis of Oncoimmunology. <b>2016</b> , 164, 1233-1247	481

1421	Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs). <b>2016</b> , 22, 3924-36	197
1420	Role of the tumor stroma in resistance to anti-angiogenic therapy. <b>2016</b> , 25, 26-37	65
1419	Neutrophils: Critical components in experimental animal models of cancer. <b>2016</b> , 28, 197-204	29
1418	Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy. <b>2016</b> , 5, e1149674	41
1417	Myeloid-Derived Suppressor Cells: Possible Link Between Chronic Obstructive Pulmonary Disease and Lung Cancer. <b>2016</b> , 52, 29-35	5
1416	In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer. <b>2016</b> , 11, 295-303	276
1415	Enzymatic oxidative biodegradation of nanoparticles: Mechanisms, significance and applications. <b>2016</b> , 299, 58-69	72
1414	Activation of Hematopoietic Stem/Progenitor Cells Promotes Immunosuppression Within the Pre-metastatic Niche. <b>2016</b> , 76, 1335-47	83
1413	Cancer therapy targeting the fibrinolytic system. <b>2016</b> , 99, 172-179	13
1412	MDSCs in cancer: Conceiving new prognostic and therapeutic targets. <b>2016</b> , 1865, 35-48	51
1411	Expansion and functions of myeloid-derived suppressor cells in the tumor microenvironment. <b>2016</b> , 380, 253-6	56
1410	Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression. <b>2016</b> , 6, 80-95	276
1409	Immunosuppressive cells in tumor immune escape and metastasis. <b>2016</b> , 94, 509-22	168
1408	Human Head and Neck Squamous Cell Carcinoma-Associated Semaphorin 4D Induces Expansion of Myeloid-Derived Suppressor Cells. <b>2016</b> , 196, 1419-29	39
1407	Increased expression of TLR9 associated with pro-inflammatory S100A8 and IL-8 in diabetic wounds could lead to unresolved inflammation in type 2 diabetes mellitus (T2DM) cases with impaired wound healing. <b>2016</b> , 30, 99-108	33
1406	Non-Cell-Autonomous Regulation of Cellular Senescence in Cancer. <b>2016</b> , 26, 215-226	51
1405	Monocytes promote liver carcinogenesis in an oncogene-specific manner. <b>2016</b> , 64, 881-90	11
1404	Reprogramming the tumor microenvironment to enhance adoptive cellular therapy. <b>2016</b> , 28, 64-72	41

1403	Colony stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization. <b>2016</b> , 18, 797-806	114
1402	MIF Is Necessary for Late-Stage Melanoma Patient MDSC Immune Suppression and Differentiation. <b>2016</b> , 4, 101-12	42
1401	Tumor Presence Induces Global Immune Changes and Enhances Nanoparticle Clearance. <b>2016</b> , 10, 861-70	43
1400	Combination cancer immunotherapies tailored to the tumour microenvironment. <b>2016</b> , 13, 143-58	561
1399	The immunobiology of myeloid-derived suppressor cells in cancer. <b>2016</b> , 37, 1387-406	63
1398	Loss of SMAD4 Promotes Colorectal Cancer Progression by Accumulation of Myeloid-Derived Suppressor Cells through the CCL15-CCR1 Chemokine Axis. <b>2016</b> , 22, 492-501	72
1397	Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo. <b>2016</b> , 30, 570-9	85
1396	Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination. <b>2016</b> , 22, 1161-72	49
1395	All that glitters is not gold: the need to consider desirable and undesirable immune aspects of oncolytic virus therapy. <b>2016</b> , 5, e1057674	5
1394	Breaking bad habits: Targeting MDSCs to alleviate immunosuppression in prostate cancer. <b>2016</b> , 5, e1078060	6
1393	Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities. <b>2016</b> , 94, 21-35	22
1392	From T cell "exhaustion" to anti-cancer immunity. <b>2016</b> , 1865, 49-57	13
1391	More than a scaffold: Stromal modulation of tumor immunity. <b>2016</b> , 1865, 3-13	25
1390	Inhibition of vacuolar ATPase subunit in tumor cells delays tumor growth by decreasing the essential macrophage population in the tumor microenvironment. <b>2016</b> , 35, 1058-65	29
1389	TLR-signaling and proinflammatory cytokines as drivers of tumorigenesis. <b>2017</b> , 89, 127-135	100
1388	Tumor microenvironment and therapeutic response. <b>2017</b> , 387, 61-68	624
1387	The delicate balance of macrophages in colorectal cancer; their role in tumour development and therapeutic potential. <b>2017</b> , 222, 21-30	26
1386	The myeloid immune signature of enterotoxigenic <i>Bacteroides fragilis</i> -induced murine colon tumorigenesis. <b>2017</b> , 10, 421-433	96

1385	Chronic hepatitis B surface antigen seroclearance-related immune factors. <b>2017</b> , 47, 49-59	9
1384	COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells. <b>2017</b> , 114, 1117-1122	237
1383	Systemic Immunity Is Required for Effective Cancer Immunotherapy. <b>2017</b> , 168, 487-502.e15	484
1382	Macrophage Polarization: Anti-Cancer Strategies to Target Tumor-Associated Macrophage in Breast Cancer. <b>2017</b> , 118, 2484-2501	84
1381	Tumour-associated macrophages as treatment targets in oncology. <b>2017</b> , 14, 399-416	1649
1380	Tumor location determines tissue-specific recruitment of tumor-associated macrophages and antibody-dependent immunotherapy response. <b>2017</b> , 2,	48
1379	Fluorescent nanodiamonds engage innate immune effector cells: A potential vehicle for targeted anti-tumor immunotherapy. <b>2017</b> , 13, 909-920	21
1378	Pathogen boosted adoptive cell transfer immunotherapy to treat solid tumors. <b>2017</b> , 114, 740-745	16
1377	Neutrophils dominate the immune cell composition in non-small cell lung cancer. <b>2017</b> , 8, 14381	190
1376	Experimental animal modeling for immuno-oncology. <b>2017</b> , 173, 34-46	25
1375	Intrinsic Resistance of Solid Tumors to Immune Checkpoint Blockade Therapy. <b>2017</b> , 77, 817-822	88
1374	Identification of inhibitors of myeloid-derived suppressor cells activity through phenotypic chemical screening. <b>2017</b> , 6, e1258503	10
1373	IL4-induced gene 1 promotes tumor growth by shaping the immune microenvironment in melanoma. <b>2017</b> , 6, e1278331	15
1372	Initiative action of tumor-associated macrophage during tumor metastasis. <b>2017</b> , 4, 8-18	38
1371	Breast Cancer Immunology and Immunotherapy: Current Status and Future Perspectives. <b>2017</b> , 331, 1-53	30
1370	IRF7 regulates the development of granulocytic myeloid-derived suppressor cells through S100A9 transrepression in cancer. <b>2017</b> , 36, 2969-2980	26
1369	Radiotherapy and immunotherapy: a beneficial liaison?. <b>2017</b> , 14, 365-379	504
1368	Systematic Pan-Cancer Analysis Reveals Immune Cell Interactions in the Tumor Microenvironment. <b>2017</b> , 77, 1271-1282	83

1367	Mechanisms overseeing myeloid-derived suppressor cell production in neoplastic disease. <b>2017</b> , 66, 989-996	33
1366	Tumor-infiltrating neutrophils predict benefit from adjuvant chemotherapy in patients with muscle invasive bladder cancer. <b>2017</b> , 6, e1293211	37
1365	Energy metabolism drives myeloid-derived suppressor cell differentiation and functions in pathology. <b>2017</b> , 102, 325-334	31
1364	Epinephrine promotes COX-2-dependent immune suppression in myeloid cells and cancer tissues. <b>2017</b> , 62, 78-86	24
1363	Expansion of myeloid-derived suppressor cells with aging in the bone marrow of mice through a NF- $\kappa$ B-dependent mechanism. <b>2017</b> , 16, 480-487	50
1362	The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy. <b>2017</b> , 24, R123-R144	45
1361	Dendritic cell rehab: new strategies to unleash therapeutic immunity in ovarian cancer. <b>2017</b> , 66, 969-977	16
1360	Escape from IFN- $\gamma$ -dependent immunosurveillance in tumorigenesis. <b>2017</b> , 24, 10	51
1359	Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities. <b>2017</b> , 66, 979-988	37
1358	Carcinogenesis mechanisms of <i>Fusobacterium nucleatum</i> . <b>2017</b> , 89, 918-925	81
1357	NKG2D ligand RAE1 $\alpha$ induces generation and enhances the inhibitor function of myeloid-derived suppressor cells in mice. <b>2017</b> , 21, 2046-2054	9
1356	Local Activation of p53 in the Tumor Microenvironment Overcomes Immune Suppression and Enhances Antitumor Immunity. <b>2017</b> , 77, 2292-2305	70
1355	Hedgehog Signaling Links Chronic Inflammation to Gastric Cancer Precursor Lesions. <b>2017</b> , 3, 201-210	48
1354	Dynamics of myeloid cell populations during relapse-preventive immunotherapy in acute myeloid leukemia. <b>2017</b> , 102, 467-474	10
1353	MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. <b>2017</b> , 129, 1791-1801	79
1352	Cancer-immune therapy: restoration of immune response in cancer by immune cell modulation. <b>2017</b> , 60, 93-109	1
1351	DNA vaccines for prostate cancer. <b>2017</b> , 174, 27-42	25
1350	Heterogeneity of macrophage infiltration and therapeutic response in lung carcinoma revealed by 3D organ imaging. <b>2017</b> , 8, 14293	127

1349	Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche. <b>2017</b> , 102, 265-275	18
1348	Immunoregulatory functions of VISTA. <b>2017</b> , 276, 66-79	104
1347	The clinical evidence for targeting human myeloid-derived suppressor cells in cancer patients. <b>2017</b> , 102, 381-391	42
1346	Exploiting tumor-associated dendritic cell heterogeneity for novel cancer therapies. <b>2017</b> , 102, 317-324	19
1345	CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma. <b>2017</b> , 66, 1015-1023	56
1344	Immune-Mediated and Hypoxia-Regulated Programs: Accomplices in Resistance to Anti-angiogenic Therapies. <b>2018</b> , 249, 31-61	7
1343	Tumor-associated myeloid cells as guiding forces of cancer cell stemness. <b>2017</b> , 66, 1025-1036	37
1342	Nanotechnology based therapeutic modality to boost anti-tumor immunity and collapse tumor defense. <b>2017</b> , 256, 26-45	27
1341	Rationale for New Checkpoint Inhibitor Combinations in Melanoma Therapy. <b>2017</b> , 18, 597-611	11
1340	Arginase inhibition suppresses lung metastasis in the 4T1 breast cancer model independently of the immunomodulatory and anti-metastatic effects of VEGFR-2 blockade. <b>2017</b> , 6, e1316437	28
1339	Tuning cancer fate: the unremitting role of host immunity. <b>2017</b> , 7,	25
1338	A phase 2, randomized, double-blind, placebo-controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study. <b>2017</b> , 28, 996-1004	46
1337	First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors. <b>2017</b> , 35, 298-306	19
1336	Targeting Autocrine CCL5-CCR5 Axis Reprograms Immunosuppressive Myeloid Cells and Reinvigorates Antitumor Immunity. <b>2017</b> , 77, 2857-2868	76
1335	Glycolysis regulates the expansion of myeloid-derived suppressor cells in tumor-bearing hosts through prevention of ROS-mediated apoptosis. <b>2017</b> , 8, e2779	69
1334	STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy. <b>2017</b> , 77, 3619-3631	44
1333	TIM-3 plays a more important role than PD-1 in the functional impairments of cytotoxic T cells of malignant Schwannomas. <b>2017</b> , 39, 1010428317698352	11
1332	Metabolic regulation of suppressive myeloid cells in cancer. <b>2017</b> , 35, 27-35	23

1331	Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non-Small Cell Lung Cancer. <b>2017</b> , 12, 1085-1097	128
1330	Interleukin-1 and estrogen protect against disseminating dentoalveolar infections. <b>2017</b> , 9, 16-23	6
1329	CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF- $\beta$ /mTOR-HIF-1 signaling in patients with non-small cell lung cancer. <b>2017</b> , 6, e1320011	136
1328	Mutant IDH1 regulates the tumor-associated immune system in gliomas. <b>2017</b> , 31, 774-786	218
1327	Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses. <b>2017</b> , 169, 750-765.e1729	1729
1326	Novel Use of All-Trans-Retinoic Acid in A Model of Lipopolysaccharide-Immunosuppression to Decrease the Generation of Myeloid-Derived Suppressor Cells by Reducing the Proliferation of CD34+ Precursor Cells. <b>2017</b> , 48, 94-103	12
1325	Toll-like receptor 2 cells identify circulating monocytes in human and non-human primates. <b>2017</b> , 91, 364-371	8
1324	CXCL1 Is Critical for Premetastatic Niche Formation and Metastasis in Colorectal Cancer. <b>2017</b> , 77, 3655-3665	165
1323	Expansion of CD11bLy6G and CD11bCD49d myeloid cells with suppressive potential in mice with chronic inflammation and light-at-night-induced circadian disruption. <b>2017</b> , 66, 711-724	6
1322	Elemerene inhibits tumor-promoting effect of M2 macrophages in lung cancer. <b>2017</b> , 490, 514-520	44
1321	Targeting the tumor and its associated stroma: One and one can make three in adoptive T cell therapy of solid tumors. <b>2017</b> , 36, 57-65	9
1320	Bacterial Vaccines. <b>2017</b> , 77-94	
1319	Overcoming immunosuppression in bone metastases. <b>2017</b> , 117, 114-127	19
1318	Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma-New Therapeutic Targets. <b>2017</b> , 41, 998-1004	28
1317	Energy metabolic pathways control the fate and function of myeloid immune cells. <b>2017</b> , 102, 369-380	34
1316	Tadalafil has biologic activity in human melanoma. Results of a pilot trial with Tadalafil in patients with metastatic Melanoma (TaMe). <b>2017</b> , 6, e1326440	51
1315	Immunotherapeutic approaches of IL-1 neutralization in the tumor microenvironment. <b>2017</b> , 102, 293-306	27
1314	M2-like macrophage polarization in high lactic acid-producing head and neck cancer. <b>2017</b> , 108, 1128-1134	77

1313	Myeloid Populations in Systemic Autoimmune Diseases. <b>2017</b> , 53, 198-218	18
1312	Delivering safer immunotherapies for cancer. <b>2017</b> , 114, 79-101	154
1311	Expansion and activation of granulocytic, myeloid-derived suppressor cells in childhood precursor B cell acute lymphoblastic leukemia. <b>2017</b> , 102, 449-458	18
1310	PD-1 and PD-L1 in neoplastic cells and the tumor microenvironment of Merkel cell carcinoma. <b>2017</b> , 44, 740-746	24
1309	STAT3 in cancer: A double edged sword. <b>2017</b> , 98, 42-50	102
1308	Bruton's tyrosine kinase (BTK) as a promising target in solid tumors. <b>2017</b> , 58, 41-50	68
1307	Phenotype and Function of Myeloid-Derived Suppressor Cells Induced by Porphyromonas gingivalis Infection. <b>2017</b> , 85,	31
1306	Myeloid-derived suppressor cells-a new therapeutic target to overcome resistance to cancer immunotherapy. <b>2017</b> , 102, 727-740	64
1305	Epigenetic mechanisms of myeloid differentiation in the tumor microenvironment. <b>2017</b> , 35, 20-29	7
1304	C-C Chemokine Receptor Type 2-Dependent Migration of Myeloid-Derived Suppressor Cells in Protection of Islet Transplants. <b>2017</b> , 101, 1793-1800	17
1303	Gemtuzumab ozogamicin in acute myeloid leukemia. <b>2017</b> , 31, 1855-1868	128
1302	Intratumoral infection by CMV may change the tumor environment by directly interacting with tumor-associated macrophages to promote cancer immunity. <b>2017</b> , 13, 1778-1785	13
1301	Review: Biological and Molecular Differences between Tail Regeneration and Limb Scarring in Lizard: An Inspiring Model Addressing Limb Regeneration in Amniotes. <b>2017</b> , 328, 493-514	36
1300	Doxorubicin Hydrochloride Loaded Zymosan-Polyethylenimine Biopolymeric Nanoparticles for Dual 'Chemoimmunotherapeutic' Intervention in Breast Cancer. <b>2017</b> , 34, 1857-1871	8
1299	The Untold Story of Granzymes in Oncoimmunology: Novel Opportunities with Old Acquaintances. <b>2017</b> , 3, 407-422	33
1298	ZEB1-regulated inflammatory phenotype in breast cancer cells. <b>2017</b> , 11, 1241-1262	61
1297	Downregulation of lizard immuno-genes in the regenerating tail and myogenes in the scarring limb suggests that tail regeneration occurs in an immuno-privileged organ. <b>2017</b> , 254, 2127-2141	29
1296	Exosomes: New Biomarkers for Targeted Cancer Therapy. <b>2017</b> , 129-157	5



1295	Myeloid cells expressing high level of CD45 are associated with a distinct activated phenotype in glioma. <b>2017</b> , 65, 757-768	16
1294	Immunophenotype of neutrophils in oral squamous cell carcinoma patients. <b>2017</b> , 46, 703-709	9
1293	Initiation and Maintenance of Gastric Cancer: A Focus on CD44 Variant Isoforms and Cancer Stem Cells. <b>2017</b> , 4, 55-63	41
1292	The cryo-thermal therapy eradicated melanoma in mice by eliciting CD4 T-cell-mediated antitumor memory immune response. <b>2017</b> , 8, e2703	23
1291	Overview of Basic Immunology for Clinical Investigators. <b>2017</b> , 995, 1-31	4
1290	Lipocalin-2 and iron trafficking in the tumor microenvironment. <b>2017</b> , 120, 146-156	37
1289	Liposomal microparticle injection can induce myeloid-derived suppressor cells (MDSC)-like cells in vivo. <b>2017</b> , 39, 140-147	4
1288	Chemotherapeutic tumor microparticles combining low-dose irradiation reprogram tumor-promoting macrophages through a tumor-repopulating cell-curtailling pathway. <b>2017</b> , 6, e1309487	17
1287	Immune Modulatory microRNAs Involved in Tumor Attack and Tumor Immune Escape. <b>2017</b> , 109,	91
1286	SETD1B Activates iNOS Expression in Myeloid-Derived Suppressor Cells. <b>2017</b> , 77, 2834-2843	36
1285	The Promise of Targeting Macrophages in Cancer Therapy. <b>2017</b> , 23, 3241-3250	190
1284	Tumor-Associated Macrophages and Regulatory T Cells Infiltration and the Clinical Outcome in Colorectal Cancer. <b>2017</b> , 65, 445-454	92
1283	CD13 Neutrophil-like myeloid-derived suppressor cells exert immune suppression through Arginase 1 expression in pancreatic ductal adenocarcinoma. <b>2017</b> , 6, e1258504	33
1282	Molecular Oncology: Underlying Mechanisms and Translational Advancements. <b>2017</b> ,	1
1281	Myeloid-derived suppressor cells and T regulatory cells in tumors: unraveling the dark side of the force. <b>2017</b> , 102, 407-421	22
1280	Myeloid-derived suppressor cells and myeloid regulatory cells in cancer and autoimmune disorders. <b>2017</b> , 13, 378-388	13
1279	Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy?. <b>2017</b> , 17, 735-746	36
1278	Immunotherapy. <b>2017</b> ,	4

1277	T Cells Encountering Myeloid Cells Programmed for Amino Acid-dependent Immunosuppression Use Rictor/mTORC2 Protein for Proliferative Checkpoint Decisions. <b>2017</b> , 292, 15-30	37
1276	Frontline Science: Myeloid-derived suppressor cells (MDSCs) facilitate maternal-fetal tolerance in mice. <b>2017</b> , 101, 1091-1101	49
1275	Chronic Type I IFN Is Sufficient To Promote Immunosuppression through Accumulation of Myeloid-Derived Suppressor Cells. <b>2017</b> , 198, 1156-1163	29
1274	Predictive Outcomes for HER2-enriched Cancer Using Growth and Metastasis Signatures Driven By SPARC. <b>2017</b> , 15, 304-316	14
1273	Homeostatic migration and distribution of innate immune cells in primary and secondary lymphoid organs with ageing. <b>2017</b> , 187, 337-344	3
1272	CpG and transfer factor assembled on nanoparticles reduce tumor burden in mice glioma model. <b>2017</b> , 7, 11644-11651	2
1271	The Sabotaging Role of Myeloid Cells in Anti-Angiogenic Therapy: Coordination of Angiogenesis and Immune Suppression by Hypoxia. <b>2017</b> , 232, 2312-2322	18
1270	Suppression of T cells by myeloid-derived suppressor cells in cancer. <b>2017</b> , 78, 113-119	42
1269	Myeloid-Derived Suppressor Cells. <b>2017</b> , 5, 3-8	833
1268	Kinetics of Myeloid-Derived Suppressor Cell Frequency and Function during Simian Immunodeficiency Virus Infection, Combination Antiretroviral Therapy, and Treatment Interruption. <b>2017</b> , 198, 757-766	17
1267	Establishing High Dimensional Immune Signatures from Peripheral Blood via Mass Cytometry in a Discovery Cohort of Stage IV Melanoma Patients. <b>2017</b> , 198, 927-936	27
1266	Extracellular Matrix Remodeling and Stiffening Modulate Tumor Phenotype and Treatment Response. <b>2017</b> , 1, 313-334	59
1265	Re-calculating! Navigating through the osteosarcoma treatment roadblock. <b>2017</b> , 117, 54-64	18
1264	Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody. <b>2017</b> , 23, 2942-2950	96
1263	Self-renewal molecular mechanisms of colorectal cancer stem cells. <b>2017</b> , 39, 9-20	25
1262	Dynamic contrast-enhanced MR imaging in predicting progression of enhancing lesions persisting after standard treatment in glioblastoma patients: a prospective study. <b>2017</b> , 27, 3156-3166	23
1261	The novel roles of stromal fibroblasts in metronomic chemotherapy: Focusing on cancer stemness and immunity. <b>2017</b> , 4, 123-126	
1260	Targeting tumor associated macrophages: The new challenge for nanomedicine. <b>2017</b> , 34, 103-113	74

1259	The role of nitric oxide in melanoma. <b>2017</b> , 1868, 500-509	32
1258	Immunotherapy of Hepatocellular Carcinoma. <b>2017</b> ,	
1257	MMP-9-cleaved osteopontin isoform mediates tumor immune escape by inducing expansion of myeloid-derived suppressor cells. <b>2017</b> , 493, 1478-1484	22
1256	MDSCs are induced after experimental blunt chest trauma and subsequently alter antigen-specific T cell responses. <b>2017</b> , 7, 12808	15
1255	Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. <b>2017</b> , 47, 789-802.e9	142
1254	Tumor-associated neutrophils induce apoptosis of non-activated CD8 T-cells in a TNF $\alpha$ and NO-dependent mechanism, promoting a tumor-supportive environment. <b>2017</b> , 6, e1356965	64
1253	Tumor Immunology meets Immunology: Modified cancer cells as professional APC for priming naive tumor-specific CD4+ T cells. <b>2017</b> , 6, e1356149	9
1252	Breast tumors educate the proteome of stromal tissue in an individualized but coordinated manner. <b>2017</b> , 10,	21
1251	The adaptor molecule RIAM integrates signaling events critical for integrin-mediated control of immune function and cancer progression. <b>2017</b> , 10,	14
1250	Systemic Inflammation Response Index (SIRI), cancer stem cells and survival of localised gastric adenocarcinoma after curative resection. <b>2017</b> , 143, 2455-2468	54
1249	Inflammation fires up cancer metastasis. <b>2017</b> , 47, 170-176	46
1248	Molecular-Targeted Immunotherapeutic Strategy for Melanoma via Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages. <b>2017</b> , 11, 9536-9549	179
1247	Anti-Jagged Immunotherapy Inhibits MDSCs and Overcomes Tumor-Induced Tolerance. <b>2017</b> , 77, 5628-5638	43
1246	Nanomaterials for cancer immunotherapy. <b>2017</b> , 148, 16-30	173
1245	Loss of MAPK-activated protein kinase 2 enables potent dendritic cell-driven anti-tumour T cell response. <b>2017</b> , 7, 11746	4
1244	Anti-CD137 Suppresses Tumor Growth by Blocking Reverse Signaling by CD137 Ligand. <b>2017</b> , 77, 5989-6000	28
1243	Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. <b>2017</b> , 8, 593	104
1242	IL4 Receptor-Targeted Proapoptotic Peptide Blocks Tumor Growth and Metastasis by Enhancing Antitumor Immunity. <b>2017</b> , 16, 2803-2816	17

1241	Therapeutic potential of carbohydrates as regulators of macrophage activation. <b>2017</b> , 146, 23-41	22
1240	Increased Percentage of mo-MDSCs in Human Peripheral Blood May Be a Potential Indicator in the Diagnosis of Breast Cancer. <b>2017</b> , 40, 603-608	4
1239	Metabolic Interactions in the Tumor Microenvironment. <b>2017</b> , 27, 863-875	369
1238	Myeloid suppressor cells in cancer and autoimmunity. <b>2017</b> , 85, 117-125	108
1237	Obesity alters the lung myeloid cell landscape to enhance breast cancer metastasis through IL5 and GM-CSF. <b>2017</b> , 19, 974-987	127
1236	An antisense oligonucleotide targeting TGF- $\beta$ inhibits lung metastasis and induces CD86 expression in tumor-associated macrophages. <b>2017</b> , 28, 2278-2285	13
1235	Adipose Progenitor Cell Secretion of GM-CSF and MMP9 Promotes a Stromal and Immunological Microenvironment That Supports Breast Cancer Progression. <b>2017</b> , 77, 5169-5182	42
1234	Dual role of monocyte-derived dendritic cells in <i>Trypanosoma cruzi</i> infection. <b>2017</b> , 47, 1936-1948	12
1233	Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention. <b>2017</b> , 67, 378-397	303
1232	Cellular metabolism of tumor-associated macrophages - functional impact and consequences. <b>2017</b> , 591, 3022-3041	31
1231	Effect of the lymphocyte-to-monocyte ratio on the clinical outcome of chemotherapy administration in advanced melanoma patients. <b>2017</b> , 27, 32-42	15
1230	Design of nanocarriers based on complex biological barriers in vivo for tumor therapy. <b>2017</b> , 15, 56-90	79
1229	Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk. <b>2017</b> , 102, 1469-1476	31
1228	The Immunology of Melanoma. <b>2017</b> , 37, 449-471	21
1227	Migrating into the Tumor: a Roadmap for T Cells. <b>2017</b> , 3, 797-808	136
1226	Osteoblasts remotely supply lung tumors with cancer-promoting SiglecF neutrophils. <b>2017</b> , 358,	172
1225	The Contribution of Immune Cells to Angiogenesis in Inflammation and Tumor Growth. <b>2017</b> , 27-84	1
1224	Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors. <b>2017</b> , 32, 654-668.e5	293

1223	Nitric oxide mediated inhibition of antigen presentation from DCs to CD4 T cells in cancer and measurement of STAT1 nitration. <b>2017</b> , 7, 15424	37
1222	Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes. <b>2017</b> , 8, 1404	114
1221	Regulatory myeloid cells: an underexplored continent in B-cell lymphomas. <b>2017</b> , 66, 1103-1111	15
1220	RGD-Modified Albumin Nanoconjugates for Targeted Delivery of a Porphyrin Photosensitizer. <b>2017</b> , 14, 2793-2804	38
1219	Exogenous lipid uptake induces metabolic and functional reprogramming of tumor-associated myeloid-derived suppressor cells. <b>2017</b> , 6, e1344804	130
1218	Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity. <b>2017</b> , 5, 676-684	91
1217	The potential role of platelets in the consensus molecular subtypes of colorectal cancer. <b>2017</b> , 36, 273-288	26
1216	Stat6 Promotes Intestinal Tumorigenesis in a Mouse Model of Adenomatous Polyposis by Expansion of MDSCs and Inhibition of Cytotoxic CD8 Response. <b>2017</b> , 19, 595-605	25
1215	Myeloid-Derived Suppressor Cells Associated With Disease Progression in Primary HIV Infection: PD-L1 Blockade Attenuates Inhibition. <b>2017</b> , 76, 200-208	27
1214	Interferon signaling in ascites-associated macrophages is linked to a favorable clinical outcome in a subgroup of ovarian carcinoma patients. <b>2017</b> , 18, 243	27
1213	Cytokine response to the RSV antigen delivered by dendritic cell-directed vaccination in congenic chicken lines. <b>2017</b> , 48, 18	5
1212	Myeloid-derived suppressor cells and tumor escape from immune surveillance. <b>2017</b> , 39, 295-305	49
1211	Near-infrared ratiometric fluorescent detection of arginine in lysosome with a new hemicyanine derivative. <b>2017</b> , 92, 385-389	32
1210	The Diverse Biological Functions of Neutrophils, Beyond the Defense Against Infections. <b>2017</b> , 40, 311-323	46
1209	The transcriptome of lung tumor-infiltrating dendritic cells reveals a tumor-supporting phenotype and a microRNA signature with negative impact on clinical outcome. <b>2017</b> , 6, e1253655	40
1208	Double-stranded RNA promotes CTL-independent tumor cytolysis mediated by CD11bLy6G intratumor myeloid cells through the TICAM-1 signaling pathway. <b>2017</b> , 24, 385-396	23
1207	Immune-Suppressing Cellular Elements of the Tumor Microenvironment. <b>2017</b> , 1, 241-255	18
1206	Immunogenic cell death in cancer and infectious disease. <i>Nature Reviews Immunology</i> , <b>2017</b> , 17, 97-111	36.5 1257

1205	Secondary Alterations of Hepatocellular Carcinoma. <b>2017</b> , 121-149	
1204	Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1 $\beta$ , IL8, CXCL5, and Mip-1 $\beta$ . <b>2017</b> , 23, 2346-2355	101
1203	Molecular mechanisms involved in dendritic cell dysfunction in cancer. <b>2017</b> , 74, 761-776	51
1202	Loss of SMAD4 Promotes Lung Metastasis of Colorectal Cancer by Accumulation of CCR1+ Tumor-Associated Neutrophils through CCL15-CCR1 Axis. <b>2017</b> , 23, 833-844	45
1201	l-Arginine and Macrophages: Role in Classical and Alternative Activation. <b>2017</b> , 117-129	
1200	Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells. <b>2017</b> , 36, 1090-1101	73
1199	Inflammation-induced myeloid-derived suppressor cells associated with squamous cell carcinoma of the head and neck. <b>2017</b> , 39, 347-355	25
1198	Mir-223 regulates the number and function of myeloid-derived suppressor cells in multiple sclerosis and experimental autoimmune encephalomyelitis. <b>2017</b> , 133, 61-77	52
1197	Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy. <b>2017</b> , 23, 1955-1966	18
1196	Effects of Ageing on Adaptive Immune Responses. <b>2017</b> , 21-33	
1195	Tumor Cell-Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Suppressor Cells. <b>2017</b> , 7, 72-85	102
1194	The Ageing Immune System and Health. <b>2017</b> ,	1
1193	Macrophage NOS2 in Tumor Leukocytes. <b>2017</b> , 26, 1023-1043	12
1192	Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy. <b>2017</b> ,	6
1191	Targeting Myeloid-Derived Suppressor Cells in Cancer. <b>2017</b> , 1036, 105-128	36
1190	Updated Landscape of the Tumor Microenvironment and Targeting Strategies in an Era of Precision Medicine. <b>2017</b> ,	
1189	Novel GM-CSF signals via IFN- $\beta$ /IRF-1 and AKT/mTOR license monocytes for suppressor function. <b>2017</b> , 1, 947-960	58
1188	Pak2 regulates myeloid-derived suppressor cell development in mice. <b>2017</b> , 1, 1923-1933	9

1187	TLR/MyD88-mediated Innate Immunity in Intestinal Graft-versus-Host Disease. <b>2017</b> , 17, 144-151	15
1186	validation of metastasis-regulating microRNA-766 in human triple-negative breast cancer cells. <b>2017</b> , 33, 256-263	11
1185	Major Challenges and Potential Microenvironment-Targeted Therapies in Glioblastoma. <b>2017</b> , 18,	21
1184	A brief review of clinical trials involving manipulation of invariant NKT cells as a promising approach in future cancer therapies. <b>2017</b> , 42, 181-195	15
1183	Immunotherapy for Pediatric Brain Tumors. <b>2017</b> , 7,	13
1182	Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment. <b>2017</b> , 18,	22
1181	Tumor abolition and antitumor immunostimulation by physico-chemical tumor ablation. <b>2017</b> , 22, 310-347	25
1180	Resolution of Cancer-Promoting Inflammation: A New Approach for Anticancer Therapy. <b>2017</b> , 8, 71	60
1179	Human Tumor-Infiltrating Myeloid Cells: Phenotypic and Functional Diversity. <b>2017</b> , 8, 86	122
1178	Arginine Metabolism in Myeloid Cells Shapes Innate and Adaptive Immunity. <b>2017</b> , 8, 93	145
1177	Critical Role of Myeloid-Derived Suppressor Cells in Tumor-Induced Liver Immune Suppression through Inhibition of NKT Cell Function. <b>2017</b> , 8, 129	23
1176	The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments. <b>2017</b> , 8, 631	103
1175	CD95/Fas, Non-Apoptotic Signaling Pathways, and Kinases. <b>2017</b> , 8, 1216	41
1174	Interleukin-6 -Signaling Pathway Promotes Immunosuppressive Myeloid-Derived Suppressor Cells Suppression of Suppressor of Cytokine Signaling 3 in Breast Cancer. <b>2017</b> , 8, 1840	54
1173	Multiple Myeloma Cells Express Key Immunoregulatory Cytokines and Modulate the Monocyte Migratory Response. <b>2017</b> , 4, 92	5
1172	Innate Immune Pathways Associated with Lung Radioprotection by Soy Isoflavones. <b>2017</b> , 7, 7	10
1171	The Unique Molecular and Cellular Microenvironment of Ovarian Cancer. <b>2017</b> , 7, 24	123
1170	Combining Oncolytic Adenovirus with Radiation-A Paradigm for the Future of Radiosensitization. <b>2017</b> , 7, 153	26

1169	Role of Dietary Metabolites in Regulating the Host Immune Response in Gastrointestinal Disease. <b>2017, 8, 51</b>	8
1168	Evolutionary Perspective of Tumorigenesis and Antitumor Immunity: A Comparative Approach. <b>2017, 119-135</b>	1
1167	Myeloid-derived suppressor cells in ovarian cancer: friend or foe?. <b>2017, 42, 383-389</b>	8
1166	Granulocytic myeloid-derived suppressor cells suppress virus-specific CD8 T cell responses during acute Friend retrovirus infection. <b>2017, 14, 42</b>	13
1165	The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment. <b>2017, 5, 63</b>	42
1164	Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment. <b>2017, 5, 101</b>	174
1163	Immunomodulatory Activity of MicroRNAs: Potential Implications for Multiple Myeloma Treatment. <b>2017, 17, 819-838</b>	11
1162	Dissecting neutrophil complexity in cancer. <b>2017, 1, 457-470</b>	3
1161	On the origin of myeloid-derived suppressor cells. <b>2017, 8, 3649-3665</b>	109
1160	Differentiated tumor immune microenvironment of Epstein-Barr virus-associated and negative gastric cancer: implication in prognosis and immunotherapy. <b>2017, 8, 67094-67103</b>	25
1159	Carcinogenesis-relevant biological events in the pathophysiology of the efferocytosis phenomenon. <b>2017, 11, 343</b>	3
1158	The paradoxical role of tumor-infiltrating immune cells in lung cancer. <b>2017, 6, 234-241</b>	12
1157	Natural Killer Cells in the Near Future of Immuno-Oncological Therapeutic Approaches. <b>2017,</b>	
1156	Prospect of the use of checkpoint inhibitors in hepatocellular cancer treatments. <b>2017, 9, 19-27</b>	13
1155	The Process and Regulatory Components of Inflammation in Brain Oncogenesis. <b>2017, 7,</b>	51
1154	's link to colorectal neoplasia sequenced: A systematic review and future insights. <b>2017, 23, 8626-8650</b>	38
1153	Microenvironmental regulation of the progression of oral potentially malignant disorders towards malignancy. <b>2017, 8, 81617-81635</b>	10
1152	Bistability of the cytokine-immune cell network in a cancer microenvironment. <b>2017, 3, 024002</b>	5



1151	Targeting complement-mediated immunoregulation for cancer immunotherapy. <b>2018</b> , 37, 85-97	28
1150	Implications of macrophage polarization in autoimmunity. <b>2018</b> , 154, 186-195	218
1149	Tumor-infiltrating lymphocytes and ductal carcinoma in situ of the breast: friends or foes?. <b>2018</b> , 31, 1012-1025	19
1148	Epigenetic interplay between immune, stromal and cancer cells in the tumor microenvironment. <b>2018</b> , 196, 64-71	38
1147	Tumor-derived thymic stromal lymphopoietin enhances lung metastasis through an alveolar macrophage-dependent mechanism. <b>2018</b> , 7, e1419115	9
1146	Arginase-1 is neither constitutively expressed in nor required for myeloid-derived suppressor cell-mediated inhibition of T-cell proliferation. <b>2018</b> , 48, 1046-1058	30
1145	Interleukin-30/IL27p28 Shapes Prostate Cancer Stem-like Cell Behavior and Is Critical for Tumor Onset and Metastasization. <b>2018</b> , 78, 2654-2668	22
1144	Interleukin-10 produced by myeloid-derived suppressor cells is critical for the induction of Tregs and attenuation of rheumatoid inflammation in mice. <b>2018</b> , 8, 3753	84
1143	Arginase-1 Expression in Myeloid Cells Regulates Staphylococcus aureus Planktonic but Not Biofilm Infection. <b>2018</b> , 86,	23
1142	Molecular Regulation of Bone Metastasis Pathogenesis. <b>2018</b> , 46, 1423-1438	39
1141	Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non-Small Cell Lung Cancer. <b>2018</b> , 198, 777-787	79
1140	Compromised functionality of monocyte-derived dendritic cells in multiple myeloma patients may limit their use in cancer immunotherapy. <b>2018</b> , 8, 5705	28
1139	Therapeutic prospects of targeting myeloid-derived suppressor cells and immune checkpoints in cancer. <b>2018</b> , 96, 888-897	33
1138	T cell-induced CSF1 promotes melanoma resistance to PD1 blockade. <b>2018</b> , 10,	140
1137	The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy. <b>2018</b> , 10,	207
1136	Caspase-1 from Human Myeloid-Derived Suppressor Cells Can Promote T Cell-Independent Tumor Proliferation. <b>2018</b> , 6, 566-577	10
1135	Secretory IgM Exacerbates Tumor Progression by Inducing Accumulations of MDSCs in Mice. <b>2018</b> , 6, 696-710	13
1134	Dually emitting gold-silver nanoclusters as viable ratiometric fluorescent probes for cysteine and arginine. <b>2018</b> , 185, 147	25

1133	3D-3-culture: A tool to unveil macrophage plasticity in the tumour microenvironment. <b>2018</b> , 163, 185-197	107
1132	Exosomes derived from B16F0 melanoma cells alter the transcriptome of cytotoxic T cells that impacts mitochondrial respiration. <b>2018</b> , 285, 1033-1050	43
1131	Myeloid cell heterogeneity in cancer: not a single cell alike. <b>2018</b> , 330, 188-201	89
1130	B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors. <b>2018</b> , 26, 695-707	17
1129	Aneustat (OMN54) has aerobic glycolysis-inhibitory activity and also immunomodulatory activity as indicated by a first-generation PDX prostate cancer model. <b>2018</b> , 143, 419-429	5
1128	Tumor associated macrophages in gynecologic cancers. <b>2018</b> , 149, 205-213	51
1127	Metformin-Induced Reduction of CD39 and CD73 Blocks Myeloid-Derived Suppressor Cell Activity in Patients with Ovarian Cancer. <b>2018</b> , 78, 1779-1791	135
1126	Editorial: Two MDSC faces in obesity: Correcting metabolic dysfunctions but promoting tumor development. <b>2018</b> , 103, 373-375	2
1125	Myeloid-derived suppressor cells coming of age. <b>2018</b> , 19, 108-119	805
1124	Review: Limb regeneration in humans: Dream or reality?. <b>2018</b> , 217, 1-6	17
1123	Oncolytic influenza virus infection restores immunocompetence of lung tumor-associated alveolar macrophages. <b>2018</b> , 7, e1423171	17
1122	Mechanisms of Resistance to PD-1 and PD-L1 Blockade. <b>2018</b> , 24, 47-53	170
1121	Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab. <b>2018</b> , 13, 97-105	121
1120	LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer. <b>2018</b> , 172, 825-840.e18	181
1119	Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy. <b>2018</b> , 13, 521-532	74
1118	Scavenger Receptor Type B1 and Lipoprotein Nanoparticle Inhibit Myeloid-Derived Suppressor Cells. <b>2018</b> , 17, 686-697	36
1117	M2-macrophage infiltration and macrophage traits of tumor cells in urinary bladder cancer. <b>2018</b> , 36, 159.e19-159.e26	23
1116	Neutrophils and PMN-MDSC: Their biological role and interaction with stromal cells. <b>2018</b> , 35, 19-28	135

1115	Biology of Myeloid-Derived Suppressor Cells. <b>2018</b> , 181-197		2
1114	Challenges of Oncoimmunology for Ovarian and Breast Cancers. <b>2018</b> , 607-619		
1113	Challenges in Colorectal Cancer: From Vaccines to Macrophage Repolarization. <b>2018</b> , 621-639		
1112	The prognostic value of regulatory T cells infiltration in HER2-enriched breast cancer microenvironment. <b>2018</b> , 37, 144-150		8
1111	Improving immune-vascular crosstalk for cancer immunotherapy. <i>Nature Reviews Immunology</i> , <b>2018</b> , 18, 195-203	36.5	170
1110	Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms. <b>2018</b> , 24, 165-175		85
1109	Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment. <b>2018</b> , 200, 422-431		266
1108	FOXOs in cancer immunity: Knowns and unknowns. <b>2018</b> , 50, 53-64		38
1107	Frontline Science: High fat diet and leptin promote tumor progression by inducing myeloid-derived suppressor cells. <b>2018</b> , 103, 395-407		74
1106	A novel biologic platform elicits profound T cell costimulatory activity and antitumor immunity in mice. <b>2018</b> , 67, 605-613		2
1105	Although Abundant in Tumor Tissue, Mast Cells Have No Effect on Immunological Micro-milieu or Growth of HPV-Induced or Transplanted Tumors. <b>2018</b> , 22, 27-35		10
1104	Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma. <b>2018</b> , 24, 3955-3966		19
1103	The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictive factor for epithelial ovarian cancer survival. <b>2018</b> , 7, e1465166		25
1102	Identification of key pathways and genes in mutant KRAS colorectal cancer by integrated bioinformatics analysis. <b>2018</b> , 50, 615-617		
1101	Bimodal CD40/Fas-Dependent Crosstalk between iNKT Cells and Tumor-Associated Macrophages Impairs Prostate Cancer Progression. <b>2018</b> , 22, 3006-3020		32
1100	Plasticity of myeloid-derived suppressor cells in cancer. <b>2018</b> , 51, 76-82		175
1099	Targeting Myeloid-derived Suppressor Cells and Programmed Death Ligand 1 Confers Therapeutic Advantage of Ablative Hypofractionated Radiation Therapy Compared With Conventional Fractionated Radiation Therapy. <b>2018</b> , 101, 74-87		56
1098	Acute tubulointerstitial nephritis associated with atezolizumab, an anti-programmed death-ligand 1 (pd-l1) antibody therapy. <b>2018</b> , 7, e1445952		9

1097	Human cytomegalovirus reprogrammes haematopoietic progenitor cells into immunosuppressive monocytes to achieve latency. <b>2018</b> , 3, 503-513	50
1096	The cellular metabolic landscape in the tumor milieu regulates the activity of myeloid infiltrates. <b>2018</b> , 15, 421-427	14
1095	Urinary Bladder Cancer Tregs Suppress MMP2 and Potentially Regulate Invasiveness. <b>2018</b> , 6, 528-538	25
1094	Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance. <b>2018</b> , 9, 1250	88
1093	Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases. <b>2018</b> , 10,	141
1092	A tumor-myeloid cell axis, mediated via the cytokines IL-1 $\beta$ and TSLP, promotes the progression of breast cancer. <b>2018</b> , 19, 366-374	58
1091	Myeloid derived-suppressor cells: their role in cancer and obesity. <b>2018</b> , 51, 68-75	60
1090	Positive Pelvic Lymph Nodes in Prostate Cancer Harbor Immune Suppressor Cells To Impair Tumor-reactive T Cells. <b>2018</b> , 4, 75-79	15
1089	Myeloid-derived suppressor cells: Important contributors to tumor progression and metastasis. <b>2018</b> , 233, 3024-3036	103
1088	Secretase inhibitor reduces immunosuppressive cells and enhances tumour immunity in head and neck squamous cell carcinoma. <b>2018</b> , 142, 999-1009	40
1087	Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals. <b>2018</b> , 24, 62-72	39
1086	Ubiquitin Conjugation Probed by Inflammation in Myeloid-Derived Suppressor Cell Extracellular Vesicles. <b>2018</b> , 17, 315-324	11
1085	CCR5 Myeloid-Derived Suppressor Cells Are Enriched and Activated in Melanoma Lesions. <b>2018</b> , 78, 157-167	82
1084	Daunorubicin conjugated with alpha-fetoprotein selectively eliminates myeloid-derived suppressor cells (MDSCs) and inhibits experimental tumor growth. <b>2018</b> , 67, 101-111	11
1083	Humoral and Cellular Immune Dysregulation and Lung Cancer. <b>2018</b> , 137-142.e3	0
1082	Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy. <b>2018</b> , 67, 931-944	87
1081	Wnt7a induces a unique phenotype of monocyte-derived macrophages with lower phagocytic capacity and differential expression of pro- and anti-inflammatory cytokines. <b>2018</b> , 153, 203-213	11
1080	Interleukin-27 Exerts Its Antitumor Effects by Promoting Differentiation of Hematopoietic Stem Cells to M1 Macrophages. <b>2018</b> , 78, 182-194	17

1079	Lack of MHC class II molecules favors CD8 T-cell infiltration into tumors associated with an increased control of tumor growth. <b>2018</b> , 7, e1404213	9
1078	Nfia deletion in myeloid cells blocks expansion of myeloid-derived suppressor cells during sepsis. <b>2018</b> , 24, 54-65	10
1077	Human innate lymphoid cells (ILCs): Toward a uniform immune-phenotyping. <b>2018</b> , 94, 392-399	29
1076	Myeloid-Derived Suppressor Cells and Their Potential Application in Transplantation. <b>2018</b> , 102, 359-367	28
1075	Targeting both tumour-associated CXCR2 neutrophils and CCR2 macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma. <b>2018</b> , 67, 1112-1123	197
1074	Ultrastructural immunolocalization of hyaluronate in regenerating tail of lizards and amphibians supports an immune-suppressive role to favor regeneration. <b>2018</b> , 279, 176-186	3
1073	Immunotherapeutic Biomarkers and Selection Strategies. <b>2018</b> , 69-114	
1072	Conditioned media from the renal cell carcinoma cell line 786.O drives human blood monocytes to a monocytic myeloid-derived suppressor cell phenotype. <b>2018</b> , 323, 49-58	10
1071	Early Phase Cancer Immunotherapy. <b>2018</b> ,	1
1070	Primer on Cancer Immunotherapy and the Targeting of Native Proteins. <b>2018</b> , 1-28	
1069	Proteotranscriptomics Reveal Signaling Networks in the Ovarian Cancer Microenvironment. <b>2018</b> , 17, 270-289	34
1068	Prophylactic DNA vaccine targeting Foxp3 regulatory T cells depletes myeloid-derived suppressor cells and improves anti-melanoma immune responses in a murine model. <b>2018</b> , 67, 367-379	17
1067	Tumor conditions induce bone marrow expansion of granulocytic, but not monocytic, immunosuppressive leukocytes with increased CXCR2 expression in mice. <b>2018</b> , 48, 532-542	20
1066	Nanoparticle formulation improves doxorubicin efficacy by enhancing host antitumor immunity. <b>2018</b> , 269, 364-373	36
1065	CD38+ M-MDSC expansion characterizes a subset of advanced colorectal cancer patients. <b>2018</b> , 3,	40
1064	Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival. <b>2018</b> , 3,	27
1063	and colorectal cancer: A review. <b>2018</b> , 10, 71-81	125
1062	Mechanisms of Drug Resistance in Cancer Therapy. <b>2018</b> ,	

1061	Skewed Dendritic Cell Differentiation of MyD88-Deficient Donor Bone Marrow Cells, Instead of Massive Expansion as Myeloid-Derived Suppressor Cells, Aggravates GVHD. <b>2018</b> , 18, e44	3
1060	Phenotypic and Functional Diversities of Myeloid-Derived Suppressor Cells in Autoimmune Diseases. <b>2018</b> , 2018, 4316584	13
1059	Using the Spleen as an Systemic Immune Barometer Alongside Osteosarcoma Disease Progression and Immunotherapy with -PD-L1. <b>2018</b> , 2018, 8694397	14
1058	Why we should give spatially fractionated radiation therapy (GRID) a second lookEspecially in nasopharyngeal carcinoma. <b>2018</b> , 1, 1-1	0
1057	Intraperitoneal oxaliplatin administration inhibits the tumor immunosuppressive microenvironment in an abdominal implantation model of colon cancer. <b>2018</b> , 18, 2335-2341	6
1056	Current Perspectives on Novel Drug Carrier Systems and Therapies for Management of Pancreatic Cancer: An Updated Inclusive Review. <b>2018</b> , 35, 195-292	6
1055	Der Einsatz von Checkpoint-Hemmern beim Lungenkarzinom wird breiter. <b>2018</b> , 10, 34-42	
1054	A novel systemic inflammation response index (SIRI) for predicting postoperative survival of patients with esophageal squamous cell carcinoma. <b>2018</b> , 65, 503-510	51
1053	NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma. <b>2018</b> , 19,	13
1052	Human natural killer cells and other innate lymphoid cells in cancer: Friends or foes?. <b>2018</b> , 201, 14-19	33
1051	Loss of Myeloid-Specific TGF-β Signaling Decreases CTHRC1 to Downregulate bFGF and the Development of H1993-Induced Osteolytic Bone Lesions. <b>2018</b> , 10,	8
1050	Immune regulation and anti-cancer activity by lipid inflammatory mediators. <b>2018</b> , 65, 580-592	16
1049	Streptococcus gallolyticus conspires myeloid cells to promote tumorigenesis of inflammatory bowel disease. <b>2018</b> , 506, 907-911	19
1048	Aging, inflammation and cancer. <b>2018</b> , 40, 74-82	61
1047	The role of hypoxia in shaping the recruitment of proangiogenic and immunosuppressive cells in the tumor microenvironment. <b>2018</b> , 22, 7-13	17
1046	The Sweet Surrender: How Myeloid Cell Metabolic Plasticity Shapes the Tumor Microenvironment. <b>2018</b> , 6, 168	11
1045	Cancer Stem Cells and Immunosuppressive Microenvironment in Glioma. <b>2018</b> , 9, 2924	89
1044	The role of immune cell subpopulations in the growth and rejection of TC-1/A9 tumors in novel mouse strains differing in the H2-D haplotype and NKC domain. <b>2018</b> , 15, 3594-3601	1

1043	Arg1 expression defines immunosuppressive subsets of tumor-associated macrophages. <b>2018</b> , 8, 5842-5854	96
1042	Roles of Myeloid-Derived Suppressor Cell Subpopulations in Autoimmune Arthritis. <b>2018</b> , 9, 2849	23
1041	Anti-psoriatic effect of myeloid-derived suppressor cells on imiquimod-induced skin inflammation in mice. <b>2019</b> , 89, e12742	3
1040	Overview of Basic Immunology and Translational Relevance for Clinical Investigators. <b>2018</b> , 995, 1-41	2
1039	Immunotherapy. <b>2018</b> ,	3
1038	LY341495, an mGluR2/3 Antagonist, Regulates the Immunosuppressive Function of Myeloid-Derived Suppressor Cells and Inhibits Melanoma Tumor Growth. <b>2018</b> , 41, 1866-1869	5
1037	and Colorectal Cancer. <b>2018</b> , 8, 371	52
1036	IL-21 receptor signaling is essential for control of hepatocellular carcinoma growth and immunological memory for tumor challenge. <b>2018</b> , 7, e1500673	5
1035	The role of cancer stem cells in the modulation of anti-tumor immune responses. <b>2018</b> , 53, 189-200	48
1034	Mathematical models of tumor cell proliferation: A review of the literature. <b>2018</b> , 18, 1271-1286	47
1033	The role of CCR5 in directing the mobilization and biological function of CD11bGr1Ly6C polymorphonuclear myeloid cells in cancer. <b>2018</b> , 67, 1949-1953	15
1032	Myeloid-derived suppressor cells in non-neoplastic inflamed organs. <b>2018</b> , 38, 19	26
1031	The immune cell infiltrate in the microenvironment of vulvar Paget disease. <b>2018</b> , 151, 453-459	6
1030	BDCA1+CD14+ Immunosuppressive Cells in Cancer, a Potential Target?. <b>2018</b> , 6,	8
1029	Role of platelets and platelet receptors in cancer metastasis. <b>2018</b> , 11, 125	186
1028	Embelin impairs the accumulation and activation of MDSCs in colitis-associated tumorigenesis. <b>2018</b> , 7, e1498437	13
1027	Interferon- $\gamma$ Up-Regulates the Expression of PD-L1 Molecules on Immune Cells Through STAT3 and p38 Signaling. <b>2018</b> , 9, 2129	49
1026	Single-Cell Transcriptomics in Cancer Immunobiology: The Future of Precision Oncology. <b>2018</b> , 9, 2582	33

1025	Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments. <b>2018</b> , 13, e0206223	69
1024	Metformin exerts antitumor activity via induction of multiple death pathways in tumor cells and activation of a protective immune response. <b>2018</b> , 9, 25808-25825	43
1023	Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy. <b>2018</b> , 9, 2250	24
1022	IgG response to MHC class I epitope peptides is a quantitative predictive biomarker in the early course of treatment of colorectal cancer using therapeutic peptides. <b>2018</b> , 39, 2385-2392	9
1021	Translational Potential of Therapeutics Targeting Regulatory Myeloid Cells in Tuberculosis. <b>2018</b> , 8, 332	15
1020	[Immunological foundations of modern (tumor) immunotherapy]. <b>2018</b> , 39, 492-497	
1019	Innate immunity and HPV: friends or foes. <b>2018</b> , 73, e549s	16
1018	From Cancer Immunoediting to New Strategies in Cancer Immunotherapy: The Roles of Immune Cells and Mechanics in Oncology. <b>2018</b> , 1092, 113-138	11
1017	Tumor-derived granulocyte colony-stimulating factor diminishes efficacy of breast tumor cell vaccines. <b>2018</b> , 20, 126	10
1016	Radiogenomics Profiling for Glioblastoma-related Immune Cells Reveals CD49d Expression Correlation with MRI parameters and Prognosis. <b>2018</b> , 8, 16022	15
1015	Mechanism for the Decision of Ovarian Surface Epithelial Stem Cells to Undergo Neo-Oogenesis or Ovarian Tumorigenesis. <b>2018</b> , 50, 214-232	18
1014	New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1. <b>2018</b> , 12, 1753466618794133	27
1013	Myeloid-derived suppressor cells inhibit T cell activation through nitrating LCK in mouse cancers. <b>2018</b> , 115, 10094-10099	66
1012	Recruitment of CCR2 tumor associated macrophage to sites of liver metastasis confers a poor prognosis in human colorectal cancer. <b>2018</b> , 7, e1470729	54
1011	Chemotherapy Combines Effectively with Anti-PD-L1 Treatment and Can Augment Antitumor Responses. <b>2018</b> , 201, 2273-2286	21
1010	Delineating Pro-Angiogenic Myeloid Cells in Cancer Therapy. <b>2018</b> , 19,	6
1009	Prophylactic vs. Therapeutic Treatment With P2Et Polyphenol-Rich Extract Has Opposite Effects on Tumor Growth. <b>2018</b> , 8, 356	17
1008	Genetics and biology of prostate cancer. <b>2018</b> , 32, 1105-1140	199



1007	Metabolic Switch in the Tumor Microenvironment Determines Immune Responses to Anti-cancer Therapy. <b>2018</b> , 8, 284	49
1006	Negatively Regulates the Suppressive Function of Myeloid-Derived Suppressor Cells. <b>2018</b> , 6, 1352-1363	35
1005	Through the barricades: overcoming the barriers to effective antibody-based cancer therapeutics. <b>2018</b> , 28, 697-712	6
1004	Tumor-infiltrating neutrophils predict prognosis and adjuvant chemotherapeutic benefit in patients with biliary cancer. <b>2018</b> , 109, 2266-2274	17
1003	Novel Therapeutic Strategies for Solid Tumor Based on Body's Intrinsic Antitumor Immune System. <b>2018</b> , 47, 441-457	10
1002	T-cell tracking using Cerenkov and radioluminescence imaging. <b>2018</b> , 11, e201800093	9
1001	TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. <b>2018</b> , 2, 578-588	435
1000	Aerobic Glycolysis Controls Myeloid-Derived Suppressor Cells and Tumor Immunity via a Specific CEBPB Isoform in Triple-Negative Breast Cancer. <b>2018</b> , 28, 87-103.e6	140
999	Factor XIIIa-expressing inflammatory monocytes promote lung squamous cancer through fibrin cross-linking. <b>2018</b> , 9, 1988	39
998	Early TGF- $\beta$ inhibition in mice reduces the incidence of breast cancer induced bone disease in a myeloid dependent manner. <b>2018</b> , 113, 77-88	12
997	Cancer-induced systemic myeloid dysfunction: Implications for treatment and a novel nanoparticle approach for its correction. <b>2018</b> , 45, 84-94	2
996	Expression and significance of peripheral myeloid-derived suppressor cells in chronic hepatitis B patients. <b>2018</b> , 42, 462-469	9
995	The Immune Landscape of Non-Small-Cell Lung Cancer. Utility of Cytologic and Histologic Samples Obtained through Minimally Invasive Pulmonary Procedures. <b>2018</b> , 198, 24-38	11
994	Obesity as an immune-modifying factor in cancer immunotherapy. <b>2018</b> , 104, 487-497	19
993	Inhibition of pregnancy-associated granulocytic myeloid-derived suppressor cell expansion and arginase-1 production in preeclampsia. <b>2018</b> , 127, 48-54	20
992	Metabolic influence on the differentiation of suppressive myeloid cells in cancer. <b>2018</b> , 39, 1095-1104	16
991	Levels of peripheral blood polymorphonuclear myeloid-derived suppressor cells and selected cytokines are potentially prognostic of disease progression for patients with non-small cell lung cancer. <b>2018</b> , 67, 1393-1406	25
990	A designer self-assembled supramolecule amplifies macrophage immune responses against aggressive cancer. <b>2018</b> , 2, 589-599	100

989	VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML. <b>2018</b> , 7, e1469594	58
988	Immune Escape Mechanisms and Future Prospects for Immunotherapy in Neuroblastoma. <b>2018</b> , 2018, 1812535	44
987	Oxygenated lipid signaling in tumor-associated macrophages-focus on colon cancer. <b>2018</b> , 37, 289-315	9
986	Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models. <b>2018</b> , 109, 2119-2129	15
985	Mechanisms of Gastrointestinal Malignancies. <b>2018</b> , 1615-1642	1
984	Neutrophils as myeloid-derived suppressor cells. <b>2018</b> , 48 Suppl 2, e12989	35
983	Blood-based analyses of cancer: Circulating myeloid-derived suppressor cells - is a new era coming?. <b>2018</b> , 55, 376-407	9
982	Immunosuppressive Role of Myeloid-Derived Suppressor Cells and Therapeutic Targeting in Lung Cancer. <b>2018</b> , 2018, 6319649	25
981	Prognostic role of pretreatment circulating MDSCs in patients with solid malignancies: A meta-analysis of 40 studies. <b>2018</b> , 7, e1494113	41
980	Tracking the fate of adoptively transferred myeloid-derived suppressor cells in the primary breast tumor microenvironment. <b>2018</b> , 13, e0196040	8
979	Circulating and tumor-infiltrating myeloid-derived suppressor cells in cervical carcinoma patients. <b>2018</b> , 15, 9507-9515	18
978	Distinct features of dendritic cell-based immunotherapy as cancer vaccines. <b>2018</b> , 7, 16-23	10
977	Myeloid-Derived Suppressor Cell Membrane-Coated Magnetic Nanoparticles for Cancer Theranostics by Inducing Macrophage Polarization and Synergizing Immunogenic Cell Death. <b>2018</b> , 28, 1801389	104
976	Macrophages are exploited from an innate wound healing response to facilitate cancer metastasis. <b>2018</b> , 9, 2951	44
975	Arginase: A Multifaceted Enzyme Important in Health and Disease. <b>2018</b> , 98, 641-665	143
974	MicroRNAs as Immunotherapy Targets for Treating Gastroenterological Cancers. <b>2018</b> , 2018, 9740357	9
973	Neutrophils cause obstruction of eyelid sebaceous glands in inflammatory eye disease in mice. <b>2018</b> , 10,	24
972	A Novel DNA Aptamer for Dual Targeting of Polymorphonuclear Myeloid-derived Suppressor Cells and Tumor Cells. <b>2018</b> , 8, 31-44	36

971	Interleukin-1 Beta-A Friend or Foe in Malignancies?. <b>2018</b> , 19,	143
970	Monocytic Myeloid-Derived Suppressor Cells in Chronic Infections. <b>2017</b> , 8, 1895	71
969	Hypoxia Pathway Proteins As Central Mediators of Metabolism in the Tumor Cells and Their Microenvironment. <b>2018</b> , 9, 40	71
968	Generation of Human Immunosuppressive Myeloid Cell Populations in Human Interleukin-6 Transgenic NOG Mice. <b>2018</b> , 9, 152	31
967	Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression. <b>2018</b> , 9, 398	274
966	Long Non-Coding RNA HOXA Transcript Antisense RNA Myeloid-Specific 1-HOXA1 Axis Downregulates the Immunosuppressive Activity of Myeloid-Derived Suppressor Cells in Lung Cancer. <b>2018</b> , 9, 473	76
965	Hydrogen Sulfide Reduces Myeloid-Derived Suppressor Cell-Mediated Inflammatory Response in a Model of -Induced Colitis. <b>2018</b> , 9, 499	12
964	Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy. <b>2018</b> , 9, 527	204
963	Targeting VEGF/VEGFR to Modulate Antitumor Immunity. <b>2018</b> , 9, 978	237
962	Immune Microenvironment in Glioblastoma Subtypes. <b>2018</b> , 9, 1004	161
961	TNF Receptor 2 Makes Tumor Necrosis Factor a Friend of Tumors. <b>2018</b> , 9, 1170	56
960	Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses. <b>2018</b> , 9, 1288	31
959	Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors. <b>2018</b> , 9, 1310	260
958	MiRNAs at the Crossroads between Innate Immunity and Cancer: Focus on Macrophages. <b>2018</b> , 7,	34
957	miR-130a and miR-145 reprogram Gr-1CD11b myeloid cells and inhibit tumor metastasis through improved host immunity. <b>2018</b> , 9, 2611	23
956	The Role of the Estrogen Pathway in the Tumor Microenvironment. <b>2018</b> , 19,	81
955	STAT3 in Tumor-Associated Myeloid Cells: Multitasking to Disrupt Immunity. <b>2018</b> , 19,	53
954	Experimental Model of Human Malignant Mesothelioma in Athymic Mice. <b>2018</b> , 19,	9

953	Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. <b>2018</b> , 6, 74	166
952	Myeloid-Derived Suppressor Cells (MDSCs) in Aged Mice: Focus on Inflammation. <b>2018</b> , 1-21	
951	Tumor Dendritic Cells (DCs) Derived from Precursors of Conventional DCs Are Dispensable for Intratumor CTL Responses. <b>2018</b> , 201, 1306-1314	19
950	Metabolic Symbiosis and Immunomodulation: How Tumor Cell-Derived Lactate May Disturb Innate and Adaptive Immune Responses. <b>2018</b> , 8, 81	50
949	Absence of host NF- $\kappa$ B p50 induces murine glioblastoma tumor regression, increases survival, and decreases T-cell induction of tumor-associated macrophage M2 polarization. <b>2018</b> , 67, 1491-1503	16
948	Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors. <b>2018</b> , 115, 5534-5539	40
947	Curcumin enhances anti-tumor immune response in tongue squamous cell carcinoma. <b>2018</b> , 92, 32-37	50
946	Myeloid-Derived Suppressor Cells Impair B Cell Responses in Lung Cancer through IL-7 and STAT5. <b>2018</b> , 201, 278-295	51
945	IFNAR1 Controls Autocrine Type I IFN Regulation of PD-L1 Expression in Myeloid-Derived Suppressor Cells. <b>2018</b> , 201, 264-277	41
944	SOCS3 Suppression Promoted the Recruitment of CD11bGr-1F4/80MHCII Early-Stage Myeloid-Derived Suppressor Cells and Accelerated Interleukin-6-Related Tumor Invasion Affecting Myeloid Differentiation in Breast Cancer. <b>2018</b> , 9, 1699	18
943	Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance. <b>2018</b> , 50, 1-13	105
942	Inhibition of Casein Kinase 2 Disrupts Differentiation of Myeloid Cells in Cancer and Enhances the Efficacy of Immunotherapy in Mice. <b>2018</b> , 78, 5644-5655	24
941	Combination of radiation and interleukin 12 eradicates large orthotopic hepatocellular carcinoma through immunomodulation of tumor microenvironment. <b>2018</b> , 7, e1477459	26
940	Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab. <b>2018</b> , 63, 282-291	83
939	Maelstrom Directs Myeloid-Derived Suppressor Cells to Promote Esophageal Squamous Cell Carcinoma Progression via Activation of the Akt1/RelA/IL8 Signaling Pathway. <b>2018</b> , 6, 1246-1259	21
938	Clinical Relevance and Suppressive Capacity of Human Myeloid-Derived Suppressor Cell Subsets. <b>2018</b> , 24, 4834-4844	113
937	Lect2 Controls Inflammatory Monocytes to Constrain the Growth and Progression of Hepatocellular Carcinoma. <b>2019</b> , 69, 160-178	20
936	Macrophages: Their Untold Story in T Cell Activation and Function. <b>2019</b> , 342, 73-93	52

935	Myeloid-derived suppressor cells: Roles in the tumor microenvironment and tumor radiotherapy. <b>2019</b> , 144, 933-946	45
934	Interactions among myeloid regulatory cells in cancer. <b>2019</b> , 68, 645-660	28
933	Modulating T-cell-based cancer immunotherapy via particulate systems. <b>2019</b> , 27, 145-163	7
932	Functional Diversity of Myeloid-Derived Suppressor Cells: The Multitasking Hydra of Cancer. <b>2019</b> , 203, 1095-1103	11
931	CXCR2 expression on granulocyte and macrophage progenitors under tumor conditions contributes to mo-MDSC generation via SAP18/ERK/STAT3. <b>2019</b> , 10, 598	21
930	Perturbation of the Monocyte Compartment in Human Obesity. <b>2019</b> , 10, 1874	26
929	Modulates Differentiation of MDSCs Through Downregulating IL4i1 With C/EBP $\beta$ and WDR5. <b>2019</b> , 10, 1661	15
928	Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study. <b>2019</b> , 10, 1848	37
927	Allergy-Related Diseases and Risk of Breast Cancer: The Role of Skewed Immune System on This Association. <b>2019</b> , 10, 2152656719860820	7
926	NAD-Biosynthetic and Consuming Enzymes as Central Players of Metabolic Regulation of Innate and Adaptive Immune Responses in Cancer. <b>2019</b> , 10, 1720	36
925	AMPK Alpha-1 Intrinsically Regulates the Function and Differentiation of Tumor Myeloid-Derived Suppressor Cells. <b>2019</b> , 79, 5034-5047	20
924	The Complex Interaction between the Tumor Micro-Environment and Immune Checkpoints in Breast Cancer. <b>2019</b> , 11,	24
923	Targeting Interleukin(IL)-30/IL-27p28 signaling in cancer stem-like cells and host environment synergistically inhibits prostate cancer growth and improves survival. <b>2019</b> , 7, 201	5
922	Regulation of Immunity in Breast Cancer. <b>2019</b> , 11,	23
921	The Dark Side of Fibroblasts: Cancer-Associated Fibroblasts as Mediators of Immunosuppression in the Tumor Microenvironment. <b>2019</b> , 10, 1835	212
920	A PD-L1-Based Cancer Vaccine Elicits Antitumor Immunity in a Mouse Melanoma Model. <b>2019</b> , 14, 222-232	6
919	Murine Cytomegalovirus Infection of Melanoma Lesions Delays Tumor Growth by Recruiting and Repolarizing Monocytic Phagocytes in the Tumor. <b>2019</b> , 93,	7
918	Role of Regulatory Immune Cells and Molecules in Autoimmune Bullous Dermatoses. <b>2019</b> , 10, 1746	5

917	Papillomavirus Immune Evasion Strategies Target the Infected Cell and the Local Immune System. <b>2019</b> , 9, 682	60
916	Metabolic and functional reprogramming of myeloid-derived suppressor cells and their therapeutic control in glioblastoma. <b>2019</b> , 3, 47-65	31
915	Prognostic impact of circulating monocyte subsets in pediatric solid tumors. <b>2019</b> , 25, 371-379	0
914	Peri-operative monocyte count is a marker of poor prognosis in gastric cancer: increased monocytes are a characteristic of myeloid-derived suppressor cells. <b>2019</b> , 68, 1341-1350	16
913	Distinct Spatio-Temporal Dynamics of Tumor-Associated Neutrophils in Small Tumor Lesions. <b>2019</b> , 10, 1419	10
912	-positive colorectal cancer. <b>2019</b> , 18, 975-982	16
911	A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients. <b>2019</b> , 7, 192	29
910	Granulocytic Myeloid-Derived Suppressor Cells Promote the Stemness of Colorectal Cancer Cells through Exosomal S100A9. <b>2019</b> , 6, 1901278	66
909	Preliminary assessment of the feasibility of autologous myeloid-derived suppressor cell infusion in non-human primate kidney transplantation. <b>2019</b> , 56, 101225	5
908	Global Investigations of in Human Colorectal Cancer. <b>2019</b> , 9, 566	27
907	Macrophage-Mediated Subversion of Anti-Tumour Immunity. <b>2019</b> , 8,	43
906	Melanoma Extracellular Vesicles Generate Immunosuppressive Myeloid Cells by Upregulating PD-L1 via TLR4 Signaling. <b>2019</b> , 79, 4715-4728	51
905	The Tumor Microenvironment Innately Modulates Cancer Progression. <b>2019</b> , 79, 4557-4566	610
904	The macrophage tetraspan MS4A4A enhances dectin-1-dependent NK cell-mediated resistance to metastasis. <b>2019</b> , 20, 1012-1022	45
903	Coupling Microfluidic Platforms, Microfabrication, and Tissue Engineered Scaffolds to Investigate Tumor Cells Mechanobiology. <b>2019</b> , 10,	7
902	NOTCH Signaling via WNT Regulates the Proliferation of Alternative, CCR2-Independent Tumor-Associated Macrophages in Hepatocellular Carcinoma. <b>2019</b> , 79, 4160-4172	35
901	Lipid Metabolic Pathways Confer the Immunosuppressive Function of Myeloid-Derived Suppressor Cells in Tumor. <b>2019</b> , 10, 1399	54
900	Mouse CD8NKT-like cells exert dual cytotoxicity against mouse tumor cells and myeloid-derived suppressor cells. <b>2019</b> , 68, 1303-1315	12

899	NANOG helps cancer cells escape NK cell attack by downregulating ICAM1 during tumorigenesis. <b>2019</b> , 38, 416	15
898	Emerging Approaches of Cell-Based Nanosystems to Target Cancer Metastasis. <b>2019</b> , 29, 1903441	24
897	Icaritin promotes tumor T-cell infiltration and induces antitumor immunity in mice. <b>2019</b> , 49, 2235-2244	21
896	Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors. <b>2019</b> , 145, 3021-3036	11
895	Pretreatment Inflammatory Indexes as Prognostic Predictors of Survival in Patients Suffering From Synovial Sarcoma. <b>2019</b> , 9, 955	5
894	Immune effector monocyte-neutrophil cooperation induced by the primary tumor prevents metastatic progression of breast cancer. <b>2019</b> , 116, 21704-21714	38
893	ADP secreted by dying melanoma cells mediates chemotaxis and chemokine secretion of macrophages via the purinergic receptor P2Y12. <b>2019</b> , 10, 760	10
892	Activated hepatic stellate cells regulate MDSC migration through the SDF-1/CXCR4 axis in an orthotopic mouse model of hepatocellular carcinoma. <b>2019</b> , 68, 1959-1969	19
891	Gastric Cancer in the Era of Immune Checkpoint Blockade. <b>2019</b> , 2019, 1079710	15
890	The role of myeloid-derived suppressor cells in the pathogenesis of rheumatoid arthritis; anti- or pro-inflammatory cells?. <b>2019</b> , 47, 4149-4158	16
889	Pivotal Role of STAT3 in Shaping Glioblastoma Immune Microenvironment. <b>2019</b> , 8,	46
888	Exosomes Produced by Mesenchymal Stem Cells Drive Differentiation of Myeloid Cells into Immunosuppressive M2-Polarized Macrophages in Breast Cancer. <b>2019</b> , 203, 3447-3460	69
887	Role of Focal Adhesion Kinase in Small-Cell Lung Cancer and Its Potential as a Therapeutic Target. <b>2019</b> , 11,	17
886	Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies. <b>2019</b> , 20,	10
885	Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma. <b>2019</b> , 116, 23714-23723	49
884	Functional Regulation of Ginsenosides on Myeloid Immunosuppressive Cells in the Tumor Microenvironment. <b>2019</b> , 18, 1534735419886655	8
883	Tumor Associated Neutrophils. Their Role in Tumorigenesis, Metastasis, Prognosis and Therapy. <b>2019</b> , 9, 1146	152
882	CSF1R- and SHP2-Inhibitor-Loaded Nanoparticles Enhance Cytotoxic Activity and Phagocytosis in Tumor-Associated Macrophages. <b>2019</b> , 31, e1904364	72

881	Novel Biomarkers for Personalized Cancer Immunotherapy. <b>2019</b> , 11,	21
880	The Endless Saga of Monocyte Diversity. <b>2019</b> , 10, 1786	36
879	Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities. <b>2019</b> , 18, 130	123
878	Tumor-derived exosomes, myeloid-derived suppressor cells, and tumor microenvironment. <b>2019</b> , 12, 84	62
877	MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers. <b>2019</b> , 47, 235-246	63
876	Characterization of myeloid-derived suppressor cells and cytokines GM-CSF, IL-10 and MCP-1 in dogs with malignant melanoma receiving a GD3-based immunotherapy. <b>2019</b> , 216, 109912	6
875	Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms. <b>2019</b> , 21, 1113-1126	106
874	Potential role of immunological factors in early diagnosis of cancer cachexia in C26 tumor-bearing mice. <b>2019</b> , 62,	7
873	Neutrophil Heterogeneity in Cancer: From Biology to Therapies. <b>2019</b> , 10, 2155	74
872	Ultrathin Metal-Organic-Layer Mediated Radiotherapy-Radiodynamic Therapy. <b>2019</b> , 1, 1331-1353	55
871	Peptostreptococcus anaerobius promotes colorectal carcinogenesis and modulates tumour immunity. <b>2019</b> , 4, 2319-2330	120
870	Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GVHD. <b>2019</b> , 134, 1670-168233	
869	Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3. <b>2019</b> , 7, 255	81
868	The mechanism of the premetastatic niche facilitating colorectal cancer liver metastasis generated from myeloid-derived suppressor cells induced by the S1PR1-STAT3 signaling pathway. <b>2019</b> , 10, 693	30
867	Changes in the frequency of myeloid-derived suppressor cells after transarterial chemoembolization with gelatin sponge microparticles for hepatocellular carcinoma. <b>2019</b> , 2, 21-26	0
866	Die intestinale Mikrobiota in der Onkologie. <b>2019</b> , 51, 108-112	
865	Tumor-Infiltrating Immunosuppressive Cells in Cancer-Cell Plasticity, Tumor Progression and Therapy Response. <b>2019</b> , 12, 119-132	22
864	The Role of Tumor-Associated Neutrophils in Colorectal Cancer. <b>2019</b> , 20,	86



863	Potential roles and targeted therapy of the CXCLs/CXCR2 axis in cancer and inflammatory diseases. <b>2019</b> , 1871, 289-312	108
862	ARTD1 in Myeloid Cells Controls the IL-12/18-IFN- $\gamma$ Axis in a Model of Sterile Sepsis, Chronic Bacterial Infection, and Cancer. <b>2019</b> , 202, 1406-1416	7
861	Long-term characterization of activated microglia/macrophages facilitating the development of experimental brain metastasis through intravital microscopic imaging. <b>2019</b> , 16, 4	25
860	Immunotherapy in myeloma: how far have we come?. <b>2019</b> , 10, 2040620718822660	34
859	Deciphering myeloid-derived suppressor cells: isolation and markers in humans, mice and non-human primates. <b>2019</b> , 68, 687-697	103
858	Isocitrate dehydrogenase 1 mutation is associated with reduced levels of inflammation in glioma patients. <b>2019</b> , 11, 3227-3236	12
857	Identification of two distinct pathways of human myelopoiesis. <b>2019</b> , 4,	38
856	Adenocarcinoma in the transposed colon: High grade active inflammation versus low grade chronic inflammation. <b>2019</b> , 45, 1536-1541	7
855	Selectively hampered activation of lymph node-resident dendritic cells precedes profound T cell suppression and metastatic spread in the breast cancer sentinel lymph node. <b>2019</b> , 7, 133	16
854	Neutrophil-to-Lymphocyte Ratio in Rectal Cancer-Novel Biomarker of Tumor Immunogenicity During Radiotherapy or Confounding Variable?. <b>2019</b> , 20,	14
853	Combining immunotherapies to treat non-small cell lung cancer. <b>2019</b> , 13, 621-634	0
852	SIRP $\alpha$ /CD47 axis controls the maintenance of transplant tolerance sustained by myeloid-derived suppressor cells. <b>2019</b> , 19, 3263-3275	11
851	Tumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile. <b>2019</b> , 7, 154	6
850	Multifaceted Role of the Placental Growth Factor (PlGF) in the Antitumor Immune Response and Cancer Progression. <b>2019</b> , 20,	29
849	Targeting the Tumor Microenvironment of Leukemia and Lymphoma. <b>2019</b> , 5, 351-364	32
848	Resveratrol inhibits radiation and hypoxia-induced macrophages infiltration via Prx-1/NF- $\kappa$ B/HIF-1 $\beta$ signaling pathway. <b>2019</b> , 12, 4203-4211	10
847	Intravital 2-photon imaging reveals distinct morphology and infiltrative properties of glioblastoma-associated macrophages. <b>2019</b> , 116, 14254-14259	32
846	Identification of monocyte-like precursors of granulocytes in cancer as a mechanism for accumulation of PMN-MDSCs. <b>2019</b> , 216, 2150-2169	43

845	Epigenetic modulation of immunity: towards new therapeutic avenues in hepatocellular carcinoma?. <b>2019</b> , 68, 1727-1728	0
844	Autologous Hematopoietic Stem Cells Are a Preferred Source to Generate Dendritic Cells for Immunotherapy in Multiple Myeloma Patients. <b>2019</b> , 10, 1079	4
843	An overview of the immune response and Arginase I on CHIKV immunopathogenesis. <b>2019</b> , 135, 103581	2
842	The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer. <b>2019</b> , 14, 1046-1060	28
841	High Salt Inhibits Tumor Growth by Enhancing Anti-tumor Immunity. <b>2019</b> , 10, 1141	18
840	Pyruvate Kinase M2: a Metabolic Bug in Re-Wiring the Tumor Microenvironment. <b>2019</b> , 12, 149-167	13
839	Theophylline induces differentiation and modulates cytoskeleton dynamics and cytokines secretion in human melanoma-initiating cells. <b>2019</b> , 230, 121-131	12
838	Myeloid-Derived Suppressor Cells: Ductile Targets in Disease. <b>2019</b> , 10, 949	50
837	The roles of glucose metabolic reprogramming in chemo- and radio-resistance. <b>2019</b> , 38, 218	67
836	Myeloid Cell Crosstalk Regulates the Efficacy of the DNA/ALVAC/gp120 HIV Vaccine Candidate. <b>2019</b> , 10, 1072	11
835	Role of myeloid-derived suppressor cells in immune checkpoint inhibitor therapy in cancer. <b>2019</b> , 42, 560-566	20
834	The Role of Extracellular Vesicles as Modulators of the Tumor Microenvironment, Metastasis and Drug Resistance in Colorectal Cancer. <b>2019</b> , 11,	29
833	Targeting EZH2 histone methyltransferase activity alleviates experimental intestinal inflammation. <b>2019</b> , 10, 2427	49
832	Endocrine Resistance in Hormone Receptor Positive Breast Cancer-From Mechanism to Therapy. <b>2019</b> , 10, 245	75
831	Myeloid-Derived Suppressor Cells: Not Only in Tumor Immunity. <b>2019</b> , 10, 1099	66
830	Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer. <b>2019</b> , 25, 5351-5363	36
829	Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events. <b>2019</b> , 6, 119	83
828	Assessment of tumor-associated immune cells in laryngeal squamous cell carcinoma. <b>2019</b> , 145, 1761-1772	13

827	Mammary tumors compromise time-of-day differences in hypothalamic gene expression and circadian behavior and physiology in mice. <b>2019</b> , 80, 805-817	7
826	Targeting the tumour immune microenvironment for cancer therapy in human gastrointestinal malignancies. <b>2019</b> , 458, 123-135	25
825	Gastric Tumorigenesis: Role of Inflammation and Helicobacter pylori. <b>2019</b> , 3-23	0
824	Myeloid-Derived Suppressor Cells in Lung Transplantation. <b>2019</b> , 10, 900	9
823	Temporal and spatial profile of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) in ischemic stroke in mice. <b>2019</b> , 14, e0215482	3
822	Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression. <b>2019</b> , 10, 771	94
821	Radiotherapy Both Promotes and Inhibits Myeloid-Derived Suppressor Cell Function: Novel Strategies for Preventing the Tumor-Protective Effects of Radiotherapy. <b>2019</b> , 9, 215	31
820	Additive effects of inhibiting both mTOR and glutamine metabolism on the arthritis in SKG mice. <b>2019</b> , 9, 6374	7
819	The Interplay of Autophagy and Tumor Microenvironment in Colorectal Cancer-Ways of Enhancing Immunotherapy Action. <b>2019</b> , 11,	28
818	Receptor-Interacting Protein Kinase 3 Deficiency Recruits Myeloid-Derived Suppressor Cells to Hepatocellular Carcinoma Through the Chemokine (C-X-C Motif) Ligand 1-Chemokine (C-X-C Motif) Receptor 2 Axis. <b>2019</b> , 70, 1564-1581	27
817	Tumor mechanisms of resistance to immune attack. <b>2019</b> , 164, 61-100	8
816	Cryo-thermal therapy inducing M1 macrophage polarization created CXCL10 and IL-6-rich pro-inflammatory environment for CD4 T cell-mediated anti-tumor immunity. <b>2019</b> , 36, 408-420	6
815	Immunometabolism: A new target for improving cancer immunotherapy. <b>2019</b> , 143, 195-253	15
814	PMN-MDSCs Enhance CTC Metastatic Properties through Reciprocal Interactions via ROS/Notch/Nodal Signaling. <b>2019</b> , 20,	57
813	Immune contexture defined by single cell technology for prognosis prediction and immunotherapy guidance in cancer. <b>2019</b> , 39, 21	25
812	Adoptive transfer of IFN- $\gamma$ -Induced M-MDSCs promotes immune tolerance to allografts through iNOS pathway. <b>2019</b> , 68, 545-555	9
811	Immunologische Grundlagen moderner (Tumor-)Immuntherapie. <b>2019</b> , 14, 8-13	
810	Dissecting intratumoral myeloid cell plasticity by single cell RNA-seq. <b>2019</b> , 8, 3072-3085	61

809	Azodyes as markers for tumor hypoxia imaging and therapy: An up-to-date review. <b>2019</b> , 307, 91-104	17
808	Fusobacterium nucleatum Contributes to the Carcinogenesis of Colorectal Cancer by Inducing Inflammation and Suppressing Host Immunity. <b>2019</b> , 12, 846-851	77
807	Mesenchymal stem cells: From regeneration to cancer. <b>2019</b> , 200, 42-54	40
806	The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes. <b>2019</b> , 7, 923-938	69
805	Clinical Relevance and Immunosuppressive Pattern of Circulating and Infiltrating Subsets of Myeloid-Derived Suppressor Cells (MDSCs) in Epithelial Ovarian Cancer. <b>2019</b> , 10, 691	39
804	Role of iron in cancer development by viruses. <b>2019</b> , 29, e2045	2
803	Fatty acid transport protein 2 reprograms neutrophils in cancer. <b>2019</b> , 569, 73-78	215
802	A novel combination of chemotherapy and immunotherapy controls tumor growth in mice with a human immune system. <b>2019</b> , 8, 1596005	12
801	Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment. <b>2019</b> , 13, 67-81	28
800	Heterogeneity of the Head and Neck Squamous Cell Carcinoma Immune Landscape and Its Impact on Immunotherapy. <b>2019</b> , 7, 52	107
799	Differential Effects of Depleting versus Programming Tumor-Associated Macrophages on Engineered T Cells in Pancreatic Ductal Adenocarcinoma. <b>2019</b> , 7, 977-989	23
798	Early myeloid-derived suppressor cells (HLA-DR/CD33CD16) expanded by granulocyte colony-stimulating factor prevent acute graft-versus-host disease (GVHD) in humanized mouse and might contribute to lower GVHD in patients post allo-HSCT. <b>2019</b> , 12, 31	21
797	Discovery and mechanisms of host defense to oncogenesis: targeting the $\alpha$ -defensin-1 peptide as a natural tumor inhibitor. <b>2019</b> , 20, 774-786	7
796	Induction of breast cancer stem cells by M1 macrophages through Lin-28B-let-7-HMGA2 axis. <b>2019</b> , 452, 213-225	31
795	Mass spectrometry-based proteome profiling of extracellular vesicles and their roles in cancer biology. <b>2019</b> , 51, 1-10	64
794	Targeting the Post-Irradiation Tumor Microenvironment in Glioblastoma via Inhibition of CXCL12. <b>2019</b> , 11,	9
793	Prognostic Value of Preoperative Systemic Immune-Inflammation Index in Patients with Cervical Cancer. <b>2019</b> , 9, 3284	74
792	The Contribution of the Immune System in Bone Metastasis Pathogenesis. <b>2019</b> , 20,	44

791	Mouse Model of Mutated in Colorectal Cancer Gene Deletion Reveals Novel Pathways in Inflammation and Cancer. <b>2019</b> , 7, 819-839	4
790	The Pseudogene Promotes the Suppressive Function and Differentiation of Monocytic MDSCs. <b>2019</b> , 7, 813-827	45
789	Myeloid-Derived Suppressor Cells in Sepsis. <b>2019</b> , 10, 327	79
788	Cowpea Mosaic Virus Promotes Anti-Tumor Activity and Immune Memory in a Mouse Ovarian Tumor Model. <b>2019</b> , 2, 1900003	20
787	GM-CSF Promotes the Expansion and Differentiation of Cord Blood Myeloid-Derived Suppressor Cells, Which Attenuate Xenogeneic Graft-vs.-Host Disease. <b>2019</b> , 10, 183	20
786	Phototrophic purple bacteria as optoacoustic in vivo reporters of macrophage activity. <b>2019</b> , 10, 1191	15
785	Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39. <b>2019</b> , 22, 729-740	166
784	Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer. <b>2021</b> , 11, 14426	4
783	Activation of autophagy reverses gemcitabine-induced immune inhibition of RAW264.7 macrophages by promoting TNF- $\alpha$ and MHC-II expression. <b>2021</b> , 69, 352-362	0
782	The dual role of complement in cancers, from destroying tumors to promoting tumor development. <b>2021</b> , 143, 155522	1
781	CD8 T cell differentiation and dysfunction in cancer. <i>Nature Reviews Immunology</i> , <b>2021</b> ,	36.5 40
780	Increase in polymorphonuclear myeloid-derived suppressor cells and regulatory T-cells in children with B-cell acute lymphoblastic leukemia. <b>2021</b> , 11, 15039	2
779	The receptor for advanced glycation endproducts (RAGE) decreases survival of tumor-bearing mice by enhancing the generation of lung metastasis-associated myeloid-derived suppressor cells. <b>2021</b> , 365, 104379	5
778	Inflammation and tumor progression: signaling pathways and targeted intervention. <b>2021</b> , 6, 263	107
777	Harnessing the Activation of RIG-I Like Receptors to Inhibit Glioblastoma Tumorigenesis. <b>2021</b> , 14, 710171	3
776	Regulation and Functions of Protumoral Unconventional T Cells in Solid Tumors. <b>2021</b> , 13,	1
775	ITLN1 inhibits tumor neovascularization and myeloid derived suppressor cells accumulation in colorectal carcinoma. <b>2021</b> , 40, 5925-5937	1
774	Rapamycin delays allograft rejection in obese graft recipients through induction of myeloid-derived suppressor cells. <b>2021</b> , 236, 1-11	0

773	Epithelial-mesenchymal transition: When tumor cells meet myeloid-derived suppressor cells. <b>2021</b> , 1876, 188564	5
772	Extracellular Vesicles Secreted by Tumor Cells Promote the Generation of Suppressive Monocytes. <b>2021</b> , 5, 647-658	0
771	Curcumin as an Adjuvant to Cancer Immunotherapy. <b>2021</b> , 11, 675923	3
770	Cutting both ways: the innate immune response to oncolytic virotherapy. <b>2021</b> ,	2
769	Multimodal Intralesional Therapy for Reshaping the Myeloid Compartment of Tumors Resistant to Anti-PD-L1 Therapy via IRF8 Expression. <b>2021</b> , 207, 1298-1309	2
768	Tumor microenvironment of human breast cancer, and feline mammary carcinoma as a potential study model. <b>2021</b> , 1876, 188587	4
767	MicroRNA-150 inhibits myeloid-derived suppressor cells proliferation and function through negative regulation of ARG-1 in sepsis. <b>2021</b> , 278, 119626	1
766	Analysis of the circulating myeloid-derived suppressor cells during androgen deprivation therapy for prostate cancer. <b>2021</b> , 4, 367-370	0
765	Ewing Sarcoma-Derived Extracellular Vesicles Impair Dendritic Cell Maturation and Function. <b>2021</b> , 10,	2
764	Possible Immunotherapeutic Strategies Based on Carcinogen-Dependent Subgroup Classification for Oral Cancer. <b>2021</b> , 8, 717038	0
763	A Novel Oral Arginase 1/2 Inhibitor Enhances the Antitumor Effect of PD-1 Inhibition in Murine Experimental Gliomas by Altering the Immunosuppressive Environment. <b>2021</b> , 11, 703465	5
762	Decoding the Myeloid-Derived Suppressor Cells in Lymphoid Malignancies. <b>2021</b> , 10,	0
761	PI3K inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8T cells and promoting fatty acid metabolism. <b>2021</b> , 9,	3
760	Novel Characterization of Myeloid-Derived Suppressor Cells in Tumor Microenvironment. <b>2021</b> , 9, 698532	0
759	Furin-instructed aggregated gold nanoparticles for re-educating tumor associated macrophages and overcoming breast cancer chemoresistance. <b>2021</b> , 275, 120891	19
758	Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects. <b>2021</b> , 9,	7
757	Prospective Evaluation of Radiotherapy-Induced Immunologic and Genetic Effects in Colorectal Cancer Oligo-Metastatic Patients with Lung-Limited Disease: The PRELUDE-1 Study. <b>2021</b> , 13,	2
756	Establishment of an Immune-Related Gene Signature for Risk Stratification for Patients with Glioma. <b>2021</b> , 2021, 2191709	2

755	Gain-of-function p53 mutation drives accumulation of neutrophils in pancreatic tumors, promoting resistance to immunotherapy. <b>2021</b> , 36, 109578	7
754	APLN/APLNR Signaling Controls Key Pathological Parameters of Glioblastoma. <b>2021</b> , 13,	1
753	Potential Strategies to Improve the Effectiveness of Drug Therapy by Changing Factors Related to Tumor Microenvironment. <b>2021</b> , 9, 705280	2
752	Roles of CCL2-CCR2 Axis in the Tumor Microenvironment. <b>2021</b> , 22,	7
751	Hot or cold: Bioengineering immune contextures into in vitro patient-derived tumor models. <b>2021</b> , 175, 113791	2
750	Advances of Tumorigenesis, Diagnosis at Early Stage, and Cellular Immunotherapy in Gastrointestinal Malignancies. <b>2021</b> , 11, 666340	0
749	Nanomedicines modulating myeloid-derived suppressor cells for improving cancer immunotherapy. <b>2021</b> , 39, 101163	4
748	Obesity Promotes Tumor Immune Evasion in Ovarian Cancer Through Increased Production of Myeloid-Derived Suppressor Cells via IL-6. <b>2021</b> , 13, 7355-7363	0
747	The Stromal and Immune Landscape of Nasopharyngeal Carcinoma and Its Implications for Precision Medicine Targeting the Tumor Microenvironment. <b>2021</b> , 11, 744889	2
746	Histone Deacetylase as a Valuable Predictive Biomarker and Therapeutic Target in Immunotherapy for Non-Small Cell Lung Cancer. <b>2021</b> ,	2
745	Bioengineered Models to Study Microenvironmental Regulation of Glioblastoma Metabolism. <b>2021</b> ,	
744	Tumor-Associated Macrophages in Bladder Cancer: Biological Role, Impact on Therapeutic Response and Perspectives for Immunotherapy. <b>2021</b> , 13,	4
743	Compromised anti-tumor-immune features of myeloid cell components in chronic myeloid leukemia patients. <b>2021</b> , 11, 18046	0
742	Arginase 1-Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti-PD-1 Checkpoint Blockade. <b>2021</b> , 9, 1316-1326	5
741	Interplay of Immunometabolism and Epithelial-Mesenchymal Transition in the Tumor Microenvironment. <b>2021</b> , 22,	1
740	Interferon-Induced Myeloid-Derived Suppressor Cells Aggravate Kidney Ischemia-Reperfusion Injury by Regulating Innate Immune Cells. <b>2021</b> , 1-11	0
739	Research Progress About Glioma Stem Cells in the Immune Microenvironment of Glioma. <b>2021</b> , 12, 750857	1
738	ALDH1A1 Activity in Tumor-Initiating Cells Remodels Myeloid-Derived Suppressor Cells to Promote Breast Cancer Progression. <b>2021</b> , 81, 5919-5934	9

737	The interaction of <i>Helicobacter pylori</i> with cancer immunomodulatory stromal cells: New insight into gastric cancer pathogenesis. <b>2021</b> ,	5
736	Mild and Asymptomatic COVID-19 Convalescents Present Long-Term Endotype of Immunosuppression Associated With Neutrophil Subsets Possessing Regulatory Functions. <b>2021</b> , 12, 748097	6
735	Human CD22-Transgenic, Primary Murine Lymphoma Challenges Immunotherapies in Organ-Specific Tumor Microenvironments. <b>2021</b> , 22,	0
734	Metabolic Hormones Modulate Macrophage Inflammatory Responses. <b>2021</b> , 13,	1
733	Small extracellular vesicle-mediated bidirectional crosstalk between neutrophils and tumor cells. <b>2021</b> , 61, 16-26	3
732	Regulation of immune responses through CD39 and CD73 in cancer: Novel checkpoints. <b>2021</b> , 282, 119826	9
731	The implications of nitric oxide metabolism in the treatment of glial tumors. <b>2021</b> , 150, 105172	1
730	Evolution of the protein corona affects macrophage polarization. <b>2021</b> , 191, 192-200	1
729	M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages. <b>2021</b> , 278, 121137	11
728	Evaluation of autophagy mediators in myeloid-derived suppressor cells during human tuberculosis. <b>2021</b> , 369, 104426	3
727	Pleural mesothelioma (PM) - The status of systemic therapy. <b>2021</b> , 100, 102265	1
726	Cellular and molecular actions of bisphosphonates. <b>2022</b> , 921-942	
725	Intrinsic and acquired cancer immunotherapy resistance. <b>2022</b> , 463-497	
724	Targeted delivery and reprogramming of myeloid-derived suppressor cells (MDSCs) in cancer. <b>2022</b> , 409-435	1
723	Vascular endothelial growth factor and tumor immune microenvironment. <b>2021</b> , 105-111	
722	Can Routine Blood Biochemistry Parameters be Predictive Prognostic Marker(s) in Operated Patients with Meningioma WHO Grade 1?.	
721	Emodin Inhibits Inflammation, Carcinogenesis, and Cancer Progression in the AOM/DSS Model of Colitis-Associated Intestinal Tumorigenesis. <b>2020</b> , 10, 564674	10
720	The role of immune dysfunction in obesity-associated cancer risk, progression, and metastasis. <b>2021</b> , 78, 3423-3442	5



719	Moonlighting Proteins Are Important Players in Cancer Immunology. <b>2020</b> , 11, 613069	7
718	Biodegradation of graphdiyne oxide in classically activated (M1) macrophages modulates cytokine production. <b>2021</b> , 13, 13072-13084	3
717	Receptor-interacting protein in malignant digestive neoplasms. <b>2021</b> , 12, 4362-4371	0
716	Myeloid-derived suppressor cells in gastrointestinal cancers: A systemic review. <b>2021</b> , 13, 1-11	4
715	Targeting the STAT6 signaling pathway as a therapy against colon cancer. <b>2021</b> , 149-172	
714	Potential role of myeloid-derived suppressor cells in transition from reaction to repair phase of bone healing process. <b>2021</b> , 18, 1824-1830	2
713	Myeloid-Derived Suppressor Cell Differentiation in Cancer: Transcriptional Regulators and Enhanceosome-Mediated Mechanisms. <b>2020</b> , 11, 619253	4
712	Lipid Metabolism and Tumor Antigen Presentation. <b>2021</b> , 1316, 169-189	1
711	Lipid Metabolism in Tumor-Associated Myeloid-Derived Suppressor Cells. <b>2021</b> , 1316, 103-115	1
710	Engineered cell-based therapies: a vanguard of design-driven medicine. <b>2014</b> , 844, 369-91	2
709	Tumor-Associated Myeloid Cells in Cancer Progression. <b>2020</b> , 29-46	1
708	Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. <b>2020</b> , 1224, 117-140	50
707	The Role of the Immune Infiltrate in Distinct Cancer Types and Its Clinical Implications : Lymphocytic Infiltration in Colorectal Cancer. <b>2020</b> , 180, 197-211	2
706	Overview of Basic Immunology and Clinical Application. <b>2020</b> , 1244, 1-36	6
705	The Impact of Estrogen in the Tumor Microenvironment. <b>2020</b> , 1277, 33-52	10
704	COX-2 Signaling in the Tumor Microenvironment. <b>2020</b> , 1277, 87-104	8
703	Adoptive T-Cell Immunotherapy: Perfecting Self-Defenses. <b>2014</b> , 207-232	2
702	The Role of Innate Immune Signaling in Regulation of Tumor-Associated Myeloid Cells. <b>2015</b> , 25-47	2

701	Mechanisms of Resistance to Checkpoint Blockade Therapy. <b>2020</b> , 1248, 83-117	15
700	Modulation of Cancer Cell Metabolism and Microenvironment by Phytochemicals. <b>2020</b> , 143-165	1
699	Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer model. <b>2020</b> , 69, 2101-2112	8
698	Dendritic Cells in Viral Infection. <b>2016</b> , 207-221	1
697	Tumor cells induce LAMP2a expression in tumor-associated macrophage for cancer progression. <b>2019</b> , 40, 118-134	27
696	[An integral view of cancer (II). Fields of investigation and emerging biomarkers]. <b>2019</b> , 52, 222-233	3
695	p110PI3K as a therapeutic target of solid tumours. <b>2020</b> , 134, 1377-1397	7
694	Optical and magnetic resonance imaging approaches for investigating the tumour microenvironment: state-of-the-art review and future trends. <b>2021</b> , 32, 062001	8
693	The pd-l1/pd-1 axis blocks neutrophil cytotoxicity in cancer.	6
692	Murine cytomegalovirus infection of melanoma lesions delays tumor growth by recruiting and re-polarizing monocytic phagocytes in the tumor.	2
691	Absolute and relative differential blood count predicts survival of AJCC stage I-II melanoma patients scheduled for sentinel lymph node biopsy. <b>2020</b> , 61, e310-e318	4
690	Tumor-Induced Myeloid-Derived Suppressor Cells. 833-856	1
689	Circulating Monocytic Myeloid-Derived Suppressor Cells Are Elevated and Associated with Poor Prognosis in Acute Myeloid Leukemia. <b>2020</b> , 2020, 7363084	2
688	Vaccine-elicited CD8+ T cells cure mesothelioma by overcoming tumor-induced immunosuppressive environment. <b>2014</b> , 74, 6010-21	27
687	ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor Cells. <b>2021</b> , 19, 702-716	5
686	Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. <b>2019</b> , 4,	95
685	Heat-killed Mycobacterium tuberculosis prime-boost vaccination induces myeloid-derived suppressor cells with spleen dendritic cell-killing capability. <b>2019</b> , 5,	11
684	Mitochondrial arginase-2 is a cell-autonomous regulator of CD8+ T cell function and antitumor efficacy. <b>2019</b> , 4,	16

683	Polymorphonuclear myeloid-derived suppressor cells limit antigen cross-presentation by dendritic cells in cancer. <b>2020</b> , 5,	34
682	Akt and SHP-1 are DC-intrinsic checkpoints for tumor immunity. <b>2016</b> , 1, e89020	13
681	Tumor-infiltrating lymphocytes are dynamically desensitized to antigen but are maintained by homeostatic cytokine. <b>2016</b> , 1, e89289	17
680	Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer. <b>2017</b> , 2,	67
679	Lactoferrin-induced myeloid-derived suppressor cell therapy attenuates pathologic inflammatory conditions in newborn mice. <b>2019</b> , 129, 4261-4275	29
678	c-Maf: a bad influence in the education of macrophages. <b>2020</b> , 130, 1629-1631	3
677	Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma. <b>2020</b> , 130, 5380-5396	48
676	Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis. <b>2012</b> , 122, 3127-44	254
675	Lung tumor NF- $\kappa$ B signaling promotes T cell-mediated immune surveillance. <b>2013</b> , 123, 2509-22	70
674	Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. <b>2014</b> , 124, 687-95	1191
673	Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. <b>2013</b> , 123, 4464-78	214
672	IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. <b>2013</b> , 123, 3383-94	118
671	ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. <b>2014</b> , 124, 2626-39	209
670	Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. <b>2015</b> , 125, 3356-64	660
669	Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. <b>2015</b> , 125, 3365-76	351
668	Sepsis-induced immune dysfunction: can immune therapies reduce mortality?. <b>2016</b> , 126, 23-31	309
667	Schlafen 4-expressing myeloid-derived suppressor cells are induced during murine gastric metaplasia. <b>2016</b> , 126, 2867-80	41
666	The transcription factor BACH2 promotes tumor immunosuppression. <b>2016</b> , 126, 599-604	39

665	A proangiogenic signaling axis in myeloid cells promotes malignant progression of glioma. <b>2017</b> , 127, 1826-1838	22
664	Type 2 innate lymphoid cells treat and prevent acute gastrointestinal graft-versus-host disease. <b>2017</b> , 127, 1813-1825	67
663	Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy. <b>2017</b> , 127, 3039-3051	87
662	Role of prostanoids in gastrointestinal cancer. <b>2018</b> , 128, 2732-2742	67
661	Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma. <b>2018</b> , 128, 5505-5516	120
660	ELF5 Drives Lung Metastasis in Luminal Breast Cancer through Recruitment of Gr1+ CD11b+ Myeloid-Derived Suppressor Cells. <b>2015</b> , 13, e1002330	44
659	Cell-extrinsic effects of tumor ER stress imprint myeloid dendritic cells and impair CD8+ T cell priming. <b>2012</b> , 7, e51845	87
658	Human S100A9 protein is stabilized by inflammatory stimuli via the formation of proteolytically-resistant homodimers. <b>2013</b> , 8, e61832	25
657	High myeloperoxidase positive cell infiltration in colorectal cancer is an independent favorable prognostic factor. <b>2013</b> , 8, e64814	75
656	Myeloid clusters are associated with a pro-metastatic environment and poor prognosis in smoking-related early stage non-small cell lung cancer. <b>2013</b> , 8, e65121	14
655	Myeloid-derived suppressor cells modulate immune responses independently of NADPH oxidase in the ovarian tumor microenvironment in mice. <b>2013</b> , 8, e69631	16
654	Persistent salmonellosis causes pancreatitis in a murine model of infection. <b>2014</b> , 9, e92807	8
653	Evaluation of the therapeutic potential of bone marrow-derived myeloid suppressor cell (MDSC) adoptive transfer in mouse models of autoimmunity and allograft rejection. <b>2014</b> , 9, e100013	41
652	Myeloid derived suppressor cells are present at high frequency in neonates and suppress in vitro T cell responses. <b>2014</b> , 9, e107816	57
651	Immune suppressive effect of cinnamaldehyde due to inhibition of proliferation and induction of apoptosis in immune cells: implications in cancer. <b>2014</b> , 9, e108402	31
650	Mathematical modeling of Interleukin-35 promoting tumor growth and angiogenesis. <b>2014</b> , 9, e110126	27
649	Tumor induced hepatic myeloid derived suppressor cells can cause moderate liver damage. <b>2014</b> , 9, e112717	13
648	Establishment of Ial <sup>-/-</sup> myeloid lineage cell line that resembles myeloid-derived suppressive cells. <b>2015</b> , 10, e0121001	9

647	Characterization of Liver Monocytic Myeloid-Derived Suppressor Cells and Their Role in a Murine Model of Non-Alcoholic Fatty Liver Disease. <b>2016</b> , 11, e0149948	13
646	The Role of Myeloid-Derived Suppressor Cells in Patients with Solid Tumors: A Meta-Analysis. <b>2016</b> , 11, e0164514	95
645	Neem leaf glycoprotein prevents post-surgical sarcoma recurrence in Swiss mice by differentially regulating cytotoxic T and myeloid-derived suppressor cells. <b>2017</b> , 12, e0175540	5
644	Downregulation of adaptor protein MyD88 compromises the angiogenic potential of B16 murine melanoma. <b>2017</b> , 12, e0179897	3
643	Paradoxical myeloid-derived suppressor cell reduction in the bone marrow of SIV chronically infected macaques. <b>2017</b> , 13, e1006395	22
642	The Future of Combining Carbon-Ion Radiotherapy with Immunotherapy: Evidence and Progress in Mouse Models. <b>2016</b> , 3, 61-70	29
641	An Insight Into the Immunologic Events and Risk Assessment in Renal Transplantation. <b>2016</b> , 8, 367-72	6
640	Regulating Tumor Myeloid-Derived Suppressor Cells by MicroRNAs. <b>2015</b> , 2,	24
639	Efferocytosis creates a tumor microenvironment supportive of tumor survival and metastasis. <b>2015</b> , 2,	13
638	TRAF3: a novel tumor suppressor gene in macrophages. <b>2015</b> , 2, e1009	13
637	Neutrophil elastase from myeloid cells promotes TSC2-null tumor growth. <b>2020</b> , 27, 261-274	4
636	Myelopoiesis, metabolism and therapy: a crucial crossroads in cancer progression. <b>2019</b> , 3, 284-294	25
635	Necroptosis, tumor necrosis and tumorigenesis. <b>2019</b> , 4, 1-8	27
634	The combination of immunotherapy and radiation therapy for non-small cell lung cancer. <b>2018</b> , 7, 90	1
633	[The immunosuppressive microenvironment of malignant gliomas]. <b>2015</b> , 77, 54-63	8
632	Romo1 is involved in the immune response of glioblastoma by regulating the function of macrophages. <b>2020</b> , 12, 1114-1127	6
631	Estrogens drive myeloid-derived suppressor cell accumulation. <b>2017</b> , 4, 5-6	3
630	Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment. <b>2016</b> , 7, 50277-50289	30

629	Monocyte-derived factors including PLA2G7 induced by macrophage-nasopharyngeal carcinoma cell interaction promote tumor cell invasiveness. <b>2016</b> , 7, 55473-55490	15
628	The functions and clinical applications of tumor-derived exosomes. <b>2016</b> , 7, 60736-60751	60
627	The transcriptional signature of human ovarian carcinoma macrophages is associated with extracellular matrix reorganization. <b>2016</b> , 7, 75339-75352	61
626	Downregulation of sphingosine kinase-1 induces protective tumor immunity by promoting M1 macrophage response in melanoma. <b>2016</b> , 7, 71873-71886	28
625	The role of tumor microenvironment in therapeutic resistance. <b>2017</b> , 8, 3933-3945	123
624	Accumulation of myeloid-derived suppressor cells (MDSCs) induced by low levels of IL-6 correlates with poor prognosis in bladder cancer. <b>2017</b> , 8, 38378-38388	56
623	The peripheral immune status of granulocytic myeloid-derived suppressor cells correlates the survival in advanced gastric cancer patients receiving cisplatin-based chemotherapy. <b>2017</b> , 8, 95083-95094	14
622	Myeloid-specific genetic ablation of ATP-binding cassette transporter ABCA1 is protective against cancer. <b>2017</b> , 8, 71965-71980	18
621	Prognostic value of granulocyte colony-stimulating factor in patients with non-metastatic clear cell renal cell carcinoma. <b>2017</b> , 8, 69961-69971	7
620	Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growth. <b>2017</b> , 8, 81754-81775	22
619	Ascites-derived IL-6 and IL-10 synergistically expand CD14HLA-DR myeloid-derived suppressor cells in ovarian cancer patients. <b>2017</b> , 8, 76843-76856	53
618	Activation of VIP signaling enhances immunosuppressive effect of MDSCs on CMV-induced adaptive immunity. <b>2017</b> , 8, 81873-81879	4
617	S100A9 MDSC and TAM-mediated EGFR-TKI resistance in lung adenocarcinoma: the role of. <b>2018</b> , 9, 7631-7643	17
616	Novel adherent CD11b Gr-1 tumor-infiltrating cells initiate an immunosuppressive tumor microenvironment. <b>2018</b> , 9, 11209-11226	6
615	Characterization of increasing stages of invasiveness identifies stromal/cancer cell crosstalk in rat models of mesothelioma. <b>2018</b> , 9, 16311-16329	7
614	The inhibition of malignant melanoma cell invasion of bone by the TLR7 agonist R848 is dependent upon pro-inflammatory cytokines produced by bone marrow macrophages. <b>2018</b> , 9, 29934-29943	4
613	deficiency is characterised by altered cytokine levels and promotion of intestinal tumourigenesis. <b>2018</b> , 9, 36430-36443	2
612	CD90 MSCs modulate intratumoral immunity to confer antitumor activity in a mouse model of ovarian cancer. <b>2019</b> , 10, 4479-4491	5

611	Low-dose metronomic cyclophosphamide complements the actions of an intratumoral C-class CpG TLR9 agonist to potentiate innate immunity and drive potent T cell-mediated anti-tumor responses. <b>2019</b> , 10, 7220-7237	4
610	cGAS-STING pathway in oncogenesis and cancer therapeutics. <b>2020</b> , 11, 2930-2955	12
609	Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer. <b>2015</b> , 6, 11310-26	37
608	Expansion of myeloid-derived suppressor cells with arginase activity lasts longer in aged than in young mice after CpG-ODN plus IFA treatment. <b>2015</b> , 6, 13448-61	7
607	Deregulation of PPAR $\alpha$ target genes in tumor-associated macrophages by fatty acid ligands in the ovarian cancer microenvironment. <b>2015</b> , 6, 13416-33	58
606	The MUTYH base excision repair gene protects against inflammation-associated colorectal carcinogenesis. <b>2015</b> , 6, 19671-84	10
605	Cysteine cathepsin activity suppresses osteoclastogenesis of myeloid-derived suppressor cells in breast cancer. <b>2015</b> , 6, 27008-22	29
604	Extracting tumor tissue immune status from expression profiles: correlating renal cancer prognosis with tumor-associated immunome. <b>2015</b> , 6, 33191-205	1
603	Immature myeloid progenitors promote disease progression in a mouse model of Barrett's-like metaplasia. <b>2015</b> , 6, 32980-3005	6
602	Antigen spreading-induced CD8+T cells confer protection against the lethal challenge of wild-type malignant mesothelioma by eliminating myeloid-derived suppressor cells. <b>2015</b> , 6, 32426-38	14
601	Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapies. <b>2015</b> , 6, 41600-19	85
600	SHIP represses lung inflammation and inhibits mammary tumor metastasis in BALB/c mice. <b>2016</b> , 7, 3677-91	7
599	The impact of ranitidine on monocyte responses in the context of solid tumors. <b>2016</b> , 7, 10891-904	8
598	Loss of SOCS3 in myeloid cells prolongs survival in a syngeneic model of glioma. <b>2016</b> , 7, 20621-35	17
597	Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy. <b>2016</b> , 7, 42698-42715	27
596	Identification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients. <b>2016</b> , 7, 27676-88	51
595	Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer. <b>2016</b> , 7, 33210-9	98
594	Targeting tumor-associated macrophages to combat pancreatic cancer. <b>2016</b> , 7, 50735-50754	63

593	Metastatic site-specific polarization of macrophages in intracranial breast cancer metastases. <b>2016</b> , 7, 41473-41487	28
592	Myeloid-Derived Suppressor Cells in Some Oncohematological Diseases. <b>2017</b> , 10, 29-38	2
591	Nanoparticles: Properties and Applications in Cancer Immunotherapy. <b>2019</b> , 25, 1962-1979	8
590	Perspectives of Immune Suppression in the Tumor Microenvironment Promoting Oral Malignancy. <b>2018</b> , 12, 455-465	6
589	CD38 as an immunomodulator in cancer. <b>2020</b> , 16, 2853-2861	2
588	Neutrophil-to-Lymphocyte Ratio Predicts Pathological Renal Sinus Fat Invasion in Renal Cell Carcinomas of $\geq$ 7 cm with Presumed Renal Sinus Fat Invasion. <b>2019</b> , 60, 1021-1027	4
587	Friend or Foe? Recent Strategies to Target Myeloid Cells in Cancer. <b>2020</b> , 8, 351	22
586	Myeloid Cells in Glioblastoma Microenvironment. <b>2020</b> , 10,	25
585	Understanding the Differentiation, Expansion, Recruitment and Suppressive Activities of Myeloid-Derived Suppressor Cells in Cancers. <b>2020</b> , 21,	18
584	Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy. <b>2020</b> , 21,	13
583	Role of relevant immune-modulators and cytokines in hepatocellular carcinoma and premalignant hepatic lesions. <b>2018</b> , 24, 1228-1238	13
582	Neural stem cells induce M2 polarization of macrophages through the upregulation of interleukin-4. <b>2020</b> , 20, 148	3
581	Combination of preoperative fibrinogen concentration and neutrophil-to-lymphocyte ratio for prediction of the prognosis of patients with resectable breast cancer. <b>2020</b> , 20, 200	4
580	Innate immune cells and their interaction with T cells in hepatocellular carcinoma. <b>2021</b> , 21, 57	2
579	The role of the cytokines IL-27 and IL-35 in cancer. <b>2015</b> , 12, 1203-17	14
578	Role of CD204-positive tumor-associated macrophages in adult T-cell leukemia/lymphoma. <b>2014</b> , 54, 59-65	14
577	Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma. <b>2015</b> , 4, 226-38	50
576	Cord Blood Low-Density Granulocytes Correspond to an Immature Granulocytic Subset with Low Expression of S100A12. <b>2020</b> , 205, 56-66	3



575	Analysis of the Expression and Regulation of PD-1 Protein on the Surface of Myeloid-Derived Suppressor Cells (MDSCs). <b>2019</b> , 27, 63-70	24
574	Modulation of Immunosuppression by Oligonucleotide-Based Molecules and Small Molecules Targeting Myeloid-Derived Suppressor Cells. <b>2020</b> , 28, 1-17	1
573	Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest?. <b>2020</b> , 20, e11	28
572	Prognostic Role of S100A8 and S100A9 Protein Expressions in Non-small Cell Carcinoma of the Lung. <b>2019</b> , 53, 13-22	6
571	Bone metastases: When and how lung cancer interacts with bone. <b>2014</b> , 5, 149-55	30
570	Role of myeloid-derived suppressor cells in autoimmune disease. <b>2014</b> , 4, 26-33	53
569	Impact of tumour associated macrophages in pancreatic cancer. <b>2013</b> , 46, 131-8	59
568	Tumor-induced MDSC act via remote control to inhibit L-selectin-dependent adaptive immunity in lymph nodes. <b>2016</b> , 5,	57
567	Whole-Body Matter. <b>2021</b> , 317-363	
566	Bone Health in Cancer Patients. <b>2021</b> , 365-380	
565	Progranulin/GP88, A Complex and Multifaceted Player of Tumor Growth by Direct Action and via the Tumor Microenvironment. <b>2021</b> , 1329, 475-498	2
564	Histamine in cancer immunology and immunotherapy. Current status and new perspectives. <b>2021</b> , 9, e00778	2
563	A Complex Metabolic Network Confers Immunosuppressive Functions to Myeloid-Derived Suppressor Cells (MDSCs) within the Tumour Microenvironment. <b>2021</b> , 10,	2
562	Exosomes Derived from RM-1 Cells Promote the Recruitment of MDSCs into Tumor Microenvironment by Upregulating CXCR4 via TLR2/NF-B Pathway. <b>2021</b> , 2021, 5584406	1
561	Estrogens and the Schrödinger's Cat in the Ovarian Tumor Microenvironment. <b>2021</b> , 13,	1
560	Beyond immunosuppressive effects: dual roles of myeloid-derived suppressor cells in bone-related diseases. <b>2021</b> , 78, 7161-7183	1
559	Myeloid-derived suppressor cells (MDSCs) in brain cancer: challenges and therapeutic strategies. <b>2021</b> , 29, 1613-1624	1
558	Macrophage Innate Training Induced by IL-4 Activation Enhances OXPHOS Driven Anti-Mycobacterial Responses.	

557	In Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy Systemic Inflammation Response Index is a Useful Prognostic Indicator. <b>2021</b> , 27, 1609811	2
556	Myeloid-Derived Suppressive Cell Expansion Promotes Melanoma Growth and Autoimmunity by Inhibiting CD40/IL27 Regulation in Macrophages. <b>2021</b> , 81, 5977-5990	2
555	Therapeutic Values of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma: Facts and Hopes. <b>2021</b> , 13,	2
554	Graft-Versus-Host Disease Prevention by -Generated Myeloid-Derived Suppressor Cells Is Exclusively Mediated by the CD11b+CD11c+ MDSC Subpopulation. <b>2021</b> , 12, 754316	0
553	Conjugation of glucosylated polymer chains to checkpoint blockade antibodies augments their efficacy and specificity for glioblastoma. <b>2021</b> , 5, 1274-1287	4
552	Cyclooxygenases and Prostaglandins in Tumor Immunology and Microenvironment of Gastrointestinal Cancer. <b>2021</b> , 161, 1813-1829	10
551	Head and neck tumor cells treated with hypofractionated irradiation die via apoptosis and are better taken up by M1-like macrophages. <b>2021</b> , 1	1
550	Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. <b>2021</b> , 6, 362	26
549	Role of myeloid-derived suppressor cells in viral respiratory infections; Hints for discovering therapeutic targets for COVID-19. <b>2021</b> , 144, 112346	7
548	Inflammation, Tumor Progression, and Immune Suppression. <b>2013</b> , 177-196	
547	Development of Antitumor Cellular Immunity. <b>2013</b> , 107-133	
546	ChemImmunoModulation: Focus on Myeloid Regulatory Cells. <b>2013</b> , 603-619	
545	Approaches to Immunologic Monitoring of Clinical Trials. <b>2013</b> , 663-694	
544	Analysis of Myeloid-Derived Suppressor Cells in Patients with Cancer. <b>2013</b> , 707-723	
543	The Immune System in Head and Neck Squamous Cell Carcinoma: Interactions and Therapeutic Opportunities. <b>2014</b> , 275-321	
542	Myeloid-Derived Suppressor Cells and Tumor Growth. <b>2014</b> , 91-109	1
541	Cancer Immune Modulation and Immunosuppressive Cells: Current and Future Therapeutic Approaches. <b>2014</b> , 187-214	
540	Myeloid-Derived Suppressor Cells in Tumor-Induced T Cell Suppression and Tolerance. <b>2014</b> , 99-150	2

539 Reflections on Cancer Vaccines. **2014**, 65-68

538 S100A9, Inflammation, and Regulation of Immune Suppression in Cancer. **2014**, 295-310

537 Dendritic Cell-Based Cancer Vaccines. **2014**, 69-87

536 Macrophages and Tumor Development. **2014**, 185-212

535 Tumor-Associated Macrophages. **2014**, 425-443

534 Cell-Nonautonomous ER Stress-Mediated Dysregulation of Immunity by Cancer Cells. **2015**, 397-429

533 Vaccines in RCC: Clinical and Biological Relevance. **2015**, 483-525

532 Mechanisms and Modulation of Tumor Microenvironment-Induced Immune Resistance. **2015**, 143-158

531 Bacterial Cancer Therapy: How Patients Might Benefit from Salmonella Infections. **2015**, 335-376

530 Signal Transducer and Activation of Transcription 3: A Master Regulator of Myeloid-Derived Suppressor Cells. **2016**, 73-90

529 Whole-Body Matter. **2016**, 305-346

528 Myeloid Derived Suppressor Cells. **2016**, 179-192

527 Macrophage Polarization by Tumor-induced MDSCs Assay. **2016**, 6,

526 Secondary Alterations of Hepatocellular Carcinoma. **2016**, 1-29

525 Aiming the Immune System to Improve the Antitumor Efficacy of Radiation Therapy. **2016**, 159-181

524 Melanoma. **2017**, 81-94

523 Immune Suppressor Mechanisms in HCC. **2017**, 121-135

522 Introduction to Modern Immunology. **2017**, 1-22

- 521 Tumor-Promoting/Associated Inflammation and the Microenvironment: A State of the Science and New Horizons. 473-510
- 520 Immunometabolomics: The metabolic landscape of immune cells in tumor microenvironment. **2018**, 1, 72
- 519 Research Progress of Myeloid Derived Suppressor Cells in Recurrence and Metastasis of Colorectal Cancer. **2018**, 08, 902-909
- 518 The expression of class II major histocompatibility molecules on breast tumors delays T cell exhaustion, expands the T cell repertoire and slows tumor growth.
- 517 M2-polarized macrophages contribute to neovasculogenesis, leading to recurrence of oral cancer after radiation. **2018**, 64, 307-320
- 516 Chronic Inflammatory Mediators Induced Malignant Changes in Inflammatory Microenvironment of Oral Potentially Malignant Conditions - An Emerging Concept. 7, 82-89
- 515 Chronic Inflammatory Mediators Induced Malignant Changes in Tumor Microenvironment of Oral Squamous Cell Carcinoma-New Insight. 7, 90-95
- 514 Myeloid-Derived Suppressor Cells (MDSCs) in Aged Mice: Focus on Inflammation. **2019**, 711-731
- 513 KANSER GELİMİNDE İNFLAMASYONUN ROLÜ
- 512 Mechanism of resistance to immune checkpoint inhibitors.. **2019**, 2, 178-188 2
- 511 Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics. 0
- 510 The disruption of hematopoiesis in tumor progression.. **2019**, 1, 88-91 0
- 509 Microbiota, mucosal immunity, and Colon cancer. **2020**, 157-209
- 508 High-Throughput Fluorescence-Based Activity Assay for Arginase-1. **2020**, 25, 1018-1025 3
- 507 On the Nonspecific Resistance in Burn Injury: Pathophysiological Aspects (Review). **2021**, 12, 84-93
- 506 Novel Immunotherapeutic Approach in Gastric Cancer. **2020**, 47, 47-54 0
- 505 Tumor-educated monocyte-dendritic progenitors promote a metastatic switch.
- 504 Transient cell-in-cell formation underlies tumor resistance to immunotherapy. 0

503	Metronomic Anti-Cancer Therapy: A Multimodal Therapy Governed by the Tumor Microenvironment. <b>2021</b> , 13,	0
502	Breast Cancer CAFs: Spectrum of Phenotypes and Promising Targeting Avenues. <b>2021</b> , 22,	5
501	Myeloid cell subsets that express latency-associated peptide promote cancer growth by modulating T cells. <b>2021</b> , 24, 103347	0
500	Is a Prognostic Biomarker That Correlates With Cell Malignancy and the Tumor Microenvironment in Bladder Cancer. <b>2021</b> , 12, 705086	2
499	A heparan-sulfate-bearing syndecan-1 glycoform is a distinct surface marker for intra-tumoral myeloid-derived suppressor cells. <b>2021</b> , 24, 103349	
498	Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody-drug conjugates and bispecific antibodies. <b>2021</b> , 1	3
497	Trained immunity in the mucosal diseases.. <b>2022</b> , 14, e1543	0
496	Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End. <b>2021</b> , 12, 770390	6
495	Role of Cytokines in Tumor Immunity and Immune Tolerance to Cancer. <b>2020</b> , 205-233	
494	Correlation analysis of the proportion of monocytic myeloid-derived suppressor cells in colorectal cancer patients. <b>2020</b> , 15, e0243643	2
493	Targeting Inhibitory Cells Such as Tregs and MDSCs in the Tuberculous Granuloma. <b>2021</b> , 169-203	0
492	Ppard Is Essential in Acceleration of Pancreatic Ductal Adenocarcinoma Development by High-Fat Diet in Mutant Kras Mice.	0
491	Repression of MUC1 promotes expansion and suppressive function of myeloid-derived suppressor cells in pancreatic ductal adenocarcinoma and breast cancer murine models.	
490	Serum cytokines in astrocytic brain tumors: a prospective study. <b>2020</b> , 1-6	1
489	Cancer Immunology and Immuno-Oncology (Innate vs. Adaptive Cell Immunity). <b>2021</b> , 05, 032-049	
488	High-density lipoproteins: A promising tool against cancer. <b>2022</b> , 1867, 159068	2
487	Immune Dysregulation and Recurring Mutations in Myelodysplastic Syndromes Pathogenesis. <b>2021</b> , 1326, 1-10	0
486	IRE1 $\beta$ regulates macrophage polarization, PD-L1 expression and tumor survival.	0

485	Deciphering and Reversing Immunosuppressive Cells in the Treatment of Hepatocellular Carcinoma. <b>2020</b> , 20, 1-16	1
484	NAD <sup>+</sup> attenuates experimental autoimmune encephalomyelitis through induction of CD11b <sup>+</sup> gr-1 <sup>+</sup> myeloid-derived suppressor cells. <b>2020</b> , 40,	
483	Clinical and Immunological Effects of p53-Targeting Vaccines. <b>2021</b> , 9, 762796	1
482	Single-cell analysis reveals EP4 as a target for restoring T cell infiltration and sensitizing prostate cancer to immunotherapy. <b>2021</b> ,	3
481	Reconstituting Immune Surveillance in Breast Cancer: Molecular Pathophysiology and Current Immunotherapy Strategies. <b>2021</b> , 22,	2
480	The association with COPD. 38-49	
479	Identification of Hyal2-expressing tumor-associated myeloid cells in cancer: implications for cancer-related inflammation through enhanced hyaluronan degradation.	
478	The importance of advanced cytometry in defining new immune cell types and functions relevant for the immunopathogenesis of HIV infection. <b>2020</b> , 34, 2169-2185	0
477	Specific immune-regulatory transcriptional signatures reveal sex and age differences in SARS-CoV-2 infected patients.	1
476	Isolation and Phenotyping of Splenic Myeloid-Derived Suppressor Cells in Murine Cancer Models. <b>2021</b> , 2236, 19-28	2
475	Measuring Suppressive Activity and Autophagy in Myeloid-Derived Suppressor Cells. <b>2021</b> , 2236, 85-98	0
474	Control of B Cell Lymphoma by Gammaherpesvirus-Induced Memory CD8 T Cells. <b>2020</b> , 205, 3372-3382	1
473	Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer. <b>2012</b> , 4, 376-89	219
472	Obesity-driven inflammation and cancer risk: role of myeloid derived suppressor cells and alternately activated macrophages. <b>2013</b> , 3, 21-33	33
471	Role of inflammation and inflammatory mediators in colorectal cancer. <b>2014</b> , 125, 358-72; discussion 372-3	34
470	Immunological parameters as a new lead in the diagnosis of ovarian cancer. <b>2015</b> , 7, 67-72	3
469	Prognostic significance of peripheral monocytic myeloid-derived suppressor cells and monocytes in patients newly diagnosed with diffuse large b-cell lymphoma. <b>2015</b> , 8, 15173-81	22
468	Combined VEGFR and CTLA-4 blockade increases the antigen-presenting function of intratumoral DCs and reduces the suppressive capacity of intratumoral MDSCs. <b>2016</b> , 6, 2514-2531	35

467	The diverse roles of the TNF axis in cancer progression and metastasis. <b>2016</b> , 11, 1-27	65
466	Ultrathin metal-organic layer-mediated radiotherapy-radiodynamic therapy enhances immunotherapy of metastatic cancers. <b>2019</b> , 1, 1331-1353	16
465	MicroRNA 449c Mediates the Generation of Monocytic Myeloid-Derived Suppressor Cells by Targeting STAT6. <b>2020</b> , 43, 793-803	1
464	Fibrinogen-like protein 2 promotes the accumulation of myeloid-derived suppressor cells in the hepatocellular carcinoma tumor microenvironment. <b>2021</b> , 21, 47	3
463	TGF- $\beta$ Enhances the Anti-inflammatory Effect of Tumor- Infiltrating CD33+11b+HLA-DR Myeloid-Derived Suppressor Cells in Gastric Cancer: A Possible Relation to MicroRNA-494. <b>2020</b> , 21, 3393-3403 <sup>2</sup>	
462	The role and therapeutic implication of CPTs in fatty acid oxidation and cancers progression. <b>2021</b> , 11, 2477-2494	1
461	A heptamethine cyanine dye serves as a potential marker for myeloid-derived suppressor cells. <b>2021</b> , 11, 2853-2866	
460	Circulating Levels of Monocytic Myeloid-Derived Suppressor Cells (M-MDSC) and CXCL-8 in Non-Small Cell Lung Cancer (NSCLC). <b>2021</b> , 20, 15-21	1
459	Immune escape mechanisms and immunotherapy of urothelial bladder cancer. <b>2021</b> , 7, 485-500	2
458	Current Strategies for Tumor Photodynamic Therapy Combined With Immunotherapy. <b>2021</b> , 11, 738323	6
457	Targeting Immune Cells in the Tumor Microenvironment of HCC: New Opportunities and Challenges. <b>2021</b> , 9, 775462	7
456	PPP1R14B Is a Prognostic and Immunological Biomarker in Pan-Cancer. <b>2021</b> , 12, 763561	3
455	Comparative analysis of IL-1 $\beta$ blood serum concentration, neutrophil-to-lymphocytes ratio in peripheral blood, and the levels of PD-L1 expression in malignant tissues of the patients with various solid tumors. <b>2021</b> , 23, 1105-1114	
454	Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review. <b>2021</b> , 19, 117	2
453	Dysregulated Immunometabolism Is Associated with the Generation of Myeloid-Derived Suppressor Cells in Staphylococcus aureus Chronic Infection. <b>2021</b> , 1-18	0
452	TGF $\beta$ Signaling in Myeloid Cells Promotes Lung and Liver Metastasis Through Different Mechanisms. <b>2021</b> , 11, 765151	
451	Targeting hypoxia and hypoxia-inducible factor-1 in the tumor microenvironment for optimal cancer immunotherapy. <b>2021</b> ,	2
450	Harnessing the combined potential of cancer immunotherapy and nanomedicine: A new paradigm in cancer treatment. <b>2021</b> , 40, 102492	0

449	Immune Checkpoint Inhibitor Therapy for Bone Metastases: Specific Microenvironment and Current Situation. <b>2021</b> , 2021, 8970173	3
448	Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. <b>2021</b> , 22, 1740-1751	2
447	Immune System in Action.. <b>2021</b> , 1342, 1-43	
446	Blocking the A 2B Adenosine Receptor Alleviates Myocardial Damage by Inhibiting Spleen-Derived MDSC Mobilization after Acute Myocardial Infarction.	
445	Modulation of Myeloid-Derived Suppressor Cells Amplification by Tumor Microenvironment. <b>2021</b> , 11, 5039-5047	
444	Circulating Monocytes Associated with Anti-PD-1 Resistance in Human Biliary Cancer Induce T Cell Paralysis.	
443	The cross-talk between tumor-associated macrophages and tumor endothelium: Recent advances in macrophage-based cancer immunotherapy.. <b>2022</b> , 146, 112588	1
442	Fibrinogen-like protein 2 promotes the accumulation of myeloid-derived suppressor cells in the hepatocellular carcinoma tumor microenvironment. <b>2020</b> , 21, 47	3
441	TGF- $\beta$ Enhances the Anti-inflammatory Effect of Tumor- Infiltrating CD33+11b+HLA-DR Myeloid-Derived Suppressor Cells in Gastric Cancer: A Possible Relation to MicroRNA-494. <b>2020</b> , 21, 3393-3403 <sup>2</sup>	
440	A CD8 T Cell-Related Genes Expression Signature Predicts Prognosis and the Efficacy of Immunotherapy in Breast Cancer.. <b>2022</b> , 1	0
439	The Good, the Bad, and the Ugly: Neutrophils, Angiogenesis, and Cancer.. <b>2022</b> , 14,	2
438	Tumor-Associated Macrophages in Hepatocellular Carcinoma Pathogenesis, Prognosis and Therapy.. <b>2022</b> , 14,	9
437	Neutrophils Promote Tumor Progression in Oral Squamous Cell Carcinoma by Regulating EMT and JAK2/STAT3 Signaling Through Chemerin.. <b>2022</b> , 12, 812044	1
436	Engineered Mesenchymal Stem Cells as a Biotherapy Platform for Targeted Photodynamic Immunotherapy of Breast Cancer.. <b>2022</b> , e2101375	1
435	Immune-guided therapy of COVID-19.. <b>2022</b> ,	2
434	Cell Communication Network factor 4 promotes tumor-induced immunosuppression in melanoma.. <b>2022</b> , e54127	2
433	Engineering Macrophages Nanotechnology and Genetic Manipulation for Cancer Therapy.. <b>2021</b> , 11, 786913	0
432	Chemotherapy-induced infiltration of neutrophils promotes pancreatic cancer metastasis via Gas6/AXL signalling axis.. <b>2022</b> ,	1



431	Inflammation and Myeloid Cells in Cancer Progression and Metastasis.. <b>2021</b> , 9, 759691	1
430	Evolution and Targeting of Myeloid Suppressor Cells in Cancer: A Translational Perspective.. <b>2022</b> , 14,	2
429	microRNA-21 Regulates Stemness in Pancreatic Ductal Adenocarcinoma Cells.. <b>2022</b> , 23,	4
428	SAA induces suppressive neutrophils via the TLR2-mediated signaling pathway to promote progression of breast cancer.. <b>2022</b> ,	1
427	Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies.. <b>2021</b> , 9, 805195	0
426	CC-01 (chidamide plus celecoxib) modifies the tumor immune microenvironment and reduces tumor progression combined with immune checkpoint inhibitor.. <b>2022</b> , 12, 1100	2
425	Immunometabolism in biofilm infection: lessons from cancer.. <b>2022</b> , 28, 10	3
424	Somatic mutations enriched in cis-regulatory elements affect genes involved in embryonic development and immune system response in neuroblastoma.. <b>2022</b> ,	0
423	Disruption of prostaglandin E2 signaling in cancer-associated fibroblasts limits mammary carcinoma growth but promotes metastasis.. <b>2022</b> ,	1
422	Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy.. <b>2022</b> , 108114	2
421	Traditional Patchouli Essential Oil modulates the host's immune responses and gut microbiota and exhibits potent anti-cancer effects in Apc mice.. <b>2022</b> , 106082	1
420	New Discovery of Myeloid-Derived Suppressor Cell's Tale on Viral Infection and COVID-19.. <b>2022</b> , 13, 842535	0
419	Engineering CAR T cells for enhanced efficacy and safety.. <b>2022</b> , 6, 011502	0
418	Targeted therapy of tumor microenvironment by gold nanoparticles as a new therapeutic approach.. <b>2022</b> , 1-35	1
417	Myeloid-derived suppressor cell infiltration is associated with a poor prognosis in patients with hepatocellular carcinoma.. <b>2022</b> , 23, 93	1
416	The Role of Long Non-Coding RNAs in the Tumor Immune Microenvironment.. <b>2022</b> , 13, 851004	1
415	HPV and the Risk of HIV Acquisition in Women.. <b>2022</b> , 12, 814948	0
414	Colorectal cancer development is affected by the ECM molecule EMILIN-2 hinging on macrophage polarization via the TLR-4/MyD88 pathway.. <b>2022</b> , 41, 60	0

413	Circulating Tumor Cells: Does Ion Transport Contribute to Intravascular Survival, Adhesion, Extravasation, and Metastatic Organotropism?. <b>2022</b> , 1	
412	New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials.. <b>2022</b> , 18, 2775-2794	0
411	All retinoic acid as a host-directed immunotherapy for tuberculosis.. <b>2022</b> , 3, 54-72	0
410	ONP-302 Nanoparticles Inhibit Tumor Growth By Altering Tumor-Associated Macrophages And Cancer-Associated Fibroblasts.. <b>2022</b> , 13, 1933-1944	1
409	Role of macrophages in tumor development. <b>2022</b> , 113-164	
408	Targeting KCTD1 as a Potential Novel Therapy Ameliorates Hepatocellular Carcinoma Progression via the HIF-1 $\alpha$ /VEGF Pathway.	
407	Role of Tumour-Associated Macrophages in Colon Cancer Progression and Its Therapeutic Targeting. <b>2022</b> , 193-215	
406	Revealing the transcriptional heterogeneity of organ-specific metastasis in human gastric cancer using single-cell RNA Sequencing.. <b>2022</b> , 12, e730	1
405	Loss of LRRC33-Dependent TGF $\beta$ Activation Enhances Antitumor Immunity and Checkpoint Blockade Therapy.. <b>2022</b> , 10, 453-467	0
404	Coordinated Regulation of Myeloid-Derived Suppressor Cells by Cytokines and Chemokines.. <b>2022</b> , 14,	0
403	New Immunometabolic Strategy Based on Cell Type-Specific Metabolic Reprogramming in the Tumor Immune Microenvironment.. <b>2022</b> , 11,	0
402	Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma.. <b>2022</b> , 15, 17	2
401	Loss of YTHDF1 in gastric tumors restores sensitivity to antitumor immunity by recruiting mature dendritic cells.. <b>2022</b> , 10,	0
400	Pretreatment Albumin-to-Fibrinogen Ratio is a Promising Biomarker for Predicting Postoperative Clinical Outcomes in Patients with Colorectal Cancer.. <b>2022</b> , 1-14	0
399	HOXA7 promotes the metastasis of KRAS mutant colorectal cancer by regulating myeloid-derived suppressor cells.. <b>2022</b> , 22, 88	1
398	Effect of Early-Stage Human Breast Carcinoma on Monocyte Programming.. <b>2021</b> , 11, 800235	3
397	The Unfolded Protein Response at the Tumor-Immune Interface.. <b>2022</b> , 13, 823157	1
396	Different inflammatory blood markers correlate with specific outcomes in incident HPV-negative head and neck squamous cell carcinoma: a retrospective cohort study.. <b>2022</b> , 22, 243	1

395	A pH-/Enzyme-Responsive Nanoparticle Selectively Targets Endosomal Toll-like Receptors to Potentiate Robust Cancer Vaccination.. <b>2022,</b>	3
394	Immunometabolism of Myeloid-Derived Suppressor Cells: Implications for Infection and Insights from Tumor Biology.. <b>2022,</b> 23,	0
393	Entinostat decreases immune suppression to promote anti-tumor responses in a HER2+ breast tumor microenvironment.. <b>2022,</b>	1
392	Key Players of the Immunosuppressive Tumor Microenvironment and Emerging Therapeutic Strategies.. <b>2022,</b> 10, 830208	1
391	Integration of chemokine signaling with non-coding RNAs in tumor microenvironment and heterogeneity in different cancers.. <b>2022,</b>	3
390	Pivotal antitumor role of the immune checkpoint molecule B7-H1 in pancreatic cancer.. <b>2022,</b> 11, 2043037	0
389	The immune microenvironment in gastric adenocarcinoma.. <b>2022,</b>	5
388	Notch-mediated lactate metabolism regulates MDSC development through the Hes1/MCT2/c-Jun axis.. <b>2022,</b> 38, 110451	3
387	Nomogram based on prognostic nutrition index and Chest CT imaging signs predicts lymph node metastasis in NSCLC patients.. <b>2022,</b>	0
386	Roles of RNA-binding proteins in immune diseases and cancer.. <b>2022,</b>	0
385	Tumor-Derived Exosome and Immune Modulation.	0
384	Targeted Gene Expression Profiling of Human Myeloid Cells From Blood and Lung Compartments of Patients With Tuberculosis and Other Lung Diseases.. <b>2022,</b> 13, 839747	0
383	Advanced Biomaterials for Cell-Specific Modulation and Restore of Cancer Immunotherapy.. <b>2022,</b> e2200027	3
382	MDSCs and T cells in solid tumors and non-Hodgkin lymphomas: an immunosuppressive speech.. <b>2022,</b>	1
381	Beyond Immunosuppression: The Multifaceted Functions of Tumor-Promoting Myeloid Cells in Breast Cancers.. <b>2022,</b> 13, 838040	0
380	Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers.. <b>2022,</b> 14,	3
379	Hotspots and Frontiers in Inflammatory Tumor Microenvironment Research: A Scientometric and Visualization Analysis.. <b>2022,</b> 13, 862585	0
378	Lactylation-driven METTL3-mediated RNA mA modification promotes immunosuppression of tumor-infiltrating myeloid cells.. <b>2022,</b>	11

377	Context-dependent triggering of STING-interferon signaling by CD11b agonists supports anti-tumor immunity in mouse models and human cancer patients.	
376	Cytokine-Induced Senescence in the Tumor Microenvironment and Its Effects on Anti-Tumor Immune Responses.. <b>2022</b> , 14,	0
375	Harnessing Liquid Biopsies to Guide Immune Checkpoint Inhibitor Therapy.. <b>2022</b> , 14,	3
374	Dual Relationship Between Stromal Cells and Immune Cells in the Tumor Microenvironment.. <b>2022</b> , 13, 864739	1
373	Glioblastoma microenvironment: The stromal interactions.. <b>2022</b> , 232, 153813	1
372	Impact of Lipid Metabolism on Antitumor Immune Response.. <b>2022</b> , 14,	0
371	Coagulation and inflammation in cancer: Limitations and prospects for treatment.. <b>2022</b> , 188727	1
370	CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities.. <b>2022</b> , 25, 69-77	4
369	Targeting Myeloid-Derived Suppressor Cells Derived From Surgical Stress: The Key to Prevent Post-surgical Metastasis.. <b>2021</b> , 8, 783218	1
368	What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?. <b>2021</b> , 12, 773168	1
367	Neutrophil Homeostasis and Emergency Granulopoiesis: The Example of Systemic Juvenile Idiopathic Arthritis.. <b>2021</b> , 12, 766620	1
366	CCL5 production in lung cancer cells leads to an altered immune microenvironment and promotes tumor development.. <b>2022</b> , 11, 2010905	1
365	Myeloid-Derived Suppressor Cells in Prostate Cancer: Present Knowledge and Future Perspectives.. <b>2021</b> , 11,	1
364	Myeloid-Derived Suppressor Cells: A Multifaceted Accomplice in Tumor Progression.. <b>2021</b> , 9, 740827	2
363	Protective and pathological roles of regulatory immune cells in human cytomegalovirus infection following hematopoietic stem cell transplantation.. <b>2021</b> , e2319	
362	Suppressing MDSC Recruitment to the Tumor Microenvironment by Antagonizing CXCR2 to Enhance the Efficacy of Immunotherapy.. <b>2021</b> , 13,	2
361	Androgen conspires with the CD8 T cell exhaustion program and contributes to sex bias in cancer.. <b>2022</b> ,	4
360	Crosstalk between $\beta$ Catenin and CCL2 Drives Migration of Monocytes towards Glioblastoma Cells.. <b>2022</b> , 23,	1

359	Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future Directions.. <b>2022</b> , 11,	4
358	Elevated circulating myeloid-derived suppressor cells associated with poor prognosis in B-cell non-Hodgkin's lymphoma patients.. <b>2022</b> , 10, e616	0
357	Subcellular delivery of lipid nanoparticles to endoplasmic reticulum and mitochondria.. <b>2022</b> , e1803	0
356	CXCR2 Small-Molecule Antagonist Combats Chemoresistance and Enhances Immunotherapy in Triple-Negative Breast Cancer.. <b>2022</b> , 13, 862125	0
355	Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions.. <b>2022</b> ,	2
354	Image_1.tif. <b>2018</b> ,	
353	Image_2.tif. <b>2018</b> ,	
352	Data_Sheet_1.PDF. <b>2019</b> ,	
351	Image_1.pdf. <b>2019</b> ,	
350	Image_1.TIF. <b>2020</b> ,	
349	Image_2.TIF. <b>2020</b> ,	
348	Image_3.TIF. <b>2020</b> ,	
347	Image_4.TIF. <b>2020</b> ,	
346	Image_5.TIF. <b>2020</b> ,	
345	Image_6.TIF. <b>2020</b> ,	
344	Video_1.AVI. <b>2020</b> ,	
343	Video_2.AVI. <b>2020</b> ,	
342	Video_3.MP4. <b>2020</b> ,	

341 Video\_4.MP4. 2020,

340 Video\_5.MP4. 2020,

339 Video\_6.MP4. 2020,

338 Video\_7.AVI. 2020,

337 Data\_Sheet\_1.PDF. 2019,

336 Data\_Sheet\_1.pdf. 2020,

335 Table\_1.docx. 2020,

334 Data\_Sheet\_1.PDF. 2019,

333 Image\_1.TIF. 2019,

332 Image\_2.TIF. 2019,

331 Image\_3.TIF. 2019,

330 Table\_1.DOCX. 2019,

329 Presentation\_1.pdf. 2020,

328 Table\_1.XLSX. 2020,

327 Presentation\_1.PDF. 2018,

326 Image\_1.JPEG. 2019,

325 Image\_1.jpeg. 2020,

324 Image\_2.jpeg. 2020,

323 Image\_3.jpeg. 2020,

322 Image\_4.jpeg. 2020,

321 Table\_1.pdf. 2020,

320 table\_1.docx. 2018,

319 table\_2.docx. 2018,

318 table\_3.docx. 2018,

317 table\_4.docx. 2018,

316 Data\_Sheet\_1.PDF. 2019,

315 Table\_1.XLSX. 2019,

314 Image\_1.TIF. 2019,

313 Image\_10.TIF. 2019,

312 Image\_11.TIF. 2019,

311 Image\_12.TIF. 2019,

310 Image\_13.TIF. 2019,

309 Image\_14.TIF. 2019,

308 Image\_2.TIF. 2019,

307 Image\_3.TIF. 2019,

306 Image\_4.TIF. 2019,

305 Image\_5.TIF. 2019,

304 Image\_6.TIF. 2019,

303 Image\_7.TIF. 2019,

302 Image\_8.TIF. 2019,

301 Image\_9.tif. 2019,

300 Data\_Sheet\_1.pdf. 2019,

299 Table\_1.XLSX. 2019,

298 Data\_Sheet\_1.pdf. 2019,

297 Video\_1.AVI. 2019,

296 Video\_2.AVI. 2019,

295 Video\_3.AVI. 2019,

294 Video\_4.AVI. 2019,

293 Video\_5.AVI. 2019,

292 Table\_1.pdf. 2019,

291 Table\_1.pdf. 2020,

290 Data\_Sheet\_1.PDF. 2020,

289 Image\_1.tif. 2020,

288 Image\_2.tif. 2020,



287 Image\_3.tif. 2020,

286 Table\_1.xlsx. 2020,

285 Table\_2.docx. 2020,

284 Image\_1.pdf. 2020,

283 Image\_2.pdf. 2020,

282 Image\_3.pdf. 2020,

281 Image\_4.pdf. 2020,

280 Table\_1.pdf. 2020,

279 DataSheet\_1.pdf. 2021,

278 Data\_Sheet\_1.docx. 2018,

277 Arachidonic acid, a clinically adverse mediator in the ovarian cancer microenvironment, impairs JAK-STAT signaling in macrophages by perturbing lipid raft structures.. 2022, 1

276 Direct and indirect regulation of the tumor immune microenvironment by VEGF.. 2022, 0

275 Pathogenetic role and clinical significance of Interleukin-1 $\beta$  in cancer.. 2022, 0

274 Diurnal expression of PD-1 on tumor-associated macrophages underlies the dosing time-dependent anti-tumor effects of the PD-1/PD-L1 inhibitor BMS-1 in B16/BL6 melanoma-bearing mice.. 2022, 1

273 Immunogenic Cell Death in Cancer Therapy.. 2022, 14, 40-53 0

272 Differential immune landscapes in appendicular versus axial skeleton.. 2022, 17, e0267642

271 Characterization of Immunogenicity of Malignant Cells with Stemness in Intrahepatic Cholangiocarcinoma by Single-Cell RNA Sequencing.. 2022, 2022, 3558200 1

270 Impact of the Tumor Microenvironment for Esophageal Tumor Development-An Opportunity for Prevention?. 2022, 14,

269	Staggered Stacking Covalent Organic Frameworks for Boosting Cancer Immunotherapy. 2201542	5
268	Immune effects of CDK4/6 inhibitors in patients with HR/HER2 metastatic breast cancer: Relief from immunosuppression is associated with clinical response.. 2022, 79, 104010	0
267	Hypoxia as a Modulator of Inflammation and Immune Response in Cancer.. 2022, 14,	1
266	Clinical Significance of a CD3/CD8-Based Immunoscore in Neuroblastoma Patients Using Digital Pathology. 2022, 13,	
265	Cancer Stem Cells (CSCs), Circulating Tumor Cells (CTCs) and Their Interplay with Cancer Associated Fibroblasts (CAFs): A New World of Targets and Treatments. 2022, 14, 2408	0
264	High-throughput single-cell sequencing in cancer research.. 2022, 7, 145	1
263	Ductal Carcinoma in Situ: Molecular Changes Accompanying Disease Progression.. 2022,	2
262	Modified-Dose Pembrolizumab and Prognostic Outcomes among Non-Small Cell Lung Cancer Patients: A Chart Review Study. 2022, 19, 5999	
261	Generation of human myeloid suppressor cells in the in vitro experimental model. 2020, 23, 157-162	
260	Timing of the Major Metabolic Switches in Immune Cell Activation and Differentiation During Cancer Development. 2022, 187-218	
259	Immuno-onco-metabolism and Therapeutic Resistance. 2022, 45-89	3
258	Cancer evolution: special focus on the immune aspect of cancer.. 2022,	0
257	Long non-coding RNAs and cancer mechanisms: Immune cells and inflammatory cytokines in the tumor microenvironment.. 2022, 39, 108	1
256	Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets.. 2022, 15, 61	7
255	Enabling CAR-T cells for solid tumors: Rage against the suppressive tumor microenvironment. 2022,	3
254	Immune cell responses in pancreatic cancer and their clinical application. 2022, 20, 205873922110443	1
253	Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy. 2022, 10, 1181	1
252	Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy. 2022,	2

251	The Role of Myeloid Cells in GBM Immunosuppression. <b>2022</b> , 13,	0
250	G-CSF / GM-CSF -induced hematopoietic dysregulation in the progression of solid tumors.	1
249	Tissue-Resident Innate Immune Cell-Based Therapy: A Cornerstone of Immunotherapy Strategies for Cancer Treatment. <b>2022</b> , 10,	0
248	PD-1/PD-L1, MDSC Pathways, and Checkpoint Inhibitor Therapy in Ph(-) Myeloproliferative Neoplasm: A Review. <b>2022</b> , 23, 5837	0
247	Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression.	3
246	Circadian Rhythm Disruption Increases Tumor Growth Rate and Accumulation of Myeloid-Derived Suppressor Cells. 2200031	
245	Nanotechnology and Immunomodulators in Cancer. <b>2022</b> , 125-186	0
244	Myeloid Derived Suppressor Cells Migrate in Response to Flow and Lymphatic Endothelial Cell Interaction in the Breast Tumor Microenvironment. <b>2022</b> , 14, 3008	0
243	Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy. <b>2022</b> , 7,	8
242	Drug Resistance in Colorectal Cancer: From Mechanism to Clinic. <b>2022</b> , 14, 2928	4
241	Cancer Cachexia and Antitumor Immunity: Common Mediators and Potential Targets for New Therapies. <b>2022</b> , 12, 880	0
240	Decoding lymphomyeloid divergence and immune hyporesponsiveness in G-CSF-primed human bone marrow by single-cell RNA-seq. <b>2022</b> , 8,	0
239	CAR T Cell Locomotion in Solid Tumor Microenvironment. <b>2022</b> , 11, 1974	1
238	Bone Metastasis and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC): Microenvironment and Possible Clinical Implications. <b>2022</b> , 23, 6832	1
237	Prognostic utility of preoperative inflammatory markers in patients with intrahepatic cholangiocarcinoma after hepatic resection: A systematic review and meta-analysis.	0
236	Role of sanguinarine in regulating immunosuppression in a Lewis lung cancer mouse model. <b>2022</b> , 110, 108964	0
235	Peripheral expansion of myeloid derived suppressor cells is related to disease activity and damage accrual in inflammatory myopathies.	0
234	Blocking the A2B adenosine receptor alleviates myocardial damage by inhibiting spleen-derived MDSC mobilisation after acute myocardial infarction. <b>2022</b> , 54, 1616-1626	0

233	Crosstalk between angiogenesis and immune regulation in the tumor microenvironment. <b>2022</b> , 45, 401-416	1
232	Arginase 1 is a key driver of immune suppression in pancreatic cancer.	0
231	Immunosenescence: A Critical Factor Associated With Organ Injury After Sepsis. 13,	0
230	Immunologic Strategies in Pancreatic Cancer: Making Cold Tumors Hot.	3
229	Myeloid mechano-metabolic programming restricts anti-tumor immunity.	0
228	Stem Cells in the Tumor Immune Microenvironment Part of the Cure or Part of the Disease? Ontogeny and Dichotomy of Stem and Immune Cells has Led to better Understanding.	
227	TGF- $\beta$ Enhances Immunosuppression of Myeloid-Derived Suppressor Cells to Induce Transplant Immune Tolerance Through Affecting Arg-1 Expression. 13,	0
226	Immune-based therapies in penile cancer.	1
225	Myeloid-Derived Suppressor Cells as Key Players and Promising Therapy Targets in Prostate Cancer. 12,	2
224	Mathematical Modeling and Analysis of CD200/CD200R in Cancer Treatment. <b>2022</b> , 84,	
223	Neutrophils: New Critical Regulators of Glioma. 13,	0
222	Tumor-associated neutrophils and neutrophil-targeted cancer therapies. <b>2022</b> , 188762	1
221	Understanding the bidirectional interactions between two-dimensional materials, microorganisms, and the immune system. <b>2022</b> , 188, 114422	0
220	Myeloid derived suppressor cells and innate immune system interaction in tumor microenvironment. <b>2022</b> , 305, 120755	2
219	Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation. 12,	0
218	Prognostic implications of preoperative systemic inflammatory markers in oral squamous cell carcinoma, and correlations with the local immune tumor microenvironment. 13,	1
217	Host-Related Factors as Targetable Drivers of Immunotherapy Response in Non-Small Cell Lung Cancer Patients. 13,	0
216	The Immunotherapy and Immunosuppressive Signaling in Therapy-Resistant Prostate Cancer. <b>2022</b> , 10, 1778	1

215	Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin. <b>2022</b> , 11,	0
214	Myeloid-Derived Suppressor Cells and CD68+CD163+M2-Like Macrophages as Therapeutic Response Biomarkers Are Associated with Plasma Inflammatory Cytokines: A Preliminary Study for Non-Small Cell Lung Cancer Patients in Radiotherapy. <b>2022</b> , 2022, 1-16	0
213	Adoptive Cellular Therapy for Pediatric Solid Tumors: Beyond Chimeric Antigen Receptor-T Cell Therapy. <b>2022</b> , 28, 322-327	
212	Systemic delivery of gemcitabine analogue and STAT3 siRNA promotes antitumor immunity against melanoma.	
211	Interaction between microbiota and immunity and its implication in colorectal cancer. 13,	0
210	Galectin-8 is a major ligand of LILRB4 prompting MDSC functions in the tumor microenvironment.	
209	Astrocyte immunometabolic regulation of the tumour microenvironment drives glioblastoma pathogenicity.	1
208	Effects of helicobacter pylori on tumor microenvironment and immunotherapy responses. 13,	0
207	Predictive value of Leukocyte ImmunoTest (LIT) in cancer patients: a prospective cohort study. 12,	
206	The Extracellular Matrix: A Key Accomplice of Cancer Stem Cell Migration, Metastasis Formation, and Drug Resistance in PDAC. <b>2022</b> , 14, 3998	2
205	Lactate score predicts survival, immune cell infiltration and response to immunotherapy in breast cancer. 13,	
204	The Effects of Tamoxifen on Tolerogenic Cells in Cancer. <b>2022</b> , 11, 1225	0
203	A brief glimpse of a tangled web in a small world: Tumor microenvironment. 9,	0
202	Single-cell transcriptomics reveals shared immunosuppressive landscapes of mouse and human neuroblastoma. <b>2022</b> , 10, e004807	0
201	The multifaceted mechanisms of malignant glioblastoma progression and clinical implications.	0
200	Development and validation of a necroptosis-related gene prognostic score to predict prognosis and efficiency of immunotherapy in gastric cancer. 13,	2
199	Myeloid-Derived Suppressor Cells: New Insights into the Pathogenesis and Therapy of MDS. <b>2022</b> , 11, 4908	0
198	Pannexin1 channel-dependent secretome from apoptotic tumor cells shapes immune-escape microenvironment. <b>2022</b> ,	

- 197 CD147 mediates epidermal malignant transformation through the RSK2/AP-1 pathway. **2022**, 41, 0
- 196 The Biocomplex Assembled from Antigen Peptide and Toll-like Receptor Agonist Improved the Immunity against Pancreatic Adenocarcinoma In Vivo. **2022**, 2022, 1-10
- 195 Prospective Evaluation of Immune Activation Associated with Response to Radioembolization Assessed with PET/CT in Women with Breast Cancer Liver Metastasis. 0
- 194 Spleen Macrophages: Population Composition and Functions. **2022**, 16, 291-301
- 193 Melanoma-derived small extracellular vesicles remodel the systemic onco-immunity via disrupting hematopoietic stem cell proliferation and differentiation. **2022**, 545, 215841 0
- 192 Myeloid mechano-metabolic programming restricts anti-tumor immunity. 0
- 191 Shaping of the Immune Landscape by Chemokine Receptors that Impacts the Clinical Outcome in Triple-Negative Breast Cancer. **2022**, 0
- 190 Cancer prognosis and immune system. **2022**, 75-144 0
- 189 An overview of cancer and the human microbiome. **2022**, 0
- 188 Obesity and breast cancer. **2023**, 83-113 0
- 187 Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy. **2022**, 15, 1
- 186 Single-cell and spatial transcriptome analyses revealed cell heterogeneity and immune environment alternations in metastatic axillary lymph nodes in breast cancer. 1
- 185 Myeloid-derived suppressor cells in colorectal cancer: prognostic biomarkers and therapeutic targets. 497-510 0
- 184 Clinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma. **2022**, 14, 4209 1
- 183 The Microbiome-Immune Axis Therapeutic Effects in Cancer Treatments. **2022**, 32, 1086-1097 0
- 182 GPNMB: a potent inducer of immunosuppression in cancer. **2022**, 41, 4573-4590 0
- 181 Correlation of Tryptophan Metabolic Pathway with Immune Activation and Chemosensitivity in Patients with Lung Adenocarcinoma. **2022**, 2022, 1-18 0
- 180 Circulating monocytes associated with anti-PD-1 resistance in human biliary cancer induce T'cell paralysis. **2022**, 40, 111384 1

179	Targeting tumour-reprogrammed myeloid cells: the new battleground in cancer immunotherapy.	1
178	Systemic immune-inflammation landscape in brain metastasis needing neurosurgical resection: Analysis of 230 consecutive cases in a single center. <b>2022</b> , 10,	0
177	Lactate metabolism in human health and disease. <b>2022</b> , 7,	7
176	New Insights into SARS-CoV-2 and Cancer Cross-Talk: Does a Novel Oncogenesis Driver Emerge?. <b>2022</b> , 10, 1607	2
175	miR-acious new avenues for cancer immunotherapy. 13,	0
174	Dendritic Cells: The Long and Evolving Road towards Successful Targetability in Cancer. <b>2022</b> , 11, 3028	2
173	Mass cytometry-based peripheral blood analysis as a novel tool for early detection of solid tumours: a multicentre study. <a href="#">gutjnl-2022-327496</a>	0
172	Deregulated hyaluronan metabolism in the tumor microenvironment drives cancer inflammation and tumor-associated immune suppression. 13,	1
171	Exploring the role of mast cells in the progression of liver disease. 13,	0
170	Macrophage innate training induced by IL-4 and IL-13 activation enhances OXPHOS driven anti-mycobacterial responses. 11,	1
169	CXCL10 promotes the accumulation of mo-MDSCs by activating p38 MAPK signaling under tumor conditions.	1
168	CD24 blockade promotes anti-tumor immunity in oral squamous cell carcinoma.	0
167	Immunomodulatory-Photodynamic Nanostimulators for Invoking Pyroptosis to Augment Tumor Immunotherapy. 2201233	3
166	The role of polyamine metabolism in remodeling immune responses and blocking therapy within the tumor immune microenvironment. 13,	0
165	Fusobacterium nucleatum, a key pathogenic factor and microbial biomarker for colorectal cancer. <b>2022</b> ,	2
164	The Interplay of Tumor Vessels and Immune Cells Affects Immunotherapy of Glioblastoma. <b>2022</b> , 10, 2292	1
163	Tumor-derived interleukin-34 creates an immunosuppressive and chemoresistant tumor microenvironment by modulating myeloid-derived suppressor cells in triple-negative breast cancer.	2
162	The Role of Neutrophils in Oncolytic Orf Virus-Mediated Cancer Immunotherapy. <b>2022</b> , 11, 2858	0

161	Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. <b>2022</b> , 21,	5
160	Mitigating the prevalence and function of myeloid-derived suppressor cells by redirecting myeloid differentiation using a novel immune modulator. <b>2022</b> , 10, e004710	0
159	Recent developments in application of single-cell RNA sequencing in the tumour immune microenvironment and cancer therapy. <b>2022</b> , 9,	0
158	Role of myeloid-derived suppressor cells in the formation of pre-metastatic niche. 12,	1
157	Prognostic analysis and risk stratification of lung adenocarcinoma undergoing EGFR-TKI therapy with time-serial CT-based radiomics signature.	0
156	Cancer-Associated Fibroblasts: The Origin, Biological Characteristics and Role in Cancer A Glance on Colorectal Cancer. <b>2022</b> , 14, 4394	0
155	Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial. OF1-OF15	1
154	Decreased Polymorphonuclear Myeloid-Derived Suppressor Cells and ROS Production Correlated Closely with Bronchopulmonary Dysplasia in Preterm Infants. <b>2022</b> , 2022, 1-8	0
153	The role of autophagy in colorectal cancer: Impact on pathogenesis and implications in therapy. 9,	2
152	Tristetraprolin limits age-related expansion of myeloid-derived suppressor cells. 13,	0
151	A lactate-related LncRNA model for predicting prognosis, immune landscape and therapeutic response in breast cancer. 13,	0
150	The role of macrophage subtypes and exosomes in immunomodulation. <b>2022</b> , 27,	4
149	Therapeutic Implications of UVB Irradiation in Cancer by Enhancing Anti-Tumor Immunity □	0
148	Chemotherapy-induced complement signaling modulates immunosuppression and metastatic relapse in breast cancer. <b>2022</b> , 13,	0
147	Fibroblast activation protein-based theranostics in pancreatic cancer. 12,	0
146	The multiple roles of LDH in cancer.	3
145	Single-cell analysis reveals nanosecond pulsed electric field ablation induced myeloid cells remodeling in pancreatic cancer. <b>2022</b> , 148, 108266	0
144	Biological and molecular studies on specific immune cells treated with checkpoint inhibitors for the thera-personal approach of breast cancer patients (ex-vivo study). <b>2021</b> , 29, 319-329	0



143	PTEN in Immunity. <b>2022</b> , 95-115	0
142	Three Pillars or Three Illusions of Oncoimmunology. <b>2022</b> , 1-19	0
141	Cilt Kanserlerinin Ayırıcısında İnflamatuar Belirtilerin Yeri. <b>2022</b> , 12, 761-769	0
140	Breast cancer liver metastasis: Pathogenesis and clinical implications. 12,	0
139	The Tumor Microenvironment Reprograms Immune Cells.	1
138	Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4. <b>2022</b> , 22,	1
137	Effects of microenvironment in osteosarcoma on chemoresistance and the promise of immunotherapy as an osteosarcoma therapeutic modality. 13,	0
136	Heterogeneity of glioblastoma stem cells in the context of the immune microenvironment and geospatial organization. 12,	0
135	A cutting-edge immunomodulatory interlinkage between HOTAIR and MALAT1 in tumor-associated macrophages in breast cancer: A personalized immunotherapeutic approach. 9,	0
134	DCLK1 suppresses tumor-specific cytotoxic T lymphocyte function through recruitment of MDSCs via the CXCL1-CXCR2 axis. <b>2022</b> ,	0
133	Immune Checkpoint Inhibitors and RAS/ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma. <b>2022</b> , 12, 1562	1
132	Granulocytic MDSC with Deficient CCR5 Alleviates Lipogenesis and Inflammation in Nonalcoholic Fatty Liver Disease. <b>2022</b> , 23, 13048	0
131	Targeting depletion of myeloid-derived suppressor cells potentiates PD-L1 blockade efficacy in gastric and colon cancers. <b>2022</b> , 11,	2
130	Immunotherapeutic Approaches for Treating Hepatocellular Carcinoma. <b>2022</b> , 14, 5013	2
129	Managing the TME to improve the efficacy of cancer therapy. 13,	0
128	Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors. <b>2022</b> , 14, 5108	3
127	Peroxyntirite in the tumor microenvironment changes the profile of antigens allowing escape from cancer immunotherapy. <b>2022</b> , 40, 1173-1189.e6	0
126	The Innate Immune Microenvironment in Metastatic Breast Cancer. <b>2022</b> , 11, 5986	1

- 125 The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers. 13, ○
- 124 Cutting edges and therapeutic opportunities on tumor-associated macrophages in lung cancer. 13, ○
- 123 A promising research direction for colorectal cancer immunotherapy: The regulatory mechanism of CCL5 in colorectal cancer. 12, ○
- 122 Chemokine Physiology in Cancer. ○
- 121 Nanomodulation and nanotherapeutics of tumor-microenvironment. **2022**, 8, 100099 ○
- 120 Combining all-trans retinoid acid treatment targeting myeloid-derived suppressive cells with cryo-thermal therapy enhances antitumor immunity in breast cancer. 13, 1
- 119 Targeting myeloid suppressive cells revives cytotoxic anti-tumor responses in pancreatic cancer. **2022**, 25, 105317 ○
- 118 A double-edged sword in tumor angiogenesis and progression. Dual roles of mast cells, macrophages, and neutrophils. **2022**, 240, 154167 1
- 117 Targeting hypoxia-inducible factor-1alpha: A new strategy for triple-negative breast cancer therapy. **2022**, 156, 113861 ○
- 116 Delicaflavone reactivates anti-tumor immune responses by abrogating monocytic myeloid cell-mediated immunosuppression. **2023**, 108, 154508 ○
- 115 Cancer-cell-intrinsic mechanisms regulate MDSCs through cytokine networks. **2022**, ○
- 114 The Tumor Microenvironment. **2022**, 1-49 ○
- 113 Tailoring biomaterials and applications targeting tumor-associated macrophages in cancers. 13, ○
- 112 Gut fungi enhances immunosuppressive function of myeloid-derived suppressor cells by activating PKM2-dependent glycolysis to promote colorectal tumorigenesis. **2022**, 11, ○
- 111 Autophagy protects against high-doseMycobacterium tuberculosisinfection. ○
- 110 Annexin A2/TLR2/MYD88 pathway induces arginase 1 expression in tumor-associated neutrophils. **2022**, 132, ○
- 109 The effects of dendritic cell-based vaccines in the tumor microenvironment: Impact on myeloid-derived suppressor cells. 13, 1
- 108 The predictive value of peripheral blood cells and lymphocyte subsets in oesophageal squamous cell cancer patients with neoadjuvant chemoradiotherapy. 13, ○

107	Engineering Energy-Responsive Magnetic Nanomaterials to Improve the Efficacy of Dendritic Cell-Based Immunotherapy. 2200234	0
106	Extracellular Vesicles in Multiple Myeloma Tracking the Code to a Better Understanding of the Disease. <b>2022</b> , 14, 5575	0
105	The effect of neoadjuvant chemotherapy on the tumor immune microenvironment in gastrointestinal tumors. 12,	0
104	Candida tropicalis induces NLRP3 inflammasome activation via glycogen metabolism-dependent glycolysis and JAK-STAT1 signaling pathway in myeloid-derived suppressor cells to promote colorectal carcinogenesis. <b>2022</b> , 113, 109430	0
103	Myeloid-derived suppressor cells: Cancer, autoimmune diseases, and more. <b>2022</b> , 13, 1273-1285	1
102	Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes. <b>2022</b> , 14, 5656	1
101	Aging tumour cells to cure cancer: Pro-senescence therapy for cancer. <b>2017</b> , 147, w14367	4
100	Emerging nano-strategies against tumour microenvironment (TME): a review. <b>2023</b> , 9, 100112	0
99	Characteristics of MCR on myeloid cells from C57BL/6 mice with Plasmodium yoelii nigeriensis infection. <b>2023</b> , 253, 111540	0
98	Quxie Capsule Alleviates Colitis-associated Colorectal Cancer Through Modulating the Gut Microbiota and Suppressing A. fumigatus-induced Aerobic Glycolysis. <b>2022</b> , 21, 153473542211385	0
97	The role of erythrocytes and erythroid progenitor cells in tumors. <b>2022</b> , 17, 1641-1656	0
96	Tumor Microenvironment Complexity: A Pathological Milieu that Innately Modulates Cancer Progression. <b>2022</b> , 1-28	0
95	Immunosuppressive environment in response to androgen deprivation treatment in prostate cancer. 13,	0
94	Selective depletion of polymorphonuclear myeloid derived suppressor cells in tumor beds with near infrared photoimmunotherapy enhances host immune response. <b>2022</b> , 11,	1
93	Radiotherapy in combination with CD47 blockade elicits a macrophage-mediated abscopal effect. <b>2022</b> , 3, 1351-1366	2
92	CXCL1 promotes colon cancer progression through activation of NF- $\kappa$ B/P300 signaling pathway. <b>2022</b> , 17,	0
91	ARID1A loss induces polymorphonuclear myeloid-derived suppressor cell chemotaxis and promotes prostate cancer progression. <b>2022</b> , 13,	1
90	PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study. 13,	0

89	CD244 regulates both innate and adaptive immune axes in melanoma by inhibiting autophagy-mediated M1 macrophage maturation.	0
88	Exosomes from cisplatin-induced dormant cancer cells facilitate the formation of premetastatic niche in bone marrow through activating glycolysis of BMSCs. 12,	0
87	Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment.	3
86	Myeloid-derived suppressor cells (MDSCs) depletion by cabozantinib improves the efficacy of anti-HER2 antibody-based immunotherapy in a 4T1-HER2 murine breast cancer model. <b>2022</b> , 113, 109470	1
85	The emerging role of regulatory cell-based therapy in autoimmune disease. 13,	1
84	Arginase-1+ bone marrow myeloid cells are reduced in myeloproliferative neoplasms and correlate with clinical phenotype, fibrosis, and molecular driver.	0
83	Tumor-derived OBP2A promotes prostate cancer castration resistance. <b>2023</b> , 220,	0
82	Resistance to Antiangiogenic Therapy in Hepatocellular Carcinoma: From Molecular Mechanisms to Clinical Impact. <b>2022</b> , 14, 6245	0
81	In situ vaccination with cowpea mosaic virus elicits systemic antitumor immunity and potentiates immune checkpoint blockade. <b>2022</b> , 10, e005834	0
80	Chemotherapy: A partnership with immunotherapy in n on-small cell lung cancer.	0
79	Cancer cell-derived type I interferons instruct tumor monocyte polarization. <b>2022</b> , 41, 111769	0
78	Biomimetic Active Materials Guided Immunogenic Cell Death for Enhanced Cancer Immunotherapy. 2201412	0
77	Obesity and breast cancer. <b>2022</b> , 18, 40-51	0
76	Myeloid-derived suppressor cell: A crucial player in autoimmune diseases. 13,	0
75	The poorly immunogenic tumor microenvironment of pancreatic cancer: the impact of radiation therapy, and strategies targeting resistance. <b>2022</b> , 14, 1393-1405	0
74	TH17 cells boosted by nanoparticle-bound fungal motifs.	1
73	Glucose metabolism and tumour microenvironment in pancreatic cancer: A key link in cancer progression. 13,	0
72	The mononuclear phagocyte system in hepatocellular carcinoma. 28, 6345-6355	0

71	Tumor-promoting function and regulatory landscape of PD-L2 in B-cell lymphoma.	0
70	Nanoparticle accumulation in liver may induce resistance to immune checkpoint blockade therapy.	0
69	Construction of a metabolism-related gene prognostic model to predict survival of pancreatic cancer patients. <b>2022</b> , e12378	0
68	The Yin-Yang of myeloid cells in the leukemic microenvironment: Immunological role and clinical implications. 13,	0
67	Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer. <b>2023</b> , 14,	2
66	Intratumour <i>Fusobacterium nucleatum</i> and immune response to oesophageal cancer.	0
65	Granulocytic myeloid-derived suppressor cells increase infection risk via the IDO/IL-10 pathway in patients with hepatitis B virus-related liver failure. 13,	0
64	Monocyte-neutrophil entanglement in glioblastoma. <b>2023</b> , 133,	1
63	Cancer Stem Cell Relationship with Pro-Tumoral Inflammatory Microenvironment. <b>2023</b> , 11, 189	1
62	Endoplasmic reticulum stress mediates the myeloid-derived immune suppression associated with cancer and infectious disease. <b>2023</b> , 21,	0
61	Research progress of abnormal lactate metabolism and lactate modification in immunotherapy of hepatocellular carcinoma. 12,	1
60	Nicotinamide N-methyltransferase promotes M2 macrophage polarization by IL6 and MDSC conversion by GM-CSF in gallbladder carcinoma. Publish Ahead of Print,	0
59	The prognostic significance of tumor-associated neutrophils and circulating neutrophils in glioblastoma (WHO CNS5 classification). <b>2023</b> , 23,	0
58	The complex network of transcription factors, immune checkpoint inhibitors and stemness features in colorectal cancer: A recent update. <b>2023</b> , 89, 1-17	0
57	Modified method for differentiation of myeloid-derived suppressor cells in vitro enhances immunosuppressive ability via glutathione metabolism. <b>2023</b> , 33, 101416	0
56	A review of computational modeling, machine learning and image analysis in cancer metastasis dynamics. <b>2022</b> , 3,	0
55	Monocytic Myeloid-Derived Suppressor Cells from Tumor Tissue Are a Differentiated Cell with Limited Fate Plasticity. <b>2022</b> , 6, 790-806	0
54	Clear Cell Renal Cell Carcinoma: From Biology to Treatment. <b>2023</b> , 15, 665	2

- 53 Folate receptor-positive circulating tumor cell count, lymphocyte count and derived neutrophil-to-lymphocyte ratio for diagnosing lung cancer relapse. 12, ○
- 52 The role of innate immune cells in the tumor microenvironment and research progress in anti-tumor therapy. 13, ○
- 51 NKT cell: Success and promises in transplantation and immunotherapy. **2023**, 385-401 ○
- 50 Immunomodulatory effect of locoregional therapy in the tumor microenvironment. **2023**, 1 ○
- 49 Cullin-5 deficiency orchestrates the tumor microenvironment to promote mammary tumor development through CREB1-CCL2 signaling. **2023**, 9, ○
- 48 Glioblastoma treatment slowly moves towards change: novel druggable targets and translational horizons in 2022. ○
- 47 Reactivation of Anticancer Immunity by Resetting Interorgan Crosstalk in Immune-Suppressive Cells with a Nanoparticulated Anti-Inflammatory Drug. 2205131 ○
- 46 Immunotherapy reverses glioma-driven dysfunction of immune system homeostasis. **2023**, 11, e004805 ○
- 45 Myeloid-derived suppressor cells: Escorts at the maternal-fetal interface. 14, ○
- 44 Arginase 1 is a key driver of immune suppression in pancreatic cancer. 12, ○
- 43 Identification of a basement membrane-based risk scoring system for prognosis prediction and individualized therapy in clear cell renal cell carcinoma. 14, ○
- 42 Roles of STAT3 in the pathogenesis and treatment of glioblastoma. 11, ○
- 41 Tim-3 regulates the immunosuppressive function of decidual MDSCs via the Fyn-STAT3-C/EBP $\beta$  pathway during *Toxoplasma gondii* infection. **2023**, 19, e1011329 ○
- 40 Strategies to overcome myeloid cell induced immune suppression in the tumor microenvironment. 13, ○
- 39 Persistent immunosuppressive effects of dibutyl phthalate exposure in adult male mice. **2023**, 878, 162741 ○
- 38 Current progress in chimeric antigen receptor-modified T cells for the treatment of metastatic breast cancer. **2023**, 162, 114648 ○
- 37 Insights on hematopoietic cell kinase: An oncogenic player in human cancer. **2023**, 160, 114339 ○
- 36 Antioxidant and Anti-Inflammatory Compounds from Edible Plants with Anti-Cancer Activity and Their Potential Use as Drugs. **2023**, 28, 1488 ○

- 35 Lnc-17Rik promotes the immunosuppressive function of Myeloid-Derived suppressive cells in esophageal cancer. **2023**, 385, 104676 ○
- 34 Therapeutic targeting of tumour myeloid cells. **2023**, 23, 216-237 ○
- 33 How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation. ○
- 32 Tumour-derived small extracellular vesicles contribute to the tumour progression through reshaping the systemic immune macroenvironment. **2023**, 128, 1249-1266 ○
- 31 IL-1 receptor-associated kinase-3 acts as an immune checkpoint in myeloid cells to limit cancer immunotherapy. **2023**, 133, ○
- 30 Hydroxyphenylpyruvate Dioxygenase Is a Metabolic Immune Checkpoint for UTX-deficient Colorectal Cancer. **2023**, ○
- 29 Oncolytic BHV-1 Is Sufficient to Induce Immunogenic Cell Death and Synergizes with Low-Dose Chemotherapy to Dampen Immunosuppressive T Regulatory Cells. **2023**, 15, 1295 ○
- 28 Dioscin modulates macrophages polarization and MDSCs differentiation to inhibit tumorigenesis of colitis-associated colorectal cancer. **2023**, 117, 109839 ○
- 27 Pericyte stem cells induce Ly6G + cell accumulation and immunotherapy resistance in pancreatic cancer. **2023**, 24, ○
- 26 In vitro differentiation of myeloid suppressor cells (MDSC-like) from an immature myelomonocytic precursor THP-1. **2023**, 515, 113441 ○
- 25 Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment. **2023**, 11, 1
- 24 Roles of Tumor Immune Microenvironment in Non-small Cell Lung Cancer. **2023**, ○
- 23 Antitumor Therapy Targeting the Tumor Microenvironment. **2023**, 2023, 1-16 ○
- 22 5-Fluorouracil Suppresses Colon Tumor through Activating the p53-Fas Pathway to Sensitize Myeloid-Derived Suppressor Cells to FasL+ Cytotoxic T Lymphocyte Cytotoxicity. **2023**, 15, 1563 ○
- 21 The role of myeloid-derived immunosuppressive cells in cardiovascular disease. **2023**, 117, 109955 ○
- 20 Early inflammatory biomarkers and melanoma survival. ○
- 19 Raddeanin A Enhances Mitochondrial DNA-cGAS/STING Axis-Mediated Antitumor Immunity by Targeting Transactive Responsive DNA-Binding Protein 43. 2206737 ○
- 18 Immune Gene Therapy of Cancer. **2023**, 1-45 ○

- 17 Interaction of gut microbiota with the tumor microenvironment: A new strategy for antitumor treatment and traditional Chinese medicine in colorectal cancer. 10, ○
- 16 The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF. **2023**, 175586 ○
- 15 Targeting myeloid-derived suppressor cells in tumor immunotherapy: Current, future and beyond. 14, ○
- 14 CX3CR1 deficiency-induced TIL tumor restriction as a novel addition for CAR-T design in solid malignancies. **2023**, 26, 106443 ○
- 13 Downregulated annexin A1 expression correlates with poor prognosis, metastasis, and immunosuppressive microenvironment in Ewing's sarcoma. **2023**, 15, 2321-2346 ○
- 12 Enhancement of immune surveillance in breast cancer by targeting hypoxic tumor endothelium: Can it be an immunological switch point?. 13, ○
- 11 Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies. **2023**, 11, ○
- 10 HPV-related anal cancer is associated with changes in the anorectal microbiome during cancer development. 14, ○
- 9 Integrated multi-omics analyses and experimental validation reveal the clinical and biological significances of APBB1IP in Colon Cancer. ○
- 8 Immunotherapy in Prostate Cancer: Recent Advances and Future Directions. 51-61 ○
- 7 Recent advances in targeting myeloid-derived suppressor cells and their applications to radiotherapy. **2023**, ○
- 6 The crosstalk between autophagy and myeloid-derived suppressor cell responses in cancer. ○
- 5 Lactate-Modulated the Immunosuppressive Function of Myeloid-Derived Suppressor Cells through TET2-mediated SGK1 demethylation. ○
- 4 Role of voltage-gated proton channel (Hv1) in cancer biology. 14, ○
- 3 Bone serves as a transfer station for secondary dissemination of breast cancer. **2023**, 11, ○
- 2 Origin and Heterogeneity of Tissue Myeloid Cells: A Focus on GMP-Derived Monocytes and Neutrophils. **2023**, 41, 375-404 ○
- 1 Single-cell transcriptomic atlas of parathyroid adenoma and parathyroid carcinoma. ○